Non-naturally occurring melanocortin analogs and uses thereof for treating substance use disorders

Abstract

Provided herein are methods of treating, preventing, reducing, or otherwise ameliorating a substance use disorder in a subject in need thereof, comprising administering to the subject a non-naturally occurring melanocortin analog. In some embodiments, the substance use disorder comprises an alcohol use disorder or an opioid use disorder.

Description

NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF FOR TREATING SUBSTANCE USE DISORDERSCROSS-REFERENCE TO RELATED APPLICATION(S)

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 607,500, filed December 7, 2023, U.S. Provisional Patent Application No. 63 / 618,843, filed January 8, 2024, U.S. Provisional Patent Application No. 63 / 557,385, filed February 23, 2024, U.S. Provisional Patent Application No. 63 / 573,429, filed April 2, 2024, of U.S. Provisional Patent Application No. 63 / 650,705, filed May 22, 2024, U.S. Provisional Patent Application No. 63 / 656,583, filed June 5, 2025, and U.S. Provisional Patent Application No. 63 / 663,648, filed June 24, 2024, all of which applications are incorporated herein by reference in their entirety.INCORPORATION BY REFERENCE OF SEQUENCE LISTING

[0002] This application contains an ST.26 compliant Sequence Listing, which is submitted concurrently in xml format and hereby incorporated by reference in its entirety. The .xml copy, created on December 9, 2024, is titled “146316_8017_WO02_SL.xml” and is 1 ,472,360 bytes in size.BACKGROUND

[0003] Opioid receptors (e.g., mu opioid receptor, delta opioid receptor) are major molecular targets for pain management. The vast majority of clinically prescribed pain medications are opioid receptor ligands (i.e. , opioid drugs) that are structurally similar to or derived from morphine or other opiates. While these medications serve as effective painkillers, usage can result in several unwanted adverse side effects, including increased tolerance, addiction, overdose, respiratory distress and constipation.

[0004] Opioid and other substance addictions, for example, alcohol and nicotine addictions, contribute to millions of premature deaths each year. Although current therapies aimed at treating addiction can be effective, many substance users are unable to overcome their addiction, despite having a desire to quit.

[0005] Even after recent advances in pain medication development, there remains considerable need for new medications to manage pain with improved therapeutic profiles (e.g., robust therapeutic activity and reduced unwanted adverse side effects) compared to conventional opioid drugs. There is also a growing demand for new therapies to treat opioid use disorders (i.e. , opioid addictions) and other addictions (e.g., alcohol use disorder, and nicotine addiction).SUMMARY

[0006] The present technology comprises methods of reducing substance use disorders and / or pain in subjects in need thereof, comprising administering to the subject, a non-naturally occurring melanocortin analog.

[0007] In some embodiments, the present technology comprises a method of reducing a pain level in a subject in need thereof relative to a control, including administering to the subject a non-naturally occurring melanocortin analog of Formula (I): X1 -X2-X3-R1-R2-R3- R4-R5-R6-R7-R8-Y1 -Y2-Y3-Y4-Y5-Y6-Y7 (I), wherein: X1 is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D- norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D- ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D- cysteine (dCys); R2 is selected from the group consisting of Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4- amino-1 ,2,4,5-tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H- [1 ,2, 3]triazolo-[1 , 5-a][1 ,4]diazepin-6(5H)-one (Ata), 4-amino-1 ,4,5,6-tetrahydroazepino[4,3- b]indol-3(2H)-one (Aia), 2-aminotetraline-2-carboxylic acid (Ate), 1 -amino-4- phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid (APPC), octohydroindole-2 -carboxylic acid (Oic), 1 -am ino-1 -cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indoline-2 -carboxylic acid (loc), 1 -amino-1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')), and T-naphthylalanine (Nal(1')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D- valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b- Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 when each of R1 or R2 and R7 are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that: when R4 is dNal(2'), then R3 is His and R7 is Pro; when R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGIn, dTyr, R6 is Trp, and the non-naturally occurring melanocortin analog is not cyclized between Cys at R2 and Cys at R7 or (ii) R3 is His and either R6 is Nal(2') or the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between R2 and R7; when R4 is p(Br)dPhe, then the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and Cys or dCys at R7; when R4 is dPhe, then (i) R3 is not His, Pro, or absent, (ii) R3 is His and either R2 is Phe or dAla or R2 is Ala and X1 is Arg or dArg, (iii) R3 is Pro and (a) R2 is Trp, and R5 is not His or R6 is not Phe or (b) R2 is not Trp or Pro, and either R5 is not dNal(2') or Nal(2') or X1 and Y3 are not both present, or (iv) R3 is absent and R2 and R7 are notboth dPen; when R4 is p(CI)dPhe, then (i) R3 is selected from Aba, Aia, and Ata or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and dCys at R7, or (b) if R1 is Nle, and Y1Y2 is not dVal-dPro, then either X1 or Y3 is present; and when R2 is dAla, then R4 is dPhe and Y1 -Y7 are absent.

[0008] In some embodiments, the present technology comprises a use of a non- naturally occurring melanocortin analog for reducing a pain level in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0009] In some embodiments, the present technology comprises a method of treating, preventing, or reducing an addiction in a subject relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0010] In some embodiments, the present technology comprises a use of a non- naturally occurring melanocortin analog for treating, preventing, or reducing an addiction in a subject relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0011] In some embodiments, the present technology comprises a method of preventing or reducing a use of or dependence on an addictive substance in a subject relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0012] In some embodiments, the present technology comprises a use of a non- naturally occurring melanocortin analog for treating, preventing, or reducing a use of or dependence on an addictive substance in a subject relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0013] In some embodiments, the present technology comprises a method of treating or preventing an opioid use disorder (OUD) in a subject in need thereof relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0014] In some embodiments, the present technology comprises a use of a non- naturally occurring melanocortin analog for treating or preventing an OUD in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0015] In some embodiments, the present technology comprises a method of treating or preventing an alcohol use disorder (AUD) in a subject in need thereof relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0016] In some embodiments, the present technology comprises a use of a non- naturally occurring melanocortin analog for treating or preventing an AUD in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0017] In some embodiments, the method or the use includes reducing a dose used or consumed of an addictive substance, relative to a control.

[0018] In some embodiments, the method or the use includes reducing a dependency on an addictive substance, relative to a control.

[0019] In some embodiments, the method or the use includes reducing a frequency of an addictive substance use, relative to a control.

[0020] In some embodiments, the method or the use includes reducing a dose or dosage of a conventional medication used to treat an addiction, relative to a control.

[0021] In some embodiments, the present technology comprises a method of augmenting an effect of a conventional medication used to treat an addiction in a subject in need thereof, relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0022] In some embodiments, the present technology comprises a use of a non- naturally occurring melanocortin analog for augmenting an effect of a conventional medication used to treat an addiction in a subject in need thereof, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0023] In some embodiments, the present technology comprises a method of reducing or eliminating a need for a conventional medication used to treat an addiction in a subject in need thereof, relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0024] In some embodiments, the present technology comprises a use of a non- naturally occurring melanocortin analog for reducing or eliminating a need for a conventional medication used to treat an addiction in a subject in need thereof, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0025] In some embodiments, the treatment of the addiction is improved during or after administration of the non-naturally occurring melanocortin analog relative to treatment of the addiction using the conventional medication to treat the addiction alone.

[0026] In some embodiments, the conventional medication to treat the addiction is selected from the group consisting of buprenorphine, naltrexone, acamprosate, methadone, naloxone, nalmefene, xycodone, levo-alpha-acetylmethadol (LAAM), codeine, lofexidine, and a slow-release morphine.

[0027] In some embodiments, the present technology comprises a method of reducing a need for a hospitalization or rehabilitation associated with addiction or use of an addictive substance, relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0028] In some embodiments, the present technology comprises a use of a non- naturally occurring melanocortin analog for reducing a need for a hospitalization or rehabilitation associated with addiction or use of an addictive substance, relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0029] In some embodiments, the present technology comprises a method of preventing or reducing a withdrawal from an addictive substance in a subject, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0030] In some embodiments, the present technology comprises a use of a non- naturally occurring melanocortin analog for preventing or reducing a withdrawal from anaddictive substance in a subject, relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0031] In some embodiments, the present technology comprises a method of preventing or reducing a symptom associated with withdrawal from an addictive substance in a subject relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0032] In some embodiments, the present technology comprises a use of a non- naturally occurring melanocortin analog for preventing or reducing a symptom associated with withdrawal from an addictive substance in a subject, relative to a control, the non- naturally occurring melanocortin analog including a sequence of Formula (I).

[0033] In some embodiments, the symptom associated with withdrawal from an addictive substance is selected from the group consisting of pain, anxiety, depression, diarrhea, dizziness, fatigue, muscle aches, nausea, sleep problems, suicidal ideation, tremors, and visual disturbances.

[0034] In some embodiments, the subject has an addiction to an addictive substance or is susceptible to an addiction to an addictive substance.

[0035] In some embodiments, the subject has used or is using one or more addictive substances.

[0036] In some embodiments, the present technology comprises a method or the use wherein the addictive substance includes a prescription medication, a substance in an over- the-counter medication, a recreational substance, or an illegal substance.

[0037] In some embodiments, the addictive substance is selected from the group consisting of an opioid, a painkiller, a stimulant, a narcotic, an alcohol, a sedative, marijuana, a cannabis, a tetrahydrocannabinol (THC), a cannabidiol (CBD), and an inhalant.

[0038] In some embodiments, the opioid is selected from the group consisting of morphine, heroin, codeine, oxycodone, hydrocodone, and fentanyl.

[0039] In some embodiments, the stimulant is selected from the group consisting of caffeine, nicotine, methamphetamines, cocaine, and amphetamines.

[0040] In some embodiments, the sedative includes a barbiturate or a benzodiazepine.

[0041] In some embodiments, the barbiturate is selected from the group consisting of phenobarbital, methohexital, butalbital, pentobarbital, primidone, and amobarbital.

[0042] In some embodiments, the benzodiazepine is selected from the group consisting of alprazolam, lorazepam, clonazepam, diazepam, and temazepam.

[0043] In some embodiments, the sedative is selected from the group consisting of tranquilizers, xylazine, eszopiclone, zaleplon, zolpidem, and zopiclone.

[0044] In some embodiments, the inhalant is selected from the group consisting of aerosols, butanes, freon, helium, nitrous oxide, propane, and nitrites.

[0045] In some embodiments, the nicotine includes a tobacco chew, a nicotine pouch, or a smoking device.

[0046] In some embodiments, the smoking device is selected from the group consisting of cigarettes, electronic cigarettes, cigars, and vape products.

[0047] In some embodiments, the control includes the subject before administration of the non-naturally occurring melanocortin analog.

[0048] In some embodiments, the control includes the subject at baseline.

[0049] In some embodiments, the non-naturally occurring melanocortin analog is a melanocortin 4 receptor (MC4R) agonist.

[0050] In some embodiments, the MC4R agonist is a full MC4R agonist.

[0051] In some embodiments, the MC4R agonist is a partial MC4R agonist.

[0052] In some embodiments, the non-naturally occurring melanocortin analog is a MC3R antagonist.

[0053] In some embodiments, the MC3R antagonist is a full MC3R antagonist.

[0054] In some embodiments, the MC3R antagonist is a partial MC3R antagonist.

[0055] In some embodiments, the non-naturally occurring melanocortin analog does not have MC3R activity.

[0056] In some embodiments, the non-naturally occurring melanocortin analog includes a sequence according to Formula (I), wherein: X1 is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D- norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D- ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D- cysteine (dCys); R2 is selected from the group consisting of Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4- amino-1 ,2,4,5-tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H- [1 ,2, 3]triazolo-[ 1 , 5-a][ 1 ,4]diazepin-6(5H)-one (Ata), 4-amino-1 ,4,5,6-tetrahydroazepino[4,3- b]indol-3(2H)-one (Aia), 2-aminotetraline-2 -carboxylic acid (Ate), 1 -amino-4- phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid (APPC), octohydroindole-2 -carboxylic acid (Oic), 1 -am ino-1 -cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indoline-2 -carboxylic acid (loc), 1 - am ino-1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')), and T-naphthylalanine (Nal(1')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D- valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b- Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selectedfrom the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-naturally occurring melanocortin analog does not include a sequence selected from the group consisting of: Ac-Nle-c[Asp- Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 194); Ac-Nle-c[Asp-Pro-His- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 5); Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg- Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 10); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dPro (SEQ ID NO: 2); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 3); Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 4); Ac-Nle- c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 6); Ac-Nle-c[Asp-Phe- His-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 7); Ac-Nle-c[Asp-Hyp-dNal(2')-Arg- Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 9); Ac-Nle-Phe-Phe-c[Asp-Phe-His-dNal(2')-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 12); Ac-dArg-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 15); Ac-dLeu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 18); Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 20); Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 21 ); Ac-dNIe- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 24); Ac-dCys-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 28); Ac-dPhe-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 29); Ac-dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 30); dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 35); Tyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 36); Ac-Nle- c[Cys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 40); Ac-Nle-c[dCys-Pro- dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 41 ); Ac-Nle-c[Cys-Pro-dNal(2')-Arg- Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 42); Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-dCys]- dVal-dPro-NH2 (SEQ ID NO: 43); Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2(SEQ ID NO: 48); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 54); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 64); Ac-Nle- c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 68); Ac-Nle-c[Asp-Ala-dNal(2')- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 69); Ac-Nle-c[Asp-Leu-dNal(2')-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 76); Ac-Nle-c[Asp-Trp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 82); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 115); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 116); Ac-Nle-c[Asp- Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 117); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 118); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dHyp-NH2 (SEQ ID NO: 119); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Hyp-NH2 (SEQ ID NO: 120); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-dHyp-NH2 (SEQ ID NO: 121 ); Ac- Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-dVal-NH2 (SEQ ID NO: 122); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dHyp-dVal-NH2 (SEQ ID NO: 123); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-Hyp-Val-NH2 (SEQ ID NO: 124); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp- Val-NH2 (SEQ ID NO: 125); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-NH2 (SEQ ID NO: 126); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2 (SEQ ID NO: 127); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 128); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dPro-NH2 (SEQ ID NO: 129); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp- Lys]-Val-NH2 (SEQ ID NO: 130); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 131 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-NH2 (SEQ ID NO: 132); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-NH2 (SEQ ID NO: 133); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-dHyp-NH2 (SEQ ID NO: 134); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp- NH2 (SEQ ID NO: 135); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ ID NO: 136); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 137); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Gly-Gly-NH2 (SEQ ID NO: 138); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 139); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 140); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dArg-NH2 (SEQ ID NO: 143); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ ID NO: 144); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO: 145); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-NH2 (SEQ ID NO: 146); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-dPro-NH2 (SEQ ID NO: 147); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsp-dPro-NH2 (SEQ ID NO: 148); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 149); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn- dPro-NH2 (SEQ ID NO: 150); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-NH2 (SEQ ID NO: 151 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-NH2 (SEQ ID NO: 152); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-NH2 (SEQ ID NO: 153); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-dAsp-NH2 (SEQ ID NO: 154); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg- NH2 (SEQ ID NO: 155); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 156); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 157); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 158); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dLys-dPro-dVal-NH2 (SEQ ID NO: 159); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-Lys-dPro-NH2 (SEQ ID NO: 160); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]- dLys-dPro-NH2 (SEQ ID NO: 161 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Val-Pro- NH2 (SEQ ID NO: 162); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 164); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 164); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 165); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-dVal-NH2 (SEQ ID NO: 166); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dArg-dPro-dVal-NH2 (SEQ ID NO: 167); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 168); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]- Arg-dVal-dPro-NH2 (SEQ ID NO: 169); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dVal- dPro-NH2 (SEQ ID NO: 170); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-dPro-NH2 (SEQ ID NO: 171 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 172); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-NH2 (SEQ ID NO: 173); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-NH2 (SEQ ID NO: 174); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dTle-dTle-dPro-NH2 (SEQ ID NO: 175); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 176); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp- Lys]-dPro-dTle-NH2 (SEQ ID NO: 177); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dTle- NH2 (SEQ ID NO: 178); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dPro-NH2 (SEQ ID NO: 179); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 180); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 181 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQ ID NO: 182); Ac- Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2 (SEQ IDNO: 183); Ac-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 184); Ac-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 185); Ac-Nle- Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 186); Ac-Nle- c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 195); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 196); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-Trp-NH2 (SEQ ID NO: 203); Ac-Nle-c[Asp-Aba-dNal(2')-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 204); Ac-Nle-c[Asp-Aia-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 205); Ac-Nle-c[Asp-Ata-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 206); Ac- Nle-c[Asp-Cpe-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 240); Ac-Nle-c[Asp-Che- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 241 ); Ac-Nle-c[Asp-Oic-dNal(2')-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 242); Ac-Nle-c[Asp-Tic-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 244); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 245); Ac-Nle-c[Asp-His-dNal(2')-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 247); Ac-Nle-c[Asp-His-dNal(2')-cisPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 248); Ac-Nle-c[Asp-Pro-dNal(2')-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 250); Ac-Nle-c[Asp-Pro-dNal(2')-cisPro(guan)Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 251 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aba-Lys]-dVal-dPro-NH2 (SEQ ID NO: 253); Ac- Nle-c[Asp-Pro-dNal(2')-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 254); Ac-Nle-c[Asp-Glu- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 255); Ac-Nle-c[Asp-Glu-dNal(2')-Arg- Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 256); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly- Lys]-dVal-dPro-NH2 (SEQ ID NO: 259); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro- dPro-Lys-Asp-NH2 (SEQ ID NO: 260); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro- dPro-dLys-dAsp-NH2 (SEQ ID NO: 261 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro- dPro-dLys-dAsp-NH2 (SEQ ID NO: 263); Ac-Nle-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 273); Ac-Arg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 274); Ac-dArg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 275); Ac-dLeu-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 327); Ac-dNle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 328); Ac-dArg- c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 329); Ac-Arg-c[dPen-Pro- dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 330); Ac-dPhe-c[dPen-Pro-dNal(2')- Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 331 ); Ac-dTyr-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 332); Ac-Ala-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal- dPro-NH2 (SEQ ID NO: 333); Ac-dHis-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 334); Ac-His-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 335); Ac-dLys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 336); Ac- Lys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 337); Ac-Nle-c[dPen- Pro-dNal(2')-Arg-Trp-dPen]-dArg-dVal-dPro-NH2 (SEQ ID NO: 344); Ac-Nle-c[dPen-Pro- dNal(2')-Arg-Trp-dPen]-dLys-dVal-dPro-NH2 (SEQ ID NO: 345); Ac-Nle-c[dPen-Pro- dNal(2')-Arg-Trp-dPen]-dArg-dPro-NH2 (SEQ ID NO: 346); Ac-Nle-c[dPen-Pro-dNal(2')- Arg-Trp-dPen]-dLys-dPro-NH2 (SEQ ID NO: 347); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp- dPen]-dVal-dHyp-NH2 (SEQ ID NO: 348); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dTle- dPro-NH2 (SEQ ID NO: 349); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-Gly-dPen]-dVal-dPro- NH2 (SEQ ID NO: 350); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 103); Ac-Nle-c[Asp-loc-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 243); Ac- Nle-c[Cys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 44); Ac-Nle-c[dCys-dNal(2')- Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 45); Ac-Nle-c[Cys-dNal(2')-Arg-Trp-dCys]-dVal- dPro-NH2 (SEQ ID NO: 46); Ac-Nle-c[dCys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 47); Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 56); Ac-Nle- c[dPen-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 62); Ac-Nle-c[Asp-dTrp- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 83); Ac-Nle-c[dPen-Ala-dNal(2')-Arg- Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 338); Ac-Nle-c[dPen-Leu-dNal(2')-Arg-Trp-dPen]- dVal-dPro-NH2 (SEQ ID NO: 339); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 223); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 464); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465); Ac- dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466); Ac-His-c[Asp- His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467); Ac-dHis-c[Asp-His- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468); Ac-Nle-Nle-c[Asp-His-p(F)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469); Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 470); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal- dVal-dPro-NH2 (SEQ ID NO: 474); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal- dPro-NH2 (SEQ ID NO: 475); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 476); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ IDNO: 477); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 478); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481 ); Ac-Lys- c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482); Ac-dLys-c[Asp-His- p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483); Ac-His-c[Asp-His-p(F)dPhe-Arg- Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 484); Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 485); Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 463); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 462); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 479); Ac- Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 473); Ac-dArg- c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480); Ac-Nle-c[Asp-Gln- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 491 ); Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489); Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 493); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 444); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 445); Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495); Ac- Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487); Ac-Nle-c[Asp- dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488); Ac-Nle-c[Asp-dTrp- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494); Ac-Nle-c[Asp-His-p(F)dPhe-Arg- dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471 ); Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]- dVal-dPro-NH2 (SEQ ID NO: 432); Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 217); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 222); Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 535); Ac- Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 538); Ac-Nle-Nle- c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 545); Ac-Nle-c[Asp-His- p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 546); Ac-Nle-c[Asp-His-p(Br)dPhe- Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 547); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg- Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 548); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]- dTle-dTle-dVal-NH2 (SEQ ID NO: 549); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro- dVal-dPro-NH2 (SEQ ID NO: 551 ); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro- NH2 (SEQ ID NO: 552); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 553); Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:555); Ac-Nle-c[Asp-dHis-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 562); Ac- Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 563); Ac-Nle-c[Asp- dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 564); Ac-Nle-c[Asp-Bip- p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 565); Ac-Nle-c[Asp-dGln-p(Br)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568); Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 569); Ac-Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 570); Ac-Nle-c[Asp-Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571 ); Ac-Nle-c[Asp-dTyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572); Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539); Ac-dHis- c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 544); Ac-dHis-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 561 ); Ac-dArg-c[Asp-His-p(Br)dPhe- Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 556); Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 542); Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 560); Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 543); Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557); Ac- Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541 ); Ac-Nle-c[Asp- His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 550); Ac-Lys-c[Asp- His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 558); Ac-Arg-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540); Ac-Nle-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 554); Ac-Nle-c[Asp-His-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]- dVal-dPro-NH2 (SEQ ID NO: 418); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621 ); Ac-Nle-c[Asp-His-dPhe-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 228); Ac-Nle-c[Asp-His-dPhe-cisPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 229); Ac-Nle-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 380); Ac-Nle- c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 398); Ac-Nle-c[Asp-Trp- Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401 ); Ac-Nle-Nle-c[Asp-Pro-dPhe- Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639); Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')- Lys]-dVal-dPro-NH2 (SEQ ID NO: 430); Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal- dPro-NH2 (SEQ ID NO: 431 ); Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 225); Ac-Nle-c[dPen-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 326); Ac-Nle-c[Asp-Pro-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 297); Ac-Nle-c[Asp- Pro-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215); Ac-Nle-c[Asp-Phe- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 525); Ac-Nle-c[Asp-dPhe-p(CI)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 526); Ac-Nle-c[Asp-Bip-p(CI)dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 527); Ac-Nle-c[Asp-Trp-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 531 ); Ac-Nle-c[Asp-Tyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533); Ac-Nle-c[Asp-dTyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534); Ac-Nle-c[Asp-dTrp-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532); Ac-Nle- c[dCys-His-p(CI)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498); Ac-Nle-c[Cys-His- p(CI)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 497); Ac-Nle-c[Asp-His-p(CI)dPhe- Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 509); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg- Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 510); Ac-Nle-c[Asp-His-p(CI)dPhe-His-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 508); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 220); Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 507); Ac-Ala-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517); Ac-Ala-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 500); Ac-Nle- Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516); Ac-Nle- c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514); Ac-Nle-c[Asp-dGln- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 530); Ac-Arg-c[Asp-dAla-His-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 268); Ac-Nle-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 378); Ac-dArg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 379); Ac-Nle-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 266); Ac-Arg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 267); Ac-Arg-c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 269); Ac- dArg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 270); Ac-Arg- c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-NH2 (SEQ ID NO: 282); and Ac-Arg-c[Asp-dAla-His- dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 283).

[0057] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence according to Formula (IA): X1 -X2-X3-R1-R2-R3-R4-R5-R6-R7-R8-Y1 -Y2-Y3-Y4 (IA), wherein: X1 isabsent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D-norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D-cysteine (dCys); R2 is selected from the group consisting of Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2- aminotetraline-2-carboxylic acid (Ate), octohydroindole-2-carboxylic acid (Oic), 1-amino-1 - cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino- 1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of dPhe, para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is Arg or His; R6 is selected from the group consisting of Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')), and T- naphthylalanine (Nal(1 ')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys,R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp andR7 is dLys; provided that: when R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGIn, dTyr, R6 is Trp, and the non-naturally occurring melanocortin analog is not cyclized between Cys at R2 and Cys at R7 or (ii) R3 is His and either R6 is Nal(2') or the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between R2 and R7, where R2 and R7 are the same; when R4 is p(Br)dPhe, then the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and Cys or dCys at R7; when R4 is dPhe, then (i) R3 is not His, Pro, or absent, (ii) R3 is His and either R2 is Phe or dAla or R2 is Ala and X1 is Arg or dArg, (iii) R3 is Pro and (a) R2 is Trp, and R5 is not His or R6 is not Phe or (b) R2 is not T rp or Pro, and either R5 is not dNal(2') or N a I (2' ) or X1 and Y3 are not both present, or (iv) R3 is absent and R2 and R7 are not both dPen; and when R4 is p(CI)dPhe, then (i) R3 is selected from Aba, Aia, and Ata or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and dCys at R7, or (b) if R1 is Nle, and Y1Y2 is not dVal-dPro, then either X1 or Y3 is present.

[0058] In some embodiments, the non-naturally occurring melanocortin analog includes a sequence according to Formula (IA), wherein: X1 is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D- norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D- ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D- cysteine (dCys); R2 is selected from the group consisting of Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2-aminotetraline- 2-carboxylic acid (Ate), octohydroindole-2 -carboxylic acid (Oic), 1 -amino-1 - cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino- 1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of dPhe, para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is Arg or His; R6 is selectedfrom the group consisting of Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')), and T- naphthylalanine (Nal(1 ')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-naturally occurring melanocortin analog does not include a sequence selected from the group consisting of: Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 223); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 464); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465); Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466); Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467); Ac-dHis- c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468); Ac-Nle-Nle-c[Asp-His- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469); Ac-Nle-c[Asp-His-p(F)dPhe-His- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal- dVal-dVal-dPro-NH2 (SEQ ID NO: 474); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro- dVal-dPro-NH2 (SEQ ID NO: 475); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro- NH2 (SEQ ID NO: 476); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 477); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 478); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481 ); Ac- Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482); Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483); Ac-His-c[Asp-His-p(F)dPhe- Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 484); Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 485); Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 463); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 462); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 479); Ac- Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 473); Ac-dArg- c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480); Ac-Nle-c[Asp-Bip- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489); Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]- dVal-dPro-NH2 (SEQ ID NO: 444); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro- NH2 (SEQ ID NO: 445); Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495); Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487); Ac- Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488); Ac-Nle-c[Asp- dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494); Ac-Nle-c[Asp-His- p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471 ); Ac-Nle-c[Cys-Pro- p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432); Ac-Nle-c[dCys-His-p(F)dPhe- Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 460); Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 217); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 222); Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 535); Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 538); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 545); Ac- Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 546); Ac-Nle-c[Asp- His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 547); Ac-Nle-c[Asp-His- p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 548); Ac-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 549); Ac-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 551 ); Ac-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 552); Ac-Nle-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 553); Ac-Ala-c[Asp-His-p(Br)dPhe- Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 555); Ac-Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 563); Ac-Nle-c[Asp-dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 564); Ac-Nle-c[Asp-Bip-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 565); Ac-Nle-c[Asp-dGln-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568); Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 569); Ac- Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 570); Ac-Nle-c[Asp- Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571 ); Ac-Nle-c[Asp-dTyr- p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572); Ac-dArg-c[Asp-His-p(Br)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539); Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 544); Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 561 ); Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 556); Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 542); Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 560); Ac- His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 543); Ac-dLys-c[Asp- His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559); Ac-Arg-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557); Ac-Lys-c[Asp-His-p(Br)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541 ); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]- dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 550); Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 558); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 540); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro- NH2 (SEQ ID NO: 554); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 418); Ac-Nle- c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621 ); Ac-Nle-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639); Ac-Nle-c[dPen-dPhe-Arg-Trp- dPen]-dVal-dPro-NH2 (SEQ ID NO: 326); Ac-Nle-c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 398); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401 ); Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 225); Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 430); Ac-Nle- c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 431 ); Ac-Nle-c[Asp-Ala-His- dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 380); Ac-Nle-c[Asp-Pro-p(CI)dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215); Ac-Nle-c[Asp-Phe-p(CI)dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 525); Ac-Nle-c[Asp-dPhe-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 526); Ac-Nle-c[Asp-Bip-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 527); Ac-Nle-c[Asp-Trp-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 531 ); Ac-Nle-c[Asp-Tyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533); Ac-Nle-c[Asp- dTyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534); Ac-Nle-c[Asp-dTrp- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532); Ac-Nle-c[dCys-His-p(CI)dPhe- Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498); Ac-Nle-c[Cys-His-p(CI)dPhe-Arg-Trp- Cys]-dVal-dPro-NH2 (SEQ ID NO: 497); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-dNal(2')-Lys]- dVal-dPro-NH2 (SEQ ID NO: 509); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Nal(2')-Lys]-dVal-dPro- NH2 (SEQ ID NO: 510); Ac-Nle-c[Asp-His-p(CI)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 508); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 220); Ac- Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 507); Ac-Ala- c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517); Ac-Ala-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 500); Ac-Nle-Nle-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516); and Ac-Nle-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514).

[0059] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula (IB): X1 -X2-X3-R1-R2-Pro-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7 (IB), wherein: X1 is absent or norleucine (Nle); X2 is absent or Nle; X3 is absent or Nle; R1 is selected from the group consisting of Nle, D-norleucine (dNIe), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis), ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D- phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R2 is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), cysteine (Cys), D-cysteine (dCys), and D-penicillamine (dPen); R4 is dPhe or para-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, and T-naphthylalanine (Nal(1 ')); R7 is selected from the group consisting of Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro,b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2 and R7 when each of R2 and R7 are independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2 and R7 when R2 is Asp or dAsp and R7 is Lys, dLys, or Orn; provided that: when R4 is p(F)dPhe, then the non-naturally occurring melanocortin analog is not cyclized between Cys at R2 and Cys at R7; and when R4 is dPhe and one or more of X1 , X2, and X3 is present, then Y3-Y7 are absent.

[0060] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula (IB), wherein: X1 -X2-X3-R1 -R2-Pro-R4-R5-R6-R7-R8-Y1 -Y2-Y3-Y4-Y5-Y6-Y7 (IB), wherein: X1 is absent or norleucine (Nle); X2 is absent or Nle; X3 is absent or Nle; R1 is selected from the group consisting of Nle, D-norleucine (dNIe), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), D- histidine (dHis), ornithine (Orn), D-omithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R2 is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), cysteine (Cys), D-cysteine (dCys), and D-penicillamine (dPen); R4 is dPhe or para-fluoro- D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, and 1 '-naphthylalanine ( Nal( 1 ')); R7 is selected from the group consisting of Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3- Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D- asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal,dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2 and R7 when each of R2 and R7 are independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2 and R7 when R2 is Asp or dAsp and R7 is Lys, dLys, or Orn; provided that the non-naturally occurring melanocortin analog does not include a sequence of: Ac- Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432); or Ac-Nle-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639).

[0061] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula(IC): X1 -X2-R1 -R2-Pro-dPhe-R5-R6-R7-Y1-Y2-Y3-Y4 (IC), wherein: X1 is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent or Nle; R1 is selected from the group consisting of aspartic acid (Asp), cysteine (Cys), and D-cysteine (dCys); R2 is selected from the group consisting of tryptophan (Trp), phenylalanine (Phe), D- phenylalanine (dPhe), histidine (His), D-histidine (dHis), tyrosine (Tyr), and D-tyrosine (dTyr); R5 is Arg; R6 is selected from the group consisting of Trp, 2'-D-naphthylalanine (dNal(2')), 2'-naphthylalanine (Nal(2')), and T-naphthylalanine (Nal(1')); R7 is selected from the group consisting of Lys, Cys, and dCys; Y1 is absent or is selected from the group consisting of D-valine (dVal), D-tert-leucine (dTle), dArg, and dLys; Y2 is absent or is selected from the group consisting of dVal, dPro, and D-hydroxyproline (dHyp); Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 and R7 when both of R1 and R7 are independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R1 and R7 when R1 is Asp and R7 is Lys;

[0062] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula(ID): X1 -R1-R2-R3-p(CI)dPhe-Arg-Trp-R7-Y1 -Y2-Y3-Y4 (ID), wherein: X1 is absent or norleucine (Nle); R1 is selected from the group consisting of Nle, arginine (Arg), D-arginine(dArg), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); R2 is aspartic acid (Asp) or D-cysteine (dCys); R3 is selected from the group consisting of His, 4-amino- 1 ,2,4,5-tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H-[1 ,2,3]triazolo-[1 ,5- a][1 ,4]diazepin-6(5H)-one (Ata), and 4-amino-1 ,4,5,6-tetrahydroazepino[4,3-b]indol-3(2H)- one (Aia); R7 is Lys or dCys; Y1 is selected from the group consisting of D-valine (dVal), D- proline (dPro), and D-tert-leucine (dTle); Y2 is absent or is selected from the group consisting of dVal, dPro, and dTle; Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2 and R7 when both of R2 and R7 are dCys; and a lactam bridge between R2 and R7 when R2 is Asp and R7 is Lys; provided that when R3 is His and R1 is Nle, then (i) Y1 Y2 is dVal-dPro, X1 is absent, and the non-naturally occurring melanocortin analog is cyclized through a disulfide bond, or (b) Y1 Y2 is not dVal- dPro and either X1 or Y3 is present.

[0063] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula (ID), wherein: X1 is absent or norleucine (Nle); R1 is selected from the group consisting of Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), and D- histidine (dHis); R2 is aspartic acid (Asp) or D-cysteine (dCys); R3 is selected from the group consisting of His, 4-amino-1 ,2,4,5-tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8- dihydro-4H-[1 ,2,3]triazolo-[1 ,5-a][1 ,4]diazepin-6(5H)-one (Ata), and 4-amino-1 ,4,5,6- tetrahydroazepino[4,3-b]indol-3(2H)-one (Aia); R7 is Lys or dCys; Y1 is selected from the group consisting of D-valine (dVal), D-proline (dPro), and D-tert-leucine (dTle); Y2 is absent or is selected from the group consisting of dVal, dPro, and dTle; Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2 and R7 when both of R2 and R7 are dCys; and a lactam bridge between R2 and R7 when R2 is Asp and R7 is Lys; provided that the non-naturally occurring melanocortin analog does not include a sequence selected from the group consisting of: Ac-Nle-c[Asp-His-p(CI)dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 220); Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 507); Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro- NH2 (SEQ ID NO: 514); and.

[0064] In some embodiments, an N-terminus of the non-naturally occurring melanocortin analog is modified by an acyl group.

[0065] In some embodiments, the acyl group is an acetyl group.

[0066] In some embodiments, an N-terminus of the non-naturally occurring melanocortin analog is not modified.

[0067] In some embodiments, a C-terminus of the non-naturally occurring melanocortin analog is modified by an amide group.

[0068] In some embodiments, a C-terminus of the non-naturally occurring melanocortin analog is not modified.

[0069] In some embodiments, Y1-Y2 are present and Y3- Y8 are absent.

[0070] In some embodiments, Y1 is D-valine and Y2 is D-proline.

[0071] In some embodiments, the present technology comprises a method or a use, w wherein Y1 is D-tert-leucine and Y2 is D-proline.

[0072] In some embodiments, R4 is dNal(2').

[0073] In some embodiments, the sequence of Formula (I) is: Ac-Nle-c[Asp-His- dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 8), wherein c represents cyclization through R2 and R8 via a lactam bond.

[0074] In some embodiments, R4 is Phe or dPhe.

[0075] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 291 ); Ac-Nle-c[Asp-Pro-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 294); Ac-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 295; E2); and Ac-Nle-c[Asp- Pro-His-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 296). wherein c represents cyclization through R2 and R7 via a lactam bond.

[0076] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-dLeu-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:298); Ac-dAla-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 299); Ac- Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 300); Ac-dNle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 301 ); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 302); Ac-dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 303); Ac-dTyr-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 304); Phe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 305); His-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 306); Trp-c[Asp-Pro-dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 307); dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 308); dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 309); dTrp-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 310); Ac-Arg-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 311 ); Ac-dLys-c[Asp-Pro-dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 312); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 313); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 314); Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 315); Ac- Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 316); and Ac-dOm-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 317), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0077] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Cys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 318); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 319); Ac- Nle-c[dPen-Pro-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 320); Ac-Nle-c[dCys- Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 321 ); Ac-Nle-c[Asp-Pro-dPhe-Arg- Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 322); and Ac-Nle-c[Cys-dPhe-Arg-Trp-Pen]-dVal- dPro-NH2 (SEQ ID NO: 324), wherein c represents cyclization through R2 and R7 via a disulfide bond.

[0078] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 351 ); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2(SEQ ID NO: 352); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp- NH2 (SEQ ID NO: 353), wherein c represents cyclization through R2 and R8 via a lactam bond.

[0079] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 354); Ac-Nle-c[Asp-Leu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 355); Ac-Nle- c[Asp-Cpe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 358); Ac-Nle-c[Asp-Che-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 359); Ac-Nle-c[Asp-Oic-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 360); Ac-Nle-c[Asp-loc-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 361 ); Ac-Nle-c[Asp-Tic-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 362); Ac-Nle- c[Asp-Hyp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 364); Ac-Nle-c[Asp-Phe-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 366); Ac-Nle-c[Asp-dPhe-dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 367); Ac-Nle-c[Asp-Bip-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 368); Ac-Nle-c[Asp-dGln-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 371 ); Ac-Nle-c[Asp-Trp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 372); Ac-Nle- c[Asp-dTrp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 373); Ac-Nle-c[Asp-Tyr-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 374); Ac-Nle-c[Asp-dTyr-dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 375); Ac-Nle-c[Asp-Aba-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 198); Ac-Nle-c[Asp-Aia-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 207); Ac-Nle-c[Asp-Ata-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 208); Ac-Nle-c[Asp-Atc- dPhe-Arg-Trp-Lys]-d al-dPro-NH2 (SEQ ID NO: 212); Ac-Nle-c[Asp-APC-dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 213); and Ac-Nle-c[Asp-APPC-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 214), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0080] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Arg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 281 ); Ac-Arg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 381 ); and Ac- dArg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 382), wherein c represents cyclization through R1 and R7 via a lactam bond.

[0081] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 226); Ac-Nle-c[Cys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 383); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 384); Ac- Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 385); Ac-Ala-c[Asp- Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 386); Ac-Lys-c[Asp-Trp-Pro- dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 387); Ac-dLys-c[Asp-Trp-Pro-dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 388); Ac-Arg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 389); Ac-dArg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 390); Ac-dHis-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 391 ); Ac-His-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 392); Ac-Nle- Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 393); Ac-Nle-c[Asp- Trp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 394); Ac-Nle-c[Asp-Trp-Leu-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 395); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(1 ']- Lys]-dVal-dPro-NH2 (SEQ ID NO: 399); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-dNal(2')-Lys]- dVal-dPro-NH2 (SEQ ID NO: 403); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro- NH2 (SEQ ID NO: 404); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 405); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 406); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 407); Ac- Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 408); Ac-Nle-c[Asp- Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 409); Ac-Nle-c[Asp-Trp-Pro- dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 410); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp- Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 411 ); Ac-Nle-c[Asp-Phe-Pro-dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 412); Ac-Nle-c[Asp-His-Pro-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 413); Ac-Nle-c[Asp-Tyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 414); Ac-Nle-c[Asp-dPhe-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 415); Ac-Nle-c[Asp-dHis-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 416); and Ac-Nle-c[Asp-dTyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 417), wherein c represents cyclization through R1 and R7 via a lactam bond or a disulfide bond.

[0082] In some embodiments, the sequence of any one of Formulae (l)-(ID) is: Ac-Nle- c[Asp-Hyp-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 419), wherein c represents cyclization through R2 and R8 via a lactam bond.

[0083] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-Phe-Phe-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 421 ); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 422); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 423); and Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 424), wherein c represents cyclization through R1 and R7 via a lactam bond.

[0084] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 187); Ac-Nle-c[Asp-Pro-dPhe-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 233); Ac- Nle-c[Asp-Pro-dPhe-Arg-Aba-Lys]-dVal-dPro-NH2 (SEQ ID NO: 234); Ac-Nle-c[Asp-Pro- dPhe-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 235); Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(1 ')- Lys]-dVal-dPro-NH2 (SEQ ID NO: 427); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Phe-Lys]-dVal- dPro-NH2 (SEQ ID NO: 429), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0085] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 218); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 433); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 434); Ac- Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 435); Ac-dArg-c[Asp- Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 436); Ac-Arg-c[Asp-Pro- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 437); Ac-Lys-c[Asp-Pro-p(F)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 438); Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 439); Ac-His-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 440); Ac-dHis-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 441 ); Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 442); Ac-Nle-c[Asp-Pro-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 443); Ac- Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 446); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 447); Ac-Nle- c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 448); Ac-Nle-c[Asp- Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 449); Ac-Nle-Nle-c[Asp-Pro- p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 450); Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe- Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 451 ); Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp- Lys]-dTle-dPro-NH2 (SEQ ID NO: 452); Ac-dArg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 453); Ac-Arg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 454); Ac-Lys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 455); Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 456); Ac-His- c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 457); Ac-dHis-c[Asp-Pro- p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 458); Ac-Nle-c[Cys-His-p(F)dPhe-Arg- Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 459); Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-Cys]- dVal-dPro-NH2 (SEQ ID NO: 460); Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro- NH2 (SEQ ID NO: 461 ); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 472); Ac-Nle-c[Asp-dGln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 492); and Ac-Nle-c[Asp-dTyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 496), wherein c represents cyclization through R2 and R7 via a lactam bond or a disulfide bond.

[0086] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Aba-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 209); Ac-Nle-c[Asp-Aia-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 210); Ac-Nle-c[Asp-Ata-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 211 ); Ac-Nle- c[dCys-His-p(CI)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 499); Ac-dArg-c[Asp- His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 501 ); Ac-Arg-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 502); Ac-Lys-c[Asp-His-p(CI)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 503); Ac-dLys-c[Asp-His-p(CI)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 504); Ac-His-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 505); Ac-dHis-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 506); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 511 ); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 512); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 513); Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 515); Ac-dArg-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 518); Ac-Arg-c[Asp- His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 519); Ac-Lys-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 520); Ac-dLys-c[Asp-His-p(CI)dPhe- Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 521 ); Ac-His-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 522); and Ac-dHis-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 523), wherein c represents cyclization through R2 and R7 via a lactam bond or a disulfide bond.

[0087] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 536); or Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 537), wherein c represents cyclization through R2 and R7 via a disulfide bond.

[0088] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 573); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 574); Ac-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 575); Ac-Nle-c[Asp-Pro-dPhe- Arg-Trp-Lys]-Val-NH2 (SEQ ID NO: 576); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 577); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 578); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dArg-NH2 (SEQ ID NO: 579); Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 580); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp- Lys]-Arg-NH2 (SEQ ID NO: 581 ); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 582); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 583); Ac- Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 584); Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-Lys-Val-Pro-NH2 (SEQ ID NO: 585); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp- Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 586); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys- dVal-dPro-NH2 (SEQ ID NO: 587); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 588); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 589); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 590); Ac- Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 591 ); Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dTle-dTle-dPro-NH2 (SEQ ID NO: 592); Ac-Nle-c[Asp-Pro-dPhe-Arg- Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 593); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dTle-NH2 (SEQ ID NO: 594); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dPro- NH2 (SEQ ID NO: 595); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 596); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 597); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQ ID NO: 598); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 599); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Trp-NH2 (SEQ ID NO: 600); Ac-Nle-c[Asp- Pro-dPhe-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 601 ); Ac-Nle-c[Asp-Pro-dPhe- Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ ID NO: 602); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asp- NH2 (SEQ ID NO: 603); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dHyp-NH2 (SEQ ID NO: 604); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ ID NO: 605); Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 606); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]- Asn-dPro-NH2 (SEQ ID NO: 607); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Hyp-NH2 (SEQ ID NO: 608); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 609); Ac-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-Gly-Gly-NH2 (SEQ ID NO: 610); Ac-Nle-c[Asp-Pro-dPhe-Arg- Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO: 611 ); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsn- dPro-NH2 (SEQ ID NO: 612); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asn-NH2 (SEQ ID NO: 613); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsp-NH2 (SEQ ID NO: 614); Ac-Nle-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 615); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp- Lys]-Lys-dPro-NH2 (SEQ ID NO: 616); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 617); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-NH2 (SEQ ID NO: 618); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-OH (SEQ ID NO: 619); Ac-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 620); Ac-Nle-c[dAsp-Pro-dPhe- Arg-Trp-dLys]-dPro-dVal-NH2 (SEQ ID NO: 622); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]- pPro-p2Val-NH2 (SEQ ID NO: 623); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-pPro-p3Val-NH2 (SEQ ID NO: 624); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-p2Val-pPro-NH2 (SEQ ID NO: 625); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-p3Val-pPro-NH2 (SEQ ID NO: 626); and Ac- Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-pPro-pPro-NH2 (SEQ ID NO: 627), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0089] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 628); Ac-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 629); and Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 630), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0090] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 631 ); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 632); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 633); Ac-His- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 634); Ac-dHis-c[Asp-Pro-dPhe- Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 635); Ac-Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 636); Ac-dOrn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal- dPro-NH2 (SEQ ID NO: 637); Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 638); Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 640); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 641 ); Ac-Arg-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 642); Ac-Lys-c[Asp-Pro-dPhe-Arg- Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 643); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 644); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 645); and Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 646), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0091] In some embodiments, the non-naturally occurring melanocortin analog includes any one of SEQ ID NOs: 8, 187, 198, 207-218, 226, 231 -235, 281 , 291 , 294-296, 298-322, 324, 351 -355, 358-362, 364, 366-368, 371-375, 381 -395, 399, 403-417, 419, 421 - 425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646.

[0092] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 187, 212, 218, 226, 291 , 295, 298-322, 324, 351-355, 358-360, 362, 364, 366-368, 371 -375, 381-395, 399, 403-417, 419, 421 -425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573- 598, 600-646.

[0093] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 187, 218, 231 -235, 291 , 295, 298-322, 351-353, 425, 427, 429, 433-443, 446-458, 573-599, 600-620, 622-646.

[0094] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 226, 383-393, 399, 403-417.

[0095] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 209-211 , 499, 501 -506, 511 -513, 515, 518-523.

[0096] In some embodiments, the non-naturally occurring melanocortin analog is present in a pharmaceutical composition.

[0097] In some embodiments, the pharmaceutical composition includes one or more pharmaceutically acceptable excipients and / or carriers.

[0098] In some embodiments, the one or more pharmaceutically acceptable excipients and / or carriers of the pharmaceutical composition include water.

[0099] In some embodiments, the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 5 mg / kg to about 20 mg / kg administered once a day for about 5 days to about 10 days; (ii) at a second dose of about 10 mg / kg to about 40 mg / kg administered once a day after administration of the first dose for about 5 days to about 10 days; (iii) at a third dose of about 5 mg / kg to about 30 mg / kg administered twice a day after administration of the second dose for at least about 5 days to about 10 days.

[0100] In some embodiments, the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 5 mg / kg administered once a day for about 7 days; (ii) at a second dose of about 15 mg / kg administered once a day after administration of the first dose for about 7 days; (iii) at a third dose of about 10 mg / kg administered twice a day after administration of the second dose for at least about 7 days.

[0101] In some embodiments, the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 10 mg / kg administered once a day for about 7 days; (ii) at a second dose of about 20 mg / kg administered once a day after administration of the first dose for about 7 days; (iii) at a third dose of about 15 mg / kg administered twice a day after administration of the second dose for at least about 7 days.

[0102] In some embodiments, the present technology comprises a method or the use wherein the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 15 mg / kg administered once a day for about 7 days; (ii) at a second dose of about 25 mg / kg administered once a day after administration of the first dose for about 7 days; (iii) at a third dose of about 20 mg / kg administered twice a day after administration of the second dose for at least about 7 days.

[0103] In some embodiments, the non-naturally occurring melanocortin analog is administered at a dose of about 0.5 mg / kg to about 10 mg / kg per body weight of the subject once daily.

[0104] In some embodiments, the non-naturally occurring melanocortin analog is administered at a dose of about 1 mg / kg or 3 mg / kg per body weight of the subject once daily.

[0105] In some embodiments, the non-naturally occurring melanocortin analog is administered at a dose of about 0.1 mg to about 100 mg once daily.

[0106] In some embodiments, the non-naturally occurring melanocortin analog is administered at a dose of about 10 mg or about 50 mg once daily.

[0107] In some embodiments, the non-naturally occurring melanocortin analog is administered via intraperitoneal, intravenous, parenteral, subcutaneous, intramuscular, intracerebroventricular, intranasal, or oral administration.

[0108] In some embodiments, the non-naturally occurring melanocortin analog crosses a blood-brain-barrier of a subject.

[0109] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 8, 187, 198, 207-218, 226, 231 -235, 281 , 291 , 294-296, 298-322, 324, 351 -355, 358-362, 364, 366-368, 371-375, 381 -395, 399, 403-417, 419, 421 -425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511 -513, 515, 518-523, 536-537, 573-599, 600-620, 622-646 and is administered at least once daily in an amount ranging from 0.001 mg / kg to 25 mg / kg per body weight of the subject.

[0110] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 8, 187, 198, 207-218, 226, 231 -235, 281 , 291 , 294-296, 298-322, 324, 351 -355, 358-362, 364, 366-368, 371-375, 381 -395, 399, 403-417, 419, 421 -425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511 -513, 515, 518-523, 536-537, 573-599, 600-620, 622-646 and is administered at least once daily in an amount ranging from 0.5 mg / kg to 10 mg / kg per body weight of the subject.

[0111] In some embodiments, the non-naturally occurring melanocortin analog is administered to a subject for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, or 5 years.

[0112] In some embodiments, the non-naturally occurring melanocortin analog is administered to a subject for 1 day, 5 days, 7 days, 14 days, 21 days, 28 days, 35 days, 40 days, 45 days, 50 days, 60 days, 75 days, 90 days, 100 days, 110 days, or 120 days.

[0113] In some embodiments, the present technology comprises a method of reducing a pain level in a subject in need thereof relative to a control, including administering to the subject a non-naturally occurring melanocortin analog of Formula (I): X1 -X2-X3-R1-R2-R3- R4-R5-R6-R7-R8-Y1 -Y2-Y3-Y4-Y5-Y6-Y7 (I), wherein: X1 is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D- norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D- ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D- cysteine (dCys); R2 is selected from the group consisting of Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4- amino-1 ,2,4,5-tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H- [1 ,2, 3]triazolo-[1 , 5-a][1 ,4]diazepin-6(5H)-one (Ata), 4-amino-1 ,4,5,6-tetrahydroazepino[4,3- b]indol-3(2H)-one (Aia), 2-aminotetraline-2 -carboxylic acid (Ate), 1 -amino-4- phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid(APPC), octohydroindole-2 -carboxylic acid (Oic), 1 -am ino-1 -cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indoline-2 -carboxylic acid (loc), 1 - am ino-1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')), and T-naphthylalanine (Nal(1')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D- valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b- Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 when each of R1 or R2 and R7 are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that: when R4 is dNal(2'), then R3 is His and R7 is Pro; when R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGIn, dTyr, R6 is Trp, and the non-naturally occurring melanocortin analog is not cyclized between Cys at R2 and Cys at R7 or (ii) R3 is His and either R6 is Nal(2') or the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between R2 and R7; when R4 is p(Br)dPhe, then the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and Cys or dCys at R7; when R4 is dPhe, then (i) R3 is not His, Pro, or absent, (ii) R3 is His and either R2 is Phe or dAla or R2 is Ala and X1 is Arg or dArg, (iii) R3 is Pro and (a) R2 is Trp,and R5 is not His or R6 is not Phe or (b) R2 is not Trp or Pro, and either R5 is not dNal(2') or Nal(2') or X1 and Y3 are not both present, or (iv) R3 is absent and R2 and R7 are not both dPen; when R4 is p(CI)dPhe, then (i) R3 is selected from Aba, Aia, and Ata or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and dCys at R7, or (b) if R1 is Nle, and Y1 Y2 is not dVal-dPro, then either X1 or Y3 is present; and when R2 is dAla, then R4 is dPhe and Y1 -Y7 are absent.

[0114] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for reducing a pain level in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0115] In some embodiments, the present technology comprises a method of treating, preventing, or reducing an addiction in a subject relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0116] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for treating, preventing, or reducing an addiction in a subject relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0117] In some embodiments, the present technology comprises a method of preventing or reducing a use of or dependence on an addictive substance in a subject relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0118] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for treating, preventing, or reducing a use of or dependence on an addictive substance in a subject relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0119] In some embodiments, the present technology comprises a method of treating or preventing an opioid use disorder (OUD) in a subject in need thereof relative to a control,including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0120] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for treating or preventing an OUD in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0121] In some embodiments, the present technology comprises a method of treating or preventing an alcohol use disorder (AUD) in a subject in need thereof relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0122] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for treating or preventing an AUD in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0123] In some embodiments, the method or the use includes reducing a dose used or consumed of an addictive substance, relative to a control.

[0124] In some embodiments, the method or the use includes reducing a dependency on an addictive substance, relative to a control.

[0125] In some embodiments, the method or the use includes reducing a frequency of an addictive substance use, relative to a control.

[0126] In some embodiments, the method or the use includes reducing a dose or dosage of a conventional medication used to treat an addiction, relative to a control.

[0127] In some embodiments, the present technology comprises a method of augmenting an effect of a conventional medication used to treat an addiction in a subject in need thereof, relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0128] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for augmenting an effect of a conventional medication usedto treat an addiction in a subject in need thereof, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0129] In some embodiments, the present technology comprises a method of reducing or eliminating a need for a conventional medication used to treat an addiction in a subject in need thereof, relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0130] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for reducing or eliminating a need for a conventional medication used to treat an addiction in a subject in need thereof, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0131] In some embodiments, the treatment of the addiction is improved during or after administration of the non-naturally occurring melanocortin analog relative to treatment of the addiction using the conventional medication to treat the addiction alone.

[0132] In some embodiments, the conventional medication to treat the addiction is selected from the group consisting of buprenorphine, naltrexone, acamprosate, methadone, naloxone, nalmefene, xycodone, levo-alpha-acetylmethadol (LAAM), codeine, lofexidine, and a slow-release morphine.

[0133] In some embodiments, the present technology comprises a method of reducing a need for a hospitalization or rehabilitation associated with addiction or use of an addictive substance, relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0134] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for reducing a need for a hospitalization or rehabilitation associated with addiction or use of an addictive substance, relative to a control, the non- naturally occurring melanocortin analog including a sequence of Formula (I).

[0135] In some embodiments, the present technology comprises a method of preventing or reducing a withdrawal from an addictive substance in a subject, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0136] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for preventing or reducing a withdrawal from an addictive substance in a subject, relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0137] In some embodiments, the present technology comprises a method of preventing or reducing a symptom associated with withdrawal from an addictive substance in a subject relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0138] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for preventing or reducing a symptom associated with withdrawal from an addictive substance in a subject, relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0139] In some embodiments, the symptom associated with withdrawal from an addictive substance is selected from the group consisting of pain, anxiety, depression, diarrhea, dizziness, fatigue, muscle aches, nausea, sleep problems, suicidal ideation, tremors, and visual disturbances.

[0140] In some embodiments, the subject has an addiction to an addictive substance or is susceptible to an addiction to an addictive substance.

[0141] In some embodiments, the subject has used or is using one or more addictive substances.

[0142] In some embodiments, the present technology comprises a method or the use wherein the addictive substance includes a prescription medication, a substance in an over- the-counter medication, a recreational substance, or an illegal substance.

[0143] In some embodiments, the addictive substance is selected from the group consisting of an opioid, a painkiller, a stimulant, a narcotic, an alcohol, a sedative, marijuana, a cannabis, a tetrahydrocannabinol (THC), a cannabidiol (CBD), and an inhalant.

[0144] In some embodiments, the opioid is selected from the group consisting of morphine, heroin, codeine, oxycodone, hydrocodone, and fentanyl.

[0145] In some embodiments, the stimulant is selected from the group consisting of caffeine, nicotine, methamphetamines, cocaine, and amphetamines.

[0146] In some embodiments, the sedative includes a barbiturate or a benzodiazepine.

[0147] In some embodiments, the barbiturate is selected from the group consisting of phenobarbital, methohexital, butalbital, pentobarbital, primidone, and amobarbital.

[0148] In some embodiments, the benzodiazepine is selected from the group consisting of alprazolam, lorazepam, clonazepam, diazepam, and temazepam.

[0149] In some embodiments, the sedative is selected from the group consisting of tranquilizers, xylazine, eszopiclone, zaleplon, zolpidem, and zopiclone.

[0150] In some embodiments, the inhalant is selected from the group consisting of aerosols, butanes, freon, helium, nitrous oxide, propane, and nitrites.

[0151] In some embodiments, the nicotine includes a tobacco chew, a nicotine pouch, or a smoking device.

[0152] In some embodiments, the smoking device is selected from the group consisting of cigarettes, electronic cigarettes, cigars, and vape products.

[0153] In some embodiments, the control includes the subject before administration of the non-naturally occurring melanocortin analog.

[0154] In some embodiments, the control includes the subject at baseline.

[0155] In some embodiments, the non-naturally occurring melanocortin analog is a melanocortin 4 receptor (MC4R) agonist.

[0156] In some embodiments, the MC4R agonist is a full MC4R agonist.

[0157] In some embodiments, the MC4R agonist is a partial MC4R agonist.

[0158] In some embodiments, the non-naturally occurring melanocortin analog is a MC3R antagonist.

[0159] In some embodiments, the MC3R antagonist is a full MC3R antagonist.

[0160] In some embodiments, the MC3R antagonist is a partial MC3R antagonist.

[0161] In some embodiments, the non-naturally occurring melanocortin analog does not have MC3R activity.

[0162] In some embodiments, the non-naturally occurring melanocortin analog includes a sequence according to Formula (I), wherein: X1 is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D- norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D- ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D- cysteine (dCys); R2 is selected from the group consisting of Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4- amino-1 ,2,4,5-tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H- [1 ,2,3]triazolo-[1 , 5-a][1 ,4]diazepin-6(5H)-one (Ata), 4-amino-1 ,4,5,6-tetrahydroazepino[4,3- b]indol-3(2H)-one (Aia), 2-aminotetraline-2-carboxylic acid (Ate), 1 -amino-4- phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid (APPC), octohydroindole-2 -carboxylic acid (Oic), 1 -am ino-1 -cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indoline-2 -carboxylic acid (loc), 1 - am ino-1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')), and T-naphthylalanine (Nal(1')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D- valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b- Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-naturally occurring melanocortin analog does not include a sequence selected from the group consisting of: Ac-Nle-c[Asp- Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 194); Ac-Nle-c[Asp-Pro-His- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 5); Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg- Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 10); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dPro (SEQ ID NO: 2); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 3); Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 4); Ac-Nle- c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 6); Ac-Nle-c[Asp-Phe- His-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 7); Ac-Nle-c[Asp-Hyp-dNal(2')-Arg- Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 9); Ac-Nle-Phe-Phe-c[Asp-Phe-His-dNal(2')-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 12); Ac-dArg-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 15); Ac-dLeu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 18); Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 20); Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 21 ); Ac-dNIe- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 24); Ac-dCys-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 28); Ac-dPhe-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 29); Ac-dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 30); dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 35); Tyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 36); Ac-Nle- c[Cys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 40); Ac-Nle-c[dCys-Pro- dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 41 ); Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 42); Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-dCys]- dVal-dPro-NH2 (SEQ ID NO: 43); Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 48); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 54); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 64); Ac-Nle- c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 68); Ac-Nle-c[Asp-Ala-dNal(2')- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 69); Ac-Nle-c[Asp-Leu-dNal(2')-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 76); Ac-Nle-c[Asp-Trp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 82); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 115); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 116); Ac-Nle-c[Asp- Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 117); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 118); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dHyp-NH2 (SEQ ID NO: 119); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Hyp-NH2 (SEQ ID NO: 120); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-dHyp-NH2 (SEQ ID NO: 121 ); Ac- Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-dVal-NH2 (SEQ ID NO: 122); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dHyp-dVal-NH2 (SEQ ID NO: 123); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-Hyp-Val-NH2 (SEQ ID NO: 124); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp- Val-NH2 (SEQ ID NO: 125); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-NH2 (SEQ ID NO: 126); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2 (SEQ ID NO: 127); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 128); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dPro-NH2 (SEQ ID NO: 129); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp- Lys]-Val-NH2 (SEQ ID NO: 130); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 131 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-NH2 (SEQ ID NO: 132); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-NH2 (SEQ ID NO: 133); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-dHyp-NH2 (SEQ ID NO: 134); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp- NH2 (SEQ ID NO: 135); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ ID NO: 136); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 137); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Gly-Gly-NH2 (SEQ ID NO: 138); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 139); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 140); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dArg-NH2 (SEQ ID NO: 143); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ ID NO: 144); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO:-M-145); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-NH2 (SEQ ID NO: 146); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-dPro-NH2 (SEQ ID NO: 147); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dAsp-dPro-NH2 (SEQ ID NO: 148); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 149); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn- dPro-NH2 (SEQ ID NO: 150); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-NH2 (SEQ ID NO: 151 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-NH2 (SEQ ID NO: 152); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-NH2 (SEQ ID NO: 153); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-dAsp-NH2 (SEQ ID NO: 154); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg- NH2 (SEQ ID NO: 155); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 156); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 157); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 158); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dLys-dPro-dVal-NH2 (SEQ ID NO: 159); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-Lys-dPro-NH2 (SEQ ID NO: 160); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]- dLys-dPro-NH2 (SEQ ID NO: 161 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Val-Pro- NH2 (SEQ ID NO: 162); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 164); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 164); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 165); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-dVal-NH2 (SEQ ID NO: 166); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dArg-dPro-dVal-NH2 (SEQ ID NO: 167); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 168); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]- Arg-dVal-dPro-NH2 (SEQ ID NO: 169); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dVal- dPro-NH2 (SEQ ID NO: 170); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-dPro-NH2 (SEQ ID NO: 171 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 172); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-NH2 (SEQ ID NO: 173); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-NH2 (SEQ ID NO: 174); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dTle-dTle-dPro-NH2 (SEQ ID NO: 175); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 176); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp- Lys]-dPro-dTle-NH2 (SEQ ID NO: 177); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dTle- NH2 (SEQ ID NO: 178); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dPro-NH2 (SEQ ID NO: 179); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 180); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 181 );Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-d al-dPro-dVal-dPro-NH2 (SEQ ID NO: 182); Ac- Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 183); Ac-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 184); Ac-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 185); Ac-Nle- Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 186); Ac-Nle- c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 195); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 196); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-Trp-NH2 (SEQ ID NO: 203); Ac-Nle-c[Asp-Aba-dNal(2')-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 204); Ac-Nle-c[Asp-Aia-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 205); Ac-Nle-c[Asp-Ata-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 206); Ac- Nle-c[Asp-Cpe-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 240); Ac-Nle-c[Asp-Che- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 241 ); Ac-Nle-c[Asp-Oic-dNal(2')-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 242); Ac-Nle-c[Asp-Tic-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 244); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 245); Ac-Nle-c[Asp-His-dNal(2')-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 247); Ac-Nle-c[Asp-His-dNal(2')-cisPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 248); Ac-Nle-c[Asp-Pro-dNal(2')-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 250); Ac-Nle-c[Asp-Pro-dNal(2')-cisPro(guan)Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 251 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aba-Lys]-dVal-dPro-NH2 (SEQ ID NO: 253); Ac- Nle-c[Asp-Pro-dNal(2')-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 254); Ac-Nle-c[Asp-Glu- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 255); Ac-Nle-c[Asp-Glu-dNal(2')-Arg- Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 256); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly- Lys]-dVal-dPro-NH2 (SEQ ID NO: 259); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro- dPro-Lys-Asp-NH2 (SEQ ID NO: 260); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro- dPro-dLys-dAsp-NH2 (SEQ ID NO: 261 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro- dPro-dLys-dAsp-NH2 (SEQ ID NO: 263); Ac-Nle-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 273); Ac-Arg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 274); Ac-dArg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 275); Ac-dLeu-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 327); Ac-dNle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 328); Ac-dArg- c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 329); Ac-Arg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 330); Ac-dPhe-c[dPen-Pro-dNal(2')- Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 331 ); Ac-dTyr-c[dPen-Pro-dNal(2')-Arg-Trp- dPen]-dVal-dPro-NH2 (SEQ ID NO: 332); Ac-Ala-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal- dPro-NH2 (SEQ ID NO: 333); Ac-dHis-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 334); Ac-His-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 335); Ac-dLys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 336); Ac- Lys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 337); Ac-Nle-c[dPen- Pro-dNal(2')-Arg-Trp-dPen]-dArg-dVal-dPro-NH2 (SEQ ID NO: 344); Ac-Nle-c[dPen-Pro- dNal(2')-Arg-Trp-dPen]-dLys-dVal-dPro-NH2 (SEQ ID NO: 345); Ac-Nle-c[dPen-Pro- dNal(2')-Arg-Trp-dPen]-dArg-dPro-NH2 (SEQ ID NO: 346); Ac-Nle-c[dPen-Pro-dNal(2')- Arg-Trp-dPen]-dLys-dPro-NH2 (SEQ ID NO: 347); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp- dPen]-dVal-dHyp-NH2 (SEQ ID NO: 348); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dTle- dPro-NH2 (SEQ ID NO: 349); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-Gly-dPen]-dVal-dPro- NH2 (SEQ ID NO: 350); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 103); Ac-Nle-c[Asp-loc-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 243); Ac- Nle-c[Cys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 44); Ac-Nle-c[dCys-dNal(2')- Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 45); Ac-Nle-c[Cys-dNal(2')-Arg-Trp-dCys]-dVal- dPro-NH2 (SEQ ID NO: 46); Ac-Nle-c[dCys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 47); Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 56); Ac-Nle- c[dPen-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 62); Ac-Nle-c[Asp-dTrp- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 83); Ac-Nle-c[dPen-Ala-dNal(2')-Arg- Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 338); Ac-Nle-c[dPen-Leu-dNal(2')-Arg-Trp-dPen]- dVal-dPro-NH2 (SEQ ID NO: 339); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 223); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 464); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465); Ac- dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466); Ac-His-c[Asp- His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467); Ac-dHis-c[Asp-His- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468); Ac-Nle-Nle-c[Asp-His-p(F)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469); Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 470); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal- dVal-dPro-NH2 (SEQ ID NO: 474); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 475); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 476); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 477); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 478); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481 ); Ac-Lys- c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482); Ac-dLys-c[Asp-His- p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483); Ac-His-c[Asp-His-p(F)dPhe-Arg- Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 484); Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 485); Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 463); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 462); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 479); Ac- Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 473); Ac-dArg- c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480); Ac-Nle-c[Asp-Gln- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 491 ); Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489); Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 493); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 444); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 445); Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495); Ac- Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487); Ac-Nle-c[Asp- dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488); Ac-Nle-c[Asp-dTrp- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494); Ac-Nle-c[Asp-His-p(F)dPhe-Arg- dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471 ); Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]- dVal-dPro-NH2 (SEQ ID NO: 432); Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 217); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 222); Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 535); Ac- Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 538); Ac-Nle-Nle- c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 545); Ac-Nle-c[Asp-His- p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 546); Ac-Nle-c[Asp-His-p(Br)dPhe- Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 547); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg- Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 548); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]- dTle-dTle-dVal-NH2 (SEQ ID NO: 549); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro- dVal-dPro-NH2 (SEQ ID NO: 551 ); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 552); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 553); Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 555); Ac-Nle-c[Asp-dHis-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 562); Ac- Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 563); Ac-Nle-c[Asp- dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 564); Ac-Nle-c[Asp-Bip- p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 565); Ac-Nle-c[Asp-dGln-p(Br)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568); Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 569); Ac-Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 570); Ac-Nle-c[Asp-Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571 ); Ac-Nle-c[Asp-dTyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572); Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539); Ac-dHis- c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 544); Ac-dHis-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 561 ); Ac-dArg-c[Asp-His-p(Br)dPhe- Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 556); Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 542); Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 560); Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 543); Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557); Ac- Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541 ); Ac-Nle-c[Asp- His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 550); Ac-Lys-c[Asp- His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 558); Ac-Arg-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540); Ac-Nle-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 554); Ac-Nle-c[Asp-His-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]- dVal-dPro-NH2 (SEQ ID NO: 418); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621 ); Ac-Nle-c[Asp-His-dPhe-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 228); Ac-Nle-c[Asp-His-dPhe-cisPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 229); Ac-Nle-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 380); Ac-Nle- c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 398); Ac-Nle-c[Asp-Trp- Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401 ); Ac-Nle-Nle-c[Asp-Pro-dPhe- Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639); Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 430); Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal- dPro-NH2 (SEQ ID NO: 431 ); Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 225); Ac-Nle-c[dPen-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 326); Ac-Nle-c[Asp-Pro-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 297); Ac-Nle-c[Asp- Pro-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215); Ac-Nle-c[Asp-Phe- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 525); Ac-Nle-c[Asp-dPhe-p(CI)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 526); Ac-Nle-c[Asp-Bip-p(CI)dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 527); Ac-Nle-c[Asp-Trp-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 531 ); Ac-Nle-c[Asp-Tyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533); Ac-Nle-c[Asp-dTyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534); Ac-Nle-c[Asp-dTrp-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532); Ac-Nle- c[dCys-His-p(CI)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498); Ac-Nle-c[Cys-His- p(CI)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 497); Ac-Nle-c[Asp-His-p(CI)dPhe- Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 509); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg- Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 510); Ac-Nle-c[Asp-His-p(CI)dPhe-His-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 508); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 220); Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 507); Ac-Ala-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517); Ac-Ala-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 500); Ac-Nle- Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516); Ac-Nle- c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514); Ac-Nle-c[Asp-dGln- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 530); Ac-Arg-c[Asp-dAla-His-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 268); Ac-Nle-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 378); Ac-dArg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 379); Ac-Nle-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 266); Ac-Arg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 267); Ac-Arg-c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 269); Ac- dArg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 270); Ac-Arg- c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-NH2 (SEQ ID NO: 282); and Ac-Arg-c[Asp-dAla-His- dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 283).

[0163] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence according to Formula (IA): X1 -X2-X3-R1-R2-R3-R4-R5-R6-R7-R8-Y1 -Y2-Y3-Y4 (IA), wherein: X1 is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D-norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D-ornithine (dOm), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D-cysteine (dCys); R2 is selected from the group consisting of Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2- aminotetraline-2-carboxylic acid (Ate), octohydroindole-2-carboxylic acid (Oic), 1-amino-1 - cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino- 1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of dPhe, para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is Arg or His; R6 is selected from the group consisting of Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')), and T- naphthylalanine (Nal(1 ')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 are independently selected from the group consistingof Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys,R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that: when R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGIn, dTyr, R6 is Trp, and the non-naturally occurring melanocortin analog is not cyclized between Cys at R2 and Cys at R7 or (ii) R3 is His and either R6 is Nal(2') or the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between R2 and R7, where R2 and R7 are the same; when R4 is p(Br)dPhe, then the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and Cys or dCys at R7; when R4 is dPhe, then (i) R3 is not His, Pro, or absent, (ii) R3 is His and either R2 is Phe or dAla or R2 is Ala and X1 is Arg or dArg, (iii) R3 is Pro and (a) R2 is Trp, and R5 is not His or R6 is not Phe or (b) R2 is not T rp or Pro, and either R5 is not dNal(2') or N a I (2' ) or X1 and Y3 are not both present, or (iv) R3 is absent and R2 and R7 are not both dPen; and when R4 is p(CI)dPhe, then (i) R3 is selected from Aba, Aia, and Ata or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and dCys at R7, or (b) if R1 is Nle, and Y1Y2 is not dVal-dPro, then either X1 or Y3 is present.

[0164] In some embodiments, the non-naturally occurring melanocortin analog includes a sequence according to Formula (IA), wherein: X1 is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D- norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D- ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D- cysteine (dCys); R2 is selected from the group consisting of Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2-aminotetraline- 2-carboxylic acid (Ate), octohydroindole-2 -carboxylic acid (Oic), 1 -amino-1 - cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1 -amino-1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of dPhe, para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is Arg or His; R6 is selected from the group consisting of Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')), and T- naphthylalanine (Nal(1 ')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-naturally occurring melanocortin analog does not include a sequence selected from the group consisting of: Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 223); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 464); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465); Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466); Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467); Ac-dHis- c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468); Ac-Nle-Nle-c[Asp-His- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469); Ac-Nle-c[Asp-His-p(F)dPhe-His- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal- dVal-dVal-dPro-NH2 (SEQ ID NO: 474); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro- dVal-dPro-NH2 (SEQ ID NO: 475); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro- NH2 (SEQ ID NO: 476); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQID NO: 477); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 478); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481 ); Ac- Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482); Ac-dLys-c[Asp- His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483); Ac-His-c[Asp-His-p(F)dPhe- Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 484); Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 485); Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 463); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 462); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 479); Ac- Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 473); Ac-dArg- c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480); Ac-Nle-c[Asp-Bip- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489); Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]- dVal-dPro-NH2 (SEQ ID NO: 444); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro- NH2 (SEQ ID NO: 445); Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495); Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487); Ac- Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488); Ac-Nle-c[Asp- dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494); Ac-Nle-c[Asp-His- p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471 ); Ac-Nle-c[Cys-Pro- p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432); Ac-Nle-c[dCys-His-p(F)dPhe- Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 460); Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 217); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 222); Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 535); Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 538); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 545); Ac- Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 546); Ac-Nle-c[Asp- His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 547); Ac-Nle-c[Asp-His- p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 548); Ac-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 549); Ac-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 551 ); Ac-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 552); Ac-Nle-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 553); Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 555); Ac-Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 563); Ac-Nle-c[Asp-dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 564); Ac-Nle-c[Asp-Bip-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 565); Ac-Nle-c[Asp-dGln-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568); Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 569); Ac- Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 570); Ac-Nle-c[Asp- Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571 ); Ac-Nle-c[Asp-dTyr- p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572); Ac-dArg-c[Asp-His-p(Br)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539); Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 544); Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 561 ); Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 556); Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 542); Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 560); Ac- His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 543); Ac-dLys-c[Asp- His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559); Ac-Arg-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557); Ac-Lys-c[Asp-His-p(Br)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541 ); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]- dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 550); Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 558); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 540); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro- NH2 (SEQ ID NO: 554); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 418); Ac-Nle- c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621 ); Ac-Nle-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639); Ac-Nle-c[dPen-dPhe-Arg-Trp- dPen]-dVal-dPro-NH2 (SEQ ID NO: 326); Ac-Nle-c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 398); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401 ); Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 225); Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 430); Ac-Nle- c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 431 ); Ac-Nle-c[Asp-Ala-His- dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 380); Ac-Nle-c[Asp-Pro-p(CI)dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215); Ac-Nle-c[Asp-Phe-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 525); Ac-Nle-c[Asp-dPhe-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 526); Ac-Nle-c[Asp-Bip-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 527); Ac-Nle-c[Asp-Trp-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 531 ); Ac- Nle-c[Asp-Tyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533); Ac-Nle-c[Asp- dTyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534); Ac-Nle-c[Asp-dTrp- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532); Ac-Nle-c[dCys-His-p(CI)dPhe- Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498); Ac-Nle-c[Cys-His-p(CI)dPhe-Arg-Trp- Cys]-dVal-dPro-NH2 (SEQ ID NO: 497); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-dNal(2')-Lys]- dVal-dPro-NH2 (SEQ ID NO: 509); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Nal(2')-Lys]-dVal-dPro- NH2 (SEQ ID NO: 510); Ac-Nle-c[Asp-His-p(CI)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 508); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 220); Ac- Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 507); Ac-Ala- c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517); Ac-Ala-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 500); Ac-Nle-Nle-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516); and Ac-Nle-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514).

[0165] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula (IB): X1 -X2-X3-R1-R2-Pro-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7 (IB), wherein: X1 is absent or norleucine (Nle); X2 is absent or Nle; X3 is absent or Nle; R1 is selected from the group consisting of Nle, D-norleucine (dNIe), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis), ornithine (Orn), D-omithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D- phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R2 is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), cysteine (Cys), D-cysteine (dCys), and D-penicillamine (dPen); R4 is dPhe or para-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, and T-naphthylalanine (Nal(1 ')); R7 is selected from the group consisting of Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline(b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2 and R7 when each of R2 and R7 are independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2 and R7 when R2 is Asp or dAsp and R7 is Lys, dLys, or Orn; provided that: when R4 is p(F)dPhe, then the non-naturally occurring melanocortin analog is not cyclized between Cys at R2 and Cys at R7; and when R4 is dPhe and one or more of X1 , X2, and X3 is present, then Y3-Y7 are absent.

[0166] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula (IB), wherein: X1 -X2-X3-R1 -R2-Pro-R4-R5-R6-R7-R8-Y1 -Y2-Y3-Y4-Y5-Y6-Y7 (IB), wherein: X1 is absent or norleucine (Nle); X2 is absent or Nle; X3 is absent or Nle; R1 is selected from the group consisting of Nle, D-norleucine (dNIe), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), D- histidine (dHis), ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R2 is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), cysteine (Cys), D-cysteine (dCys), and D-penicillamine (dPen); R4 is dPhe or para-fluoro- D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, and 1 '-naphthylalanine ( Nal( 1 ')); R7 is selected from the group consisting of Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3- Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D- asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the groupconsisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2 and R7 when each of R2 and R7 are independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2 and R7 when R2 is Asp or dAsp and R7 is Lys, dLys, or Orn; provided that the non-naturally occurring melanocortin analog does not include a sequence of: Ac- Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432); or Ac-Nle-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639).

[0167] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula (IC): X1 -X2-R1 -R2-Pro-dPhe-R5-R6-R7-Y1-Y2-Y3-Y4 (IC), wherein: X1 is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent or Nle; R1 is selected from the group consisting of aspartic acid (Asp), cysteine (Cys), and D-cysteine (dCys); R2 is selected from the group consisting of tryptophan (Trp), phenylalanine (Phe), D- phenylalanine (dPhe), histidine (His), D-histidine (dHis), tyrosine (Tyr), and D-tyrosine (dTyr); R5 is Arg; R6 is selected from the group consisting of Trp, 2'-D-naphthylalanine (dNal(2')), 2'-naphthylalanine (Nal(2')), and T-naphthylalanine (Nal(1')); R7 is selected from the group consisting of Lys, Cys, and dCys; Y1 is absent or is selected from the group consisting of D-valine (dVal), D-tert-leucine (dTle), dArg, and dLys; Y2 is absent or is selected from the group consisting of dVal, dPro, and D-hydroxyproline (dHyp); Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 and R7 when both of R1 and R7 are independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R1 and R7 when R1 is Asp and R7 is Lys;

[0168] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula (ID): X1 -R1-R2-R3-p(CI)dPhe-Arg-Trp-R7-Y1 -Y2-Y3-Y4 (ID), wherein: X1 is absent or norleucine (Nle); R1 is selected from the group consisting of Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); R2 is aspartic acid (Asp) or D-cysteine (dCys); R3 is selected from the group consisting of His, 4-amino- 1 ,2,4,5-tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H-[1 ,2,3]triazolo-[1 ,5- a][1 ,4]diazepin-6(5H)-one (Ata), and 4-amino-1 ,4,5,6-tetrahydroazepino[4,3-b]indol-3(2H)- one (Aia); R7 is Lys or dCys; Y1 is selected from the group consisting of D-valine (dVal), D- proline (dPro), and D-tert-leucine (dTle); Y2 is absent or is selected from the group consisting of dVal, dPro, and dTle; Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2 and R7 when both of R2 and R7 are dCys; and a lactam bridge between R2 and R7 when R2 is Asp and R7 is Lys; provided that when R3 is His and R1 is Nle, then (i) Y1 Y2 is dVal-dPro, X1 is absent, and the non-naturally occurring melanocortin analog is cyclized through a disulfide bond, or (b) Y1 Y2 is not dVal- dPro and either X1 or Y3 is present.

[0169] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula (ID), wherein: X1 is absent or norleucine (Nle); R1 is selected from the group consisting of Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), and D- histidine (dHis); R2 is aspartic acid (Asp) or D-cysteine (dCys); R3 is selected from the group consisting of His, 4-amino-1 ,2,4,5-tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8- dihydro-4H-[1 ,2,3]triazolo-[1 ,5-a][1 ,4]diazepin-6(5H)-one (Ata), and 4-amino-1 ,4,5,6- tetrahydroazepino[4,3-b]indol-3(2H)-one (Aia); R7 is Lys or dCys; Y1 is selected from the group consisting of D-valine (dVal), D-proline (dPro), and D-tert-leucine (dTle); Y2 is absent or is selected from the group consisting of dVal, dPro, and dTle; Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2 and R7 when both of R2 and R7 are dCys; and a lactam bridge between R2 and R7 when R2 is Asp and R7 is Lys; provided that the non-naturally occurring melanocortin analog does notinclude a sequence selected from the group consisting of: Ac-Nle-c[Asp-His-p(CI)dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 220); Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 507); Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dPro- dVal-dPro-NH2 (SEQ ID NO: 516); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro- NH2 (SEQ ID NO: 514); and.

[0170] In some embodiments, an N-terminus of the non-naturally occurring melanocortin analog is modified by an acyl group.

[0171] In some embodiments, the acyl group is an acetyl group.

[0172] In some embodiments, an N-terminus of the non-naturally occurring melanocortin analog is not modified.

[0173] In some embodiments, a C-terminus of the non-naturally occurring melanocortin analog is modified by an amide group.

[0174] In some embodiments, a C-terminus of the non-naturally occurring melanocortin analog is not modified.

[0175] In some embodiments, Y1-Y2 are present and Y3- Y8 are absent.

[0176] In some embodiments, Y1 is D-valine and Y2 is D-proline.

[0177] In some embodiments, the present technology comprises a method or a use, w wherein Y1 is D-tert-leucine and Y2 is D-proline.

[0178] In some embodiments, R4 is dNal(2').

[0179] In some embodiments, the sequence of Formula (I) is: Ac-Nle-c[Asp-His- dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 8), wherein c represents cyclization through R2 and R8 via a lactam bond.

[0180] In some embodiments, R4 is Phe or dPhe.

[0181] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 291 ); Ac-Nle-c[Asp-Pro-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 294); Ac-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 295; E2); and Ac-Nle-c[Asp-Pro-His-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 296). wherein c represents cyclization through R2 and R7 via a lactam bond.

[0182] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-dLeu-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:298); Ac-dAla-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 299); Ac- Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 300); Ac-dNle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 301 ); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 302); Ac-dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 303); Ac-dTyr-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 304); Phe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 305); His-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 306); Trp-c[Asp-Pro-dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 307); dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 308); dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 309); dTrp-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 310); Ac-Arg-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 311 ); Ac-dLys-c[Asp-Pro-dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 312); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 313); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 314); Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 315); Ac- Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 316); and Ac-dOrn-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 317), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0183] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-c[Cys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 318); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 319); Ac- Nle-c[dPen-Pro-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 320); Ac-Nle-c[dCys- Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 321 ); Ac-Nle-c[Asp-Pro-dPhe-Arg- Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 322); and Ac-Nle-c[Cys-dPhe-Arg-Trp-Pen]-dVal- dPro-NH2 (SEQ ID NO: 324), wherein c represents cyclization through R2 and R7 via a disulfide bond.

[0184] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 351 ); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 352); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp- NH2 (SEQ ID NO: 353), wherein c represents cyclization through R2 and R8 via a lactam bond.

[0185] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 354); Ac-Nle-c[Asp-Leu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 355); Ac-Nle- c[Asp-Cpe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 358); Ac-Nle-c[Asp-Che-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 359); Ac-Nle-c[Asp-Oic-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 360); Ac-Nle-c[Asp-loc-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 361 ); Ac-Nle-c[Asp-Tic-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 362); Ac-Nle- c[Asp-Hyp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 364); Ac-Nle-c[Asp-Phe-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 366); Ac-Nle-c[Asp-dPhe-dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 367); Ac-Nle-c[Asp-Bip-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 368); Ac-Nle-c[Asp-dGln-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 371 ); Ac-Nle-c[Asp-Trp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 372); Ac-Nle- c[Asp-dTrp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 373); Ac-Nle-c[Asp-Tyr-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 374); Ac-Nle-c[Asp-dTyr-dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 375); Ac-Nle-c[Asp-Aba-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 198); Ac-Nle-c[Asp-Aia-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 207); Ac-Nle-c[Asp-Ata-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 208); Ac-Nle-c[Asp-Atc- dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 212); Ac-Nle-c[Asp-APC-dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 213); and Ac-Nle-c[Asp-APPC-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 214), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0186] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Arg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 281 ); Ac-Arg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 381 ); and Ac-dArg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 382), wherein c represents cyclization through R1 and R7 via a lactam bond.

[0187] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 226); Ac-Nle-c[Cys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 383); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 384); Ac- Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 385); Ac-Ala-c[Asp- Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 386); Ac-Lys-c[Asp-Trp-Pro- dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 387); Ac-dLys-c[Asp-Trp-Pro-dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 388); Ac-Arg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 389); Ac-dArg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 390); Ac-dHis-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 391 ); Ac-His-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 392); Ac-Nle- Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 393); Ac-Nle-c[Asp- Trp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 394); Ac-Nle-c[Asp-Trp-Leu-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 395); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(1 ']- Lys]-dVal-dPro-NH2 (SEQ ID NO: 399); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-dNal(2')-Lys]- dVal-dPro-NH2 (SEQ ID NO: 403); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro- NH2 (SEQ ID NO: 404); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 405); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 406); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 407); Ac- Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 408); Ac-Nle-c[Asp- Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 409); Ac-Nle-c[Asp-Trp-Pro- dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 410); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp- Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 411 ); Ac-Nle-c[Asp-Phe-Pro-dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 412); Ac-Nle-c[Asp-His-Pro-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 413); Ac-Nle-c[Asp-Tyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 414); Ac-Nle-c[Asp-dPhe-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 415); Ac-Nle-c[Asp-dHis-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 416); and Ac-Nle-c[Asp-dTyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 417), wherein c represents cyclization through R1 and R7 via a lactam bond or a disulfide bond.

[0188] In some embodiments, the sequence of any one of Formulae (l)-(ID) is: Ac-Nle- c[Asp-Hyp-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 419), wherein c represents cyclization through R2 and R8 via a lactam bond.

[0189] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-Phe-Phe-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 421 ); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 422); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 423); and Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 424), wherein c represents cyclization through R1 and R7 via a lactam bond.

[0190] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 187); Ac-Nle-c[Asp-Pro-dPhe-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 233); Ac- Nle-c[Asp-Pro-dPhe-Arg-Aba-Lys]-dVal-dPro-NH2 (SEQ ID NO: 234); Ac-Nle-c[Asp-Pro- dPhe-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 235); Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(1 ')- Lys]-dVal-dPro-NH2 (SEQ ID NO: 427); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Phe-Lys]-dVal- dPro-NH2 (SEQ ID NO: 429), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0191] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 218); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 433); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 434); Ac- Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 435); Ac-dArg-c[Asp- Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 436); Ac-Arg-c[Asp-Pro- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 437); Ac-Lys-c[Asp-Pro-p(F)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 438); Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 439); Ac-His-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 440); Ac-dHis-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 441 ); Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 442); Ac-Nle-c[Asp-Pro-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 443); Ac- Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 446); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 447); Ac-Nle- c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 448); Ac-Nle-c[Asp- Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 449); Ac-Nle-Nle-c[Asp-Pro- p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 450); Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe- Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 451 ); Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp- Lys]-dTle-dPro-NH2 (SEQ ID NO: 452); Ac-dArg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 453); Ac-Arg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 454); Ac-Lys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 455); Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 456); Ac-His- c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 457); Ac-dHis-c[Asp-Pro- p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 458); Ac-Nle-c[Cys-His-p(F)dPhe-Arg- Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 459); Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-Cys]- dVal-dPro-NH2 (SEQ ID NO: 460); Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro- NH2 (SEQ ID NO: 461 ); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 472); Ac-Nle-c[Asp-dGln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 492); and Ac-Nle-c[Asp-dTyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 496), wherein c represents cyclization through R2 and R7 via a lactam bond or a disulfide bond.

[0192] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Aba-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 209); Ac-Nle-c[Asp-Aia-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 210); Ac-Nle-c[Asp-Ata-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 211 ); Ac-Nle- c[dCys-His-p(CI)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 499); Ac-dArg-c[Asp- His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 501 ); Ac-Arg-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 502); Ac-Lys-c[Asp-His-p(CI)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 503); Ac-dLys-c[Asp-His-p(CI)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 504); Ac-His-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 505); Ac-dHis-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 506); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 511 ); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 512); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 513); Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 515); Ac-dArg-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 518); Ac-Arg-c[Asp- His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 519); Ac-Lys-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 520); Ac-dLys-c[Asp-His-p(CI)dPhe- Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 521 ); Ac-His-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 522); and Ac-dHis-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 523), wherein c represents cyclization through R2 and R7 via a lactam bond or a disulfide bond.

[0193] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 536); or Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 537), wherein c represents cyclization through R2 and R7 via a disulfide bond.

[0194] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 573); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 574); Ac-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 575); Ac-Nle-c[Asp-Pro-dPhe- Arg-Trp-Lys]-Val-NH2 (SEQ ID NO: 576); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 577); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 578); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dArg-NH2 (SEQ ID NO: 579); Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 580); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp- Lys]-Arg-NH2 (SEQ ID NO: 581 ); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 582); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 583); Ac- Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 584); Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-Lys-Val-Pro-NH2 (SEQ ID NO: 585); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp- Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 586); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys- dVal-dPro-NH2 (SEQ ID NO: 587); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 588); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 589); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 590); Ac- Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 591 ); Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dTle-dTle-dPro-NH2 (SEQ ID NO: 592); Ac-Nle-c[Asp-Pro-dPhe-Arg- Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 593); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dTle-NH2 (SEQ ID NO: 594); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dPro- NH2 (SEQ ID NO: 595); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 596); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 597); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQ ID NO: 598); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 599); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Trp-NH2 (SEQ ID NO: 600); Ac-Nle-c[Asp- Pro-dPhe-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 601 ); Ac-Nle-c[Asp-Pro-dPhe- Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ ID NO: 602); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asp- NH2 (SEQ ID NO: 603); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dHyp-NH2 (SEQ ID NO: 604); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ ID NO: 605); Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 606); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]- Asn-dPro-NH2 (SEQ ID NO: 607); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Hyp-NH2 (SEQ ID NO: 608); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 609); Ac-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-Gly-Gly-NH2 (SEQ ID NO: 610); Ac-Nle-c[Asp-Pro-dPhe-Arg- Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO: 611 ); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsn- dPro-NH2 (SEQ ID NO: 612); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asn-NH2 (SEQ ID NO: 613); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsp-NH2 (SEQ ID NO: 614); Ac-Nle-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 615); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp- Lys]-Lys-dPro-NH2 (SEQ ID NO: 616); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 617); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-NH2 (SEQ ID NO: 618); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-OH (SEQ ID NO: 619); Ac-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 620); Ac-Nle-c[dAsp-Pro-dPhe- Arg-Trp-dLys]-dPro-dVal-NH2 (SEQ ID NO: 622); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]- pPro-p2Val-NH2 (SEQ ID NO: 623); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-pPro-p3Val-NH2 (SEQ ID NO: 624); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-p2Val-pPro-NH2 (SEQ ID NO: 625); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-p3Val-pPro-NH2 (SEQ ID NO: 626); and Ac- Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-pPro-pPro-NH2 (SEQ ID NO: 627), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0195] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 628); Ac-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 629); and Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 630), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0196] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 631 ); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 632); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 633); Ac-His- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 634); Ac-dHis-c[Asp-Pro-dPhe- Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 635); Ac-Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 636); Ac-dOrn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal- dPro-NH2 (SEQ ID NO: 637); Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 638); Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 640); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 641 ); Ac-Arg-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 642); Ac-Lys-c[Asp-Pro-dPhe-Arg- Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 643); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 644); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 645); and Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 646), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0197] In some embodiments, the non-naturally occurring melanocortin analog includes any one of SEQ ID NOs: 8, 187, 198, 207-218, 226, 231 -235, 281 , 291 , 294-296, 298-322, 324, 351 -355, 358-362, 364, 366-368, 371-375, 381 -395, 399, 403-417, 419, 421 - 425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646.

[0198] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 187, 212, 218, 226, 291 , 295, 298-322, 324, 351-355, 358-360, 362, 364, 366-368, 371 -375, 381-395, 399, 403-417, 419, 421 -425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573- 598, 600-646.

[0199] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 187, 218, 231 -235, 291 , 295, 298-322, 351-353, 425, 427, 429, 433-443, 446-458, 573-599, 600-620, 622-646.

[0200] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 226, 383-393, 399, 403-417.

[0201] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 209-211 , 499, 501 -506, 511 -513, 515, 518-523.

[0202] In some embodiments, the non-naturally occurring melanocortin analog is present in a pharmaceutical composition.

[0203] In some embodiments, the pharmaceutical composition includes one or more pharmaceutically acceptable excipients and / or carriers.

[0204] In some embodiments, the one or more pharmaceutically acceptable excipients and / or carriers of the pharmaceutical composition include water.

[0205] In some embodiments, the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 5 mg / kg to about 20 mg / kg administered once a day for about 5 days to about 10 days; (ii) at a second dose of about 10 mg / kg to about 40 mg / kg administered once a day after administration of the first dose for about 5 days to about 10 days; (iii) at a third dose of about 5 mg / kg to about 30 mg / kg administered twice a day after administration of the second dose for at least about 5 days to about 10 days.

[0206] In some embodiments, the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 5 mg / kg administered once a day for about 7 days; (ii) at a second dose of about 15 mg / kg administered once a day after administration of the first dose for about 7 days; (iii) at a third dose of about 10 mg / kg administered twice a day after administration of the second dose for at least about 7 days.

[0207] In some embodiments, the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 10 mg / kg administered once a day for about 7 days; (ii) at a second dose of about 20 mg / kg administered once a day after administration of the first dose for about 7 days; (iii) at a third dose of about 15 mg / kg administered twice a day after administration of the second dose for at least about 7 days.

[0208] In some embodiments, the present technology comprises a method or the use wherein the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 15 mg / kg administered once a day for about 7 days; (ii) at a second dose of about 25 mg / kg administered once a day after administration of the first dose for about 7 days; (iii) at a third dose of about 20 mg / kg administered twice a day after administration of the second dose for at least about 7 days.

[0209] In some embodiments, the non-naturally occurring melanocortin analog is administered at a dose of about 0.5 mg / kg to about 10 mg / kg per body weight of the subject once daily.

[0210] In some embodiments, the non-naturally occurring melanocortin analog is administered at a dose of about 1 mg / kg or 3 mg / kg per body weight of the subject once daily.

[0211] In some embodiments, the non-naturally occurring melanocortin analog is administered at a dose of about 0.1 mg to about 100 mg once daily.

[0212] In some embodiments, the non-naturally occurring melanocortin analog is administered at a dose of about 10 mg or about 50 mg once daily.

[0213] In some embodiments, the non-naturally occurring melanocortin analog is administered via intraperitoneal, intravenous, parenteral, subcutaneous, intramuscular, intracerebroventricular, intranasal, or oral administration.

[0214] In some embodiments, the non-naturally occurring melanocortin analog crosses a blood-brain-barrier of a subject.

[0215] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 8, 187, 198, 207-218, 226, 231 -235, 281 , 291 , 294-296, 298-322, 324, 351 -355, 358-362, 364, 366-368, 371-375, 381 -395, 399, 403-417, 419, 421 -425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511 -513, 515, 518-523, 536-537, 573-599, 600-620, 622-646 and is administered at least once daily in an amount ranging from 0.001 mg / kg to 25 mg / kg per body weight of the subject.

[0216] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 8, 187, 198, 207-218, 226, 231 -235, 281 , 291 , 294-296, 298-322, 324, 351 -355, 358-362, 364, 366-368, 371-375, 381 -395, 399, 403-417, 419, 421 -425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511 -513, 515, 518-523, 536-537, 573-599, 600-620, 622-646 and is administered at least once daily in an amount ranging from 0.5 mg / kg to 10 mg / kg per body weight of the subject.

[0217] In some embodiments, the non-naturally occurring melanocortin analog is administered to a subject for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, or 5 years.

[0218] In some embodiments, the non-naturally occurring melanocortin analog is administered to a subject for 1 day, 5 days, 7 days, 14 days, 21 days, 28 days, 35 days, 40 days, 45 days, 50 days, 60 days, 75 days, 90 days, 100 days, 110 days, or 120 days. In some embodiments, the present technology comprises a method of reducing a pain level in a subject in need thereof relative to a control, including administering to the subject a non- naturally occurring melanocortin analog of Formula (I): X1 -X2-X3-R1-R2-R3-R4-R5-R6-R7- R8-Y1 -Y2-Y3-Y4-Y5-Y6-Y7 (I), wherein: X1 is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D-norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D-cysteine (dCys); R2 is selected from the group consisting of Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-amino-1 ,2,4,5- tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H-[1 ,2,3]triazolo-[1 ,5- a][ 1 ,4]diazepin-6(5H)-one (Ata), 4-amino-1 ,4,5,6-tetrahydroazepino[4,3-b]indol-3(2H)-one (Aia), 2-aminotetraline-2-carboxylic acid (Ate), 1 -amino-4-phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid (APPC), octohydroindole-2-carboxylic acid (Oic), 1 -amino-1 -cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline- 3-carboxylic acid (Tic), indoline-2-carboxylic acid (loc), 1 -am ino-1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of Phe, dPhe, 2'- D-naphthylalanine (dNal(2')), para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D- phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')), and T-naphthylalanine (Nal(1 ')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3- valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D- tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 when each of R1 or R2 and R7 are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that: when R4 is dNal(2'), then R3 is His and R7 is Pro; when R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGIn, dTyr, R6 is Trp, and the non-naturally occurring melanocortin analog is not cyclized between Cys at R2 and Cys at R7 or (ii) R3 is His and either R6 is Nal(2') or the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between R2 and R7; when R4 is p(Br)dPhe, then the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and Cys or dCys at R7; when R4 is dPhe, then (i) R3 is not His, Pro, or absent, (ii) R3 is His and either R2 is Phe or dAla or R2 is Ala and X1 is Arg or dArg, (iii) R3 is Pro and (a) R2 is Trp, andR5 is not His or R6 is not Phe or (b) R2 is not Trp or Pro, and either R5 is not dNal(2') or Nal(2') or X1 and Y3 are not both present, or (iv) R3 is absent and R2 and R7 are not both dPen; when R4 is p(CI)dPhe, then (i) R3 is selected from Aba, Aia, and Ata or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non- naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and dCys at R7, or (b) if R1 is Nle, and Y1 Y2 is not dVal-dPro, then either X1 or Y3 is present; and when R2 is dAla, then R4 is dPhe and Y1 -Y7 are absent.

[0219] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for reducing a pain level in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0220] In some embodiments, the present technology comprises a method of treating, preventing, or reducing an addiction in a subject relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0221] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for treating, preventing, or reducing an addiction in a subject relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0222] In some embodiments, the present technology comprises a method of preventing or reducing a use of or dependence on an addictive substance in a subject relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0223] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for treating, preventing, or reducing a use of or dependence on an addictive substance in a subject relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0224] In some embodiments, the present technology comprises a method of treating or preventing an opioid use disorder (OUD) in a subject in need thereof relative to a control,including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0225] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for treating or preventing an OUD in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0226] In some embodiments, the present technology comprises a method of treating or preventing an alcohol use disorder (AUD) in a subject in need thereof relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0227] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for treating or preventing an AUD in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0228] In some embodiments, the method or the use includes reducing a dose used or consumed of an addictive substance, relative to a control.

[0229] In some embodiments, the method or the use includes reducing a dependency on an addictive substance, relative to a control.

[0230] In some embodiments, the method or the use includes reducing a frequency of an addictive substance use, relative to a control.

[0231] In some embodiments, the method or the use includes reducing a dose or dosage of a conventional medication used to treat an addiction, relative to a control.

[0232] In some embodiments, the present technology comprises a method of augmenting an effect of a conventional medication used to treat an addiction in a subject in need thereof, relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0233] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for augmenting an effect of a conventional medication usedto treat an addiction in a subject in need thereof, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0234] In some embodiments, the present technology comprises a method of reducing or eliminating a need for a conventional medication used to treat an addiction in a subject in need thereof, relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0235] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for reducing or eliminating a need for a conventional medication used to treat an addiction in a subject in need thereof, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0236] In some embodiments, the treatment of the addiction is improved during or after administration of the non-naturally occurring melanocortin analog relative to treatment of the addiction using the conventional medication to treat the addiction alone.

[0237] In some embodiments, the conventional medication to treat the addiction is selected from the group consisting of buprenorphine, naltrexone, acamprosate, methadone, naloxone, nalmefene, xycodone, levo-alpha-acetylmethadol (LAAM), codeine, lofexidine, and a slow-release morphine.

[0238] In some embodiments, the present technology comprises a method of reducing a need for a hospitalization or rehabilitation associated with addiction or use of an addictive substance, relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0239] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for reducing a need for a hospitalization or rehabilitation associated with addiction or use of an addictive substance, relative to a control, the non- naturally occurring melanocortin analog including a sequence of Formula (I).

[0240] In some embodiments, the present technology comprises a method of preventing or reducing a withdrawal from an addictive substance in a subject, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0241] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for preventing or reducing a withdrawal from an addictive substance in a subject, relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0242] In some embodiments, the present technology comprises a method of preventing or reducing a symptom associated with withdrawal from an addictive substance in a subject relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0243] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for preventing or reducing a symptom associated with withdrawal from an addictive substance in a subject, relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0244] In some embodiments, the symptom associated with withdrawal from an addictive substance is selected from the group consisting of pain, anxiety, depression, diarrhea, dizziness, fatigue, muscle aches, nausea, sleep problems, suicidal ideation, tremors, and visual disturbances.

[0245] In some embodiments, the subject has an addiction to an addictive substance or is susceptible to an addiction to an addictive substance.

[0246] In some embodiments, the subject has used or is using one or more addictive substances.

[0247] In some embodiments, the present technology comprises a method or the use wherein the addictive substance includes a prescription medication, a substance in an over- the-counter medication, a recreational substance, or an illegal substance.

[0248] In some embodiments, the addictive substance is selected from the group consisting of an opioid, a painkiller, a stimulant, a narcotic, an alcohol, a sedative, marijuana, a cannabis, a tetrahydrocannabinol (THC), a cannabidiol (CBD), and an inhalant.

[0249] In some embodiments, the opioid is selected from the group consisting of morphine, heroin, codeine, oxycodone, hydrocodone, and fentanyl.

[0250] In some embodiments, the stimulant is selected from the group consisting of caffeine, nicotine, methamphetamines, cocaine, and amphetamines.

[0251] In some embodiments, the sedative includes a barbiturate or a benzodiazepine.

[0252] In some embodiments, the barbiturate is selected from the group consisting of phenobarbital, methohexital, butalbital, pentobarbital, primidone, and amobarbital.

[0253] In some embodiments, the benzodiazepine is selected from the group consisting of alprazolam, lorazepam, clonazepam, diazepam, and temazepam.

[0254] In some embodiments, the sedative is selected from the group consisting of tranquilizers, xylazine, eszopiclone, zaleplon, zolpidem, and zopiclone.

[0255] In some embodiments, the inhalant is selected from the group consisting of aerosols, butanes, freon, helium, nitrous oxide, propane, and nitrites.

[0256] In some embodiments, the nicotine includes a tobacco chew, a nicotine pouch, or a smoking device.

[0257] In some embodiments, the smoking device is selected from the group consisting of cigarettes, electronic cigarettes, cigars, and vape products.

[0258] In some embodiments, the control includes the subject before administration of the non-naturally occurring melanocortin analog.

[0259] In some embodiments, the control includes the subject at baseline.

[0260] In some embodiments, the non-naturally occurring melanocortin analog is a melanocortin 4 receptor (MC4R) agonist.

[0261] In some embodiments, the MC4R agonist is a full MC4R agonist.

[0262] In some embodiments, the MC4R agonist is a partial MC4R agonist.

[0263] In some embodiments, the non-naturally occurring melanocortin analog is a MC3R antagonist.

[0264] In some embodiments, the MC3R antagonist is a full MC3R antagonist.

[0265] In some embodiments, the MC3R antagonist is a partial MC3R antagonist.

[0266] In some embodiments, the non-naturally occurring melanocortin analog does not have MC3R activity.

[0267] In some embodiments, the non-naturally occurring melanocortin analog includes a sequence according to Formula (I), wherein: X1 is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D- norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D- ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D- cysteine (dCys); R2 is selected from the group consisting of Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4- amino-1 ,2,4,5-tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H- [1 ,2,3]triazolo-[1 , 5-a][1 ,4]diazepin-6(5H)-one (Ata), 4-amino-1 ,4,5,6-tetrahydroazepino[4,3- b]indol-3(2H)-one (Aia), 2-aminotetraline-2-carboxylic acid (Ate), 1 -amino-4- phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid (APPC), octohydroindole-2 -carboxylic acid (Oic), 1 -am ino-1 -cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indoline-2 -carboxylic acid (loc), 1 - am ino-1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')), and T-naphthylalanine (Nal(1')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D- valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b- Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-naturally occurring melanocortin analog does not include a sequence selected from the group consisting of: Ac-Nle-c[Asp- Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 194); Ac-Nle-c[Asp-Pro-His- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 5); Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg- Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 10); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dPro (SEQ ID NO: 2); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 3); Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 4); Ac-Nle- c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 6); Ac-Nle-c[Asp-Phe- His-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 7); Ac-Nle-c[Asp-Hyp-dNal(2')-Arg- Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 9); Ac-Nle-Phe-Phe-c[Asp-Phe-His-dNal(2')-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 12); Ac-dArg-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 15); Ac-dLeu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 18); Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 20); Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 21 ); Ac-dNIe- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 24); Ac-dCys-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 28); Ac-dPhe-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 29); Ac-dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 30); dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 35); Tyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 36); Ac-Nle- c[Cys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 40); Ac-Nle-c[dCys-Pro- dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 41 ); Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 42); Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-dCys]- dVal-dPro-NH2 (SEQ ID NO: 43); Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 48); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 54); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 64); Ac-Nle- c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 68); Ac-Nle-c[Asp-Ala-dNal(2')- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 69); Ac-Nle-c[Asp-Leu-dNal(2')-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 76); Ac-Nle-c[Asp-Trp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 82); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 115); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 116); Ac-Nle-c[Asp- Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 117); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 118); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dHyp-NH2 (SEQ ID NO: 119); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Hyp-NH2 (SEQ ID NO: 120); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-dHyp-NH2 (SEQ ID NO: 121 ); Ac- Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-dVal-NH2 (SEQ ID NO: 122); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dHyp-dVal-NH2 (SEQ ID NO: 123); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-Hyp-Val-NH2 (SEQ ID NO: 124); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp- Val-NH2 (SEQ ID NO: 125); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-NH2 (SEQ ID NO: 126); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2 (SEQ ID NO: 127); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 128); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dPro-NH2 (SEQ ID NO: 129); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp- Lys]-Val-NH2 (SEQ ID NO: 130); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 131 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-NH2 (SEQ ID NO: 132); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-NH2 (SEQ ID NO: 133); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-dHyp-NH2 (SEQ ID NO: 134); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp- NH2 (SEQ ID NO: 135); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ ID NO: 136); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 137); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Gly-Gly-NH2 (SEQ ID NO: 138); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 139); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 140); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dArg-NH2 (SEQ ID NO: 143); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ ID NO: 144); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO:145); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-NH2 (SEQ ID NO: 146); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-dPro-NH2 (SEQ ID NO: 147); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dAsp-dPro-NH2 (SEQ ID NO: 148); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 149); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn- dPro-NH2 (SEQ ID NO: 150); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-NH2 (SEQ ID NO: 151 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-NH2 (SEQ ID NO: 152); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-NH2 (SEQ ID NO: 153); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-dAsp-NH2 (SEQ ID NO: 154); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg- NH2 (SEQ ID NO: 155); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 156); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 157); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 158); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dLys-dPro-dVal-NH2 (SEQ ID NO: 159); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-Lys-dPro-NH2 (SEQ ID NO: 160); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]- dLys-dPro-NH2 (SEQ ID NO: 161 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Val-Pro- NH2 (SEQ ID NO: 162); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 164); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 164); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 165); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-dVal-NH2 (SEQ ID NO: 166); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dArg-dPro-dVal-NH2 (SEQ ID NO: 167); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 168); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]- Arg-dVal-dPro-NH2 (SEQ ID NO: 169); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dVal- dPro-NH2 (SEQ ID NO: 170); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-dPro-NH2 (SEQ ID NO: 171 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 172); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-NH2 (SEQ ID NO: 173); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-NH2 (SEQ ID NO: 174); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dTle-dTle-dPro-NH2 (SEQ ID NO: 175); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 176); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp- Lys]-dPro-dTle-NH2 (SEQ ID NO: 177); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dTle- NH2 (SEQ ID NO: 178); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dPro-NH2 (SEQ ID NO: 179); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 180); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 181 );Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-d al-dPro-dVal-dPro-NH2 (SEQ ID NO: 182); Ac- Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 183); Ac-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 184); Ac-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 185); Ac-Nle- Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 186); Ac-Nle- c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 195); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 196); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-Trp-NH2 (SEQ ID NO: 203); Ac-Nle-c[Asp-Aba-dNal(2')-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 204); Ac-Nle-c[Asp-Aia-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 205); Ac-Nle-c[Asp-Ata-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 206); Ac- Nle-c[Asp-Cpe-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 240); Ac-Nle-c[Asp-Che- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 241 ); Ac-Nle-c[Asp-Oic-dNal(2')-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 242); Ac-Nle-c[Asp-Tic-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 244); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 245); Ac-Nle-c[Asp-His-dNal(2')-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 247); Ac-Nle-c[Asp-His-dNal(2')-cisPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 248); Ac-Nle-c[Asp-Pro-dNal(2')-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 250); Ac-Nle-c[Asp-Pro-dNal(2')-cisPro(guan)Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 251 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aba-Lys]-dVal-dPro-NH2 (SEQ ID NO: 253); Ac- Nle-c[Asp-Pro-dNal(2')-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 254); Ac-Nle-c[Asp-Glu- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 255); Ac-Nle-c[Asp-Glu-dNal(2')-Arg- Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 256); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly- Lys]-dVal-dPro-NH2 (SEQ ID NO: 259); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro- dPro-Lys-Asp-NH2 (SEQ ID NO: 260); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro- dPro-dLys-dAsp-NH2 (SEQ ID NO: 261 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro- dPro-dLys-dAsp-NH2 (SEQ ID NO: 263); Ac-Nle-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 273); Ac-Arg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 274); Ac-dArg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 275); Ac-dLeu-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 327); Ac-dNle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 328); Ac-dArg- c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 329); Ac-Arg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 330); Ac-dPhe-c[dPen-Pro-dNal(2')- Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 331 ); Ac-dTyr-c[dPen-Pro-dNal(2')-Arg-Trp- dPen]-dVal-dPro-NH2 (SEQ ID NO: 332); Ac-Ala-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal- dPro-NH2 (SEQ ID NO: 333); Ac-dHis-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 334); Ac-His-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 335); Ac-dLys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 336); Ac- Lys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 337); Ac-Nle-c[dPen- Pro-dNal(2')-Arg-Trp-dPen]-dArg-dVal-dPro-NH2 (SEQ ID NO: 344); Ac-Nle-c[dPen-Pro- dNal(2')-Arg-Trp-dPen]-dLys-dVal-dPro-NH2 (SEQ ID NO: 345); Ac-Nle-c[dPen-Pro- dNal(2')-Arg-Trp-dPen]-dArg-dPro-NH2 (SEQ ID NO: 346); Ac-Nle-c[dPen-Pro-dNal(2')- Arg-Trp-dPen]-dLys-dPro-NH2 (SEQ ID NO: 347); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp- dPen]-dVal-dHyp-NH2 (SEQ ID NO: 348); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dTle- dPro-NH2 (SEQ ID NO: 349); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-Gly-dPen]-dVal-dPro- NH2 (SEQ ID NO: 350); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 103); Ac-Nle-c[Asp-loc-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 243); Ac- Nle-c[Cys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 44); Ac-Nle-c[dCys-dNal(2')- Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 45); Ac-Nle-c[Cys-dNal(2')-Arg-Trp-dCys]-dVal- dPro-NH2 (SEQ ID NO: 46); Ac-Nle-c[dCys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 47); Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 56); Ac-Nle- c[dPen-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 62); Ac-Nle-c[Asp-dTrp- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 83); Ac-Nle-c[dPen-Ala-dNal(2')-Arg- Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 338); Ac-Nle-c[dPen-Leu-dNal(2')-Arg-Trp-dPen]- dVal-dPro-NH2 (SEQ ID NO: 339); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 223); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 464); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465); Ac- dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466); Ac-His-c[Asp- His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467); Ac-dHis-c[Asp-His- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468); Ac-Nle-Nle-c[Asp-His-p(F)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469); Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 470); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal- dVal-dPro-NH2 (SEQ ID NO: 474); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 475); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 476); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 477); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 478); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481 ); Ac-Lys- c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482); Ac-dLys-c[Asp-His- p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483); Ac-His-c[Asp-His-p(F)dPhe-Arg- Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 484); Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 485); Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 463); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 462); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 479); Ac- Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 473); Ac-dArg- c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480); Ac-Nle-c[Asp-Gln- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 491 ); Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489); Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 493); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 444); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 445); Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495); Ac- Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487); Ac-Nle-c[Asp- dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488); Ac-Nle-c[Asp-dTrp- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494); Ac-Nle-c[Asp-His-p(F)dPhe-Arg- dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471 ); Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]- dVal-dPro-NH2 (SEQ ID NO: 432); Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 217); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 222); Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 535); Ac- Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 538); Ac-Nle-Nle- c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 545); Ac-Nle-c[Asp-His- p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 546); Ac-Nle-c[Asp-His-p(Br)dPhe- Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 547); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg- Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 548); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]- dTle-dTle-dVal-NH2 (SEQ ID NO: 549); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro- dVal-dPro-NH2 (SEQ ID NO: 551 ); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 552); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 553); Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 555); Ac-Nle-c[Asp-dHis-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 562); Ac- Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 563); Ac-Nle-c[Asp- dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 564); Ac-Nle-c[Asp-Bip- p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 565); Ac-Nle-c[Asp-dGln-p(Br)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568); Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 569); Ac-Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 570); Ac-Nle-c[Asp-Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571 ); Ac-Nle-c[Asp-dTyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572); Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539); Ac-dHis- c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 544); Ac-dHis-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 561 ); Ac-dArg-c[Asp-His-p(Br)dPhe- Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 556); Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 542); Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 560); Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 543); Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557); Ac- Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541 ); Ac-Nle-c[Asp- His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 550); Ac-Lys-c[Asp- His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 558); Ac-Arg-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540); Ac-Nle-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 554); Ac-Nle-c[Asp-His-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]- dVal-dPro-NH2 (SEQ ID NO: 418); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621 ); Ac-Nle-c[Asp-His-dPhe-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 228); Ac-Nle-c[Asp-His-dPhe-cisPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 229); Ac-Nle-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 380); Ac-Nle- c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 398); Ac-Nle-c[Asp-Trp- Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401 ); Ac-Nle-Nle-c[Asp-Pro-dPhe- Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639); Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 430); Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal- dPro-NH2 (SEQ ID NO: 431 ); Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 225); Ac-Nle-c[dPen-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 326); Ac-Nle-c[Asp-Pro-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 297); Ac-Nle-c[Asp- Pro-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215); Ac-Nle-c[Asp-Phe- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 525); Ac-Nle-c[Asp-dPhe-p(CI)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 526); Ac-Nle-c[Asp-Bip-p(CI)dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 527); Ac-Nle-c[Asp-Trp-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 531 ); Ac-Nle-c[Asp-Tyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533); Ac-Nle-c[Asp-dTyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534); Ac-Nle-c[Asp-dTrp-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532); Ac-Nle- c[dCys-His-p(CI)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498); Ac-Nle-c[Cys-His- p(CI)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 497); Ac-Nle-c[Asp-His-p(CI)dPhe- Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 509); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg- Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 510); Ac-Nle-c[Asp-His-p(CI)dPhe-His-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 508); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 220); Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 507); Ac-Ala-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517); Ac-Ala-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 500); Ac-Nle- Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516); Ac-Nle- c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514); Ac-Nle-c[Asp-dGln- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 530); Ac-Arg-c[Asp-dAla-His-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 268); Ac-Nle-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 378); Ac-dArg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 379); Ac-Nle-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 266); Ac-Arg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 267); Ac-Arg-c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 269); Ac- dArg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 270); Ac-Arg- c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-NH2 (SEQ ID NO: 282); and Ac-Arg-c[Asp-dAla-His- dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 283).

[0268] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence according to Formula (IA): X1 -X2-X3-R1-R2-R3-R4-R5-R6-R7-R8-Y1 -Y2-Y3-Y4 (IA), wherein: X1 is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D-norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D-ornithine (dOm), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D-cysteine (dCys); R2 is selected from the group consisting of Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2- aminotetraline-2-carboxylic acid (Ate), octohydroindole-2-carboxylic acid (Oic), 1-amino-1 - cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino- 1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of dPhe, para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is Arg or His; R6 is selected from the group consisting of Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')), and T- naphthylalanine (Nal(1 ')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 are independently selected from the group consistingof Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys,R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that: when R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGIn, dTyr, R6 is Trp, and the non-naturally occurring melanocortin analog is not cyclized between Cys at R2 and Cys at R7 or (ii) R3 is His and either R6 is Nal(2') or the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between R2 and R7, where R2 and R7 are the same; when R4 is p(Br)dPhe, then the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and Cys or dCys at R7; when R4 is dPhe, then (i) R3 is not His, Pro, or absent, (ii) R3 is His and either R2 is Phe or dAla or R2 is Ala and X1 is Arg or dArg, (iii) R3 is Pro and (a) R2 is Trp, and R5 is not His or R6 is not Phe or (b) R2 is not T rp or Pro, and either R5 is not dNal(2') or N a I (2' ) or X1 and Y3 are not both present, or (iv) R3 is absent and R2 and R7 are not both dPen; and when R4 is p(CI)dPhe, then (i) R3 is selected from Aba, Aia, and Ata or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and dCys at R7, or (b) if R1 is Nle, and Y1Y2 is not dVal-dPro, then either X1 or Y3 is present.

[0269] In some embodiments, the non-naturally occurring melanocortin analog includes a sequence according to Formula (IA), wherein: X1 is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D- norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D- ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D- cysteine (dCys); R2 is selected from the group consisting of Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2-aminotetraline- 2-carboxylic acid (Ate), octohydroindole-2 -carboxylic acid (Oic), 1 -amino-1 - cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1 -amino-1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of dPhe, para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is Arg or His; R6 is selected from the group consisting of Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')), and T- naphthylalanine (Nal(1 ')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-naturally occurring melanocortin analog does not include a sequence selected from the group consisting of: Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 223); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 464); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465); Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466); Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467); Ac-dHis- c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468); Ac-Nle-Nle-c[Asp-His- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469); Ac-Nle-c[Asp-His-p(F)dPhe-His- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal- dVal-dVal-dPro-NH2 (SEQ ID NO: 474); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro- dVal-dPro-NH2 (SEQ ID NO: 475); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro- NH2 (SEQ ID NO: 476); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQID NO: 477); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 478); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481 ); Ac- Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482); Ac-dLys-c[Asp- His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483); Ac-His-c[Asp-His-p(F)dPhe- Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 484); Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 485); Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 463); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 462); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 479); Ac- Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 473); Ac-dArg- c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480); Ac-Nle-c[Asp-Bip- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489); Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]- dVal-dPro-NH2 (SEQ ID NO: 444); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro- NH2 (SEQ ID NO: 445); Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495); Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487); Ac- Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488); Ac-Nle-c[Asp- dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494); Ac-Nle-c[Asp-His- p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471 ); Ac-Nle-c[Cys-Pro- p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432); Ac-Nle-c[dCys-His-p(F)dPhe- Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 460); Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 217); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 222); Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 535); Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 538); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 545); Ac- Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 546); Ac-Nle-c[Asp- His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 547); Ac-Nle-c[Asp-His- p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 548); Ac-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 549); Ac-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 551 ); Ac-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 552); Ac-Nle-Nle-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 553); Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 555); Ac-Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 563); Ac-Nle-c[Asp-dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 564); Ac-Nle-c[Asp-Bip-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 565); Ac-Nle-c[Asp-dGln-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568); Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 569); Ac- Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 570); Ac-Nle-c[Asp- Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571 ); Ac-Nle-c[Asp-dTyr- p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572); Ac-dArg-c[Asp-His-p(Br)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539); Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 544); Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 561 ); Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 556); Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 542); Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 560); Ac- His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 543); Ac-dLys-c[Asp- His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559); Ac-Arg-c[Asp-His- p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557); Ac-Lys-c[Asp-His-p(Br)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541 ); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]- dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 550); Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 558); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 540); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro- NH2 (SEQ ID NO: 554); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 418); Ac-Nle- c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621 ); Ac-Nle-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639); Ac-Nle-c[dPen-dPhe-Arg-Trp- dPen]-dVal-dPro-NH2 (SEQ ID NO: 326); Ac-Nle-c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 398); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401 ); Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 225); Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 430); Ac-Nle- c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 431 ); Ac-Nle-c[Asp-Ala-His- dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 380); Ac-Nle-c[Asp-Pro-p(CI)dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215); Ac-Nle-c[Asp-Phe-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 525); Ac-Nle-c[Asp-dPhe-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 526); Ac-Nle-c[Asp-Bip-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 527); Ac-Nle-c[Asp-Trp-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 531 ); Ac- Nle-c[Asp-Tyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533); Ac-Nle-c[Asp- dTyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534); Ac-Nle-c[Asp-dTrp- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532); Ac-Nle-c[dCys-His-p(CI)dPhe- Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498); Ac-Nle-c[Cys-His-p(CI)dPhe-Arg-Trp- Cys]-dVal-dPro-NH2 (SEQ ID NO: 497); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-dNal(2')-Lys]- dVal-dPro-NH2 (SEQ ID NO: 509); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Nal(2')-Lys]-dVal-dPro- NH2 (SEQ ID NO: 510); Ac-Nle-c[Asp-His-p(CI)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 508); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 220); Ac- Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 507); Ac-Ala- c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517); Ac-Ala-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 500); Ac-Nle-Nle-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516); and Ac-Nle-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514).

[0270] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula (IB): X1 -X2-X3-R1-R2-Pro-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7 (IB), wherein: X1 is absent or norleucine (Nle); X2 is absent or Nle; X3 is absent or Nle; R1 is selected from the group consisting of Nle, D-norleucine (dNIe), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis), ornithine (Orn), D-omithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D- phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R2 is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), cysteine (Cys), D-cysteine (dCys), and D-penicillamine (dPen); R4 is dPhe or para-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, and T-naphthylalanine (Nal(1 ')); R7 is selected from the group consisting of Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline(b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2 and R7 when each of R2 and R7 are independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2 and R7 when R2 is Asp or dAsp and R7 is Lys, dLys, or Orn; provided that: when R4 is p(F)dPhe, then the non-naturally occurring melanocortin analog is not cyclized between Cys at R2 and Cys at R7; and when R4 is dPhe and one or more of X1 , X2, and X3 is present, then Y3-Y7 are absent.

[0271] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula (IB), wherein: X1 -X2-X3-R1 -R2-Pro-R4-R5-R6-R7-R8-Y1 -Y2-Y3-Y4-Y5-Y6-Y7 (IB), wherein: X1 is absent or norleucine (Nle); X2 is absent or Nle; X3 is absent or Nle; R1 is selected from the group consisting of Nle, D-norleucine (dNIe), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), D- histidine (dHis), ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R2 is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), cysteine (Cys), D-cysteine (dCys), and D-penicillamine (dPen); R4 is dPhe or para-fluoro- D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, and 1 '-naphthylalanine ( Nal( 1 ')); R7 is selected from the group consisting of Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3- Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D- asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the groupconsisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2 and R7 when each of R2 and R7 are independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2 and R7 when R2 is Asp or dAsp and R7 is Lys, dLys, or Orn; provided that the non-naturally occurring melanocortin analog does not include a sequence of: Ac- Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432); or Ac-Nle-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639).

[0272] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula (IC): X1 -X2-R1 -R2-Pro-dPhe-R5-R6-R7-Y1-Y2-Y3-Y4 (IC), wherein: X1 is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent or Nle; R1 is selected from the group consisting of aspartic acid (Asp), cysteine (Cys), and D-cysteine (dCys); R2 is selected from the group consisting of tryptophan (Trp), phenylalanine (Phe), D- phenylalanine (dPhe), histidine (His), D-histidine (dHis), tyrosine (Tyr), and D-tyrosine (dTyr); R5 is Arg; R6 is selected from the group consisting of Trp, 2'-D-naphthylalanine (dNal(2')), 2'-naphthylalanine (Nal(2')), and T-naphthylalanine (Nal(1')); R7 is selected from the group consisting of Lys, Cys, and dCys; Y1 is absent or is selected from the group consisting of D-valine (dVal), D-tert-leucine (dTle), dArg, and dLys; Y2 is absent or is selected from the group consisting of dVal, dPro, and D-hydroxyproline (dHyp); Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 and R7 when both of R1 and R7 are independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R1 and R7 when R1 is Asp and R7 is Lys;

[0273] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula (ID): X1 -R1-R2-R3-p(CI)dPhe-Arg-Trp-R7-Y1 -Y2-Y3-Y4 (ID), wherein: X1 is absent or norleucine (Nle); R1 is selected from the group consisting of Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); R2 is aspartic acid (Asp) or D-cysteine (dCys); R3 is selected from the group consisting of His, 4-amino- 1 ,2,4,5-tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H-[1 ,2,3]triazolo-[1 ,5- a][1 ,4]diazepin-6(5H)-one (Ata), and 4-amino-1 ,4,5,6-tetrahydroazepino[4,3-b]indol-3(2H)- one (Aia); R7 is Lys or dCys; Y1 is selected from the group consisting of D-valine (dVal), D- proline (dPro), and D-tert-leucine (dTle); Y2 is absent or is selected from the group consisting of dVal, dPro, and dTle; Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2 and R7 when both of R2 and R7 are dCys; and a lactam bridge between R2 and R7 when R2 is Asp and R7 is Lys; provided that when R3 is His and R1 is Nle, then (i) Y1 Y2 is dVal-dPro, X1 is absent, and the non-naturally occurring melanocortin analog is cyclized through a disulfide bond, or (b) Y1 Y2 is not dVal- dPro and either X1 or Y3 is present.

[0274] In some embodiments, the present technology comprises a method or use, wherein the non-naturally occurring melanocortin analog includes a sequence of Formula (ID), wherein: X1 is absent or norleucine (Nle); R1 is selected from the group consisting of Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), and D- histidine (dHis); R2 is aspartic acid (Asp) or D-cysteine (dCys); R3 is selected from the group consisting of His, 4-amino-1 ,2,4,5-tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8- dihydro-4H-[1 ,2,3]triazolo-[1 ,5-a][1 ,4]diazepin-6(5H)-one (Ata), and 4-amino-1 ,4,5,6- tetrahydroazepino[4,3-b]indol-3(2H)-one (Aia); R7 is Lys or dCys; Y1 is selected from the group consisting of D-valine (dVal), D-proline (dPro), and D-tert-leucine (dTle); Y2 is absent or is selected from the group consisting of dVal, dPro, and dTle; Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2 and R7 when both of R2 and R7 are dCys; and a lactam bridge between R2 and R7 when R2 is Asp and R7 is Lys; provided that the non-naturally occurring melanocortin analog does notinclude a sequence selected from the group consisting of: Ac-Nle-c[Asp-His-p(CI)dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 220); Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 507); Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dPro- dVal-dPro-NH2 (SEQ ID NO: 516); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro- NH2 (SEQ ID NO: 514); and.

[0275] In some embodiments, an N-terminus of the non-naturally occurring melanocortin analog is modified by an acyl group.

[0276] In some embodiments, the acyl group is an acetyl group.

[0277] In some embodiments, an N-terminus of the non-naturally occurring melanocortin analog is not modified.

[0278] In some embodiments, a C-terminus of the non-naturally occurring melanocortin analog is modified by an amide group.

[0279] In some embodiments, a C-terminus of the non-naturally occurring melanocortin analog is not modified.

[0280] In some embodiments, Y1-Y2 are present and Y3- Y8 are absent.

[0281] In some embodiments, Y1 is D-valine and Y2 is D-proline.

[0282] In some embodiments, the present technology comprises a method or a use, w wherein Y1 is D-tert-leucine and Y2 is D-proline.

[0283] In some embodiments, R4 is dNal(2').

[0284] In some embodiments, the sequence of Formula (I) is: Ac-Nle-c[Asp-His- dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 8), wherein c represents cyclization through R2 and R8 via a lactam bond.

[0285] In some embodiments, R4 is Phe or dPhe.

[0286] In some embodiments, the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 291 ); Ac-Nle-c[Asp-Pro-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 294); Ac-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 295; E2); and Ac-Nle-c[Asp-Pro-His-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 296). wherein c represents cyclization through R2 and R7 via a lactam bond.

[0287] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-dLeu-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:298); Ac-dAla-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 299); Ac- Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 300); Ac-dNle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 301 ); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 302); Ac-dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 303); Ac-dTyr-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 304); Phe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 305); His-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 306); Trp-c[Asp-Pro-dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 307); dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 308); dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 309); dTrp-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 310); Ac-Arg-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 311 ); Ac-dLys-c[Asp-Pro-dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 312); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 313); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 314); Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 315); Ac- Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 316); and Ac-dOrn-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 317), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0288] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Cys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 318); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 319); Ac- Nle-c[dPen-Pro-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 320); Ac-Nle-c[dCys- Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 321 ); Ac-Nle-c[Asp-Pro-dPhe-Arg- Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 322); and Ac-Nle-c[Cys-dPhe-Arg-Trp-Pen]-dVal- dPro-NH2 (SEQ ID NO: 324), wherein c represents cyclization through R2 and R7 via a disulfide bond.

[0289] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 351 ); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 352); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp- NH2 (SEQ ID NO: 353), wherein c represents cyclization through R2 and R8 via a lactam bond.

[0290] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 354); Ac-Nle-c[Asp-Leu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 355); Ac-Nle- c[Asp-Cpe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 358); Ac-Nle-c[Asp-Che-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 359); Ac-Nle-c[Asp-Oic-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 360); Ac-Nle-c[Asp-loc-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 361 ); Ac-Nle-c[Asp-Tic-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 362); Ac-Nle- c[Asp-Hyp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 364); Ac-Nle-c[Asp-Phe-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 366); Ac-Nle-c[Asp-dPhe-dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 367); Ac-Nle-c[Asp-Bip-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 368); Ac-Nle-c[Asp-dGln-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 371 ); Ac-Nle-c[Asp-Trp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 372); Ac-Nle- c[Asp-dTrp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 373); Ac-Nle-c[Asp-Tyr-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 374); Ac-Nle-c[Asp-dTyr-dPhe-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 375); Ac-Nle-c[Asp-Aba-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 198); Ac-Nle-c[Asp-Aia-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 207); Ac-Nle-c[Asp-Ata-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 208); Ac-Nle-c[Asp-Atc- dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 212); Ac-Nle-c[Asp-APC-dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 213); and Ac-Nle-c[Asp-APPC-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 214), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0291] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Arg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 281 ); Ac-Arg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 381 ); and Ac-dArg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 382), wherein c represents cyclization through R1 and R7 via a lactam bond.

[0292] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 226); Ac-Nle-c[Cys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 383); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 384); Ac- Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 385); Ac-Ala-c[Asp- Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 386); Ac-Lys-c[Asp-Trp-Pro- dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 387); Ac-dLys-c[Asp-Trp-Pro-dPhe-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 388); Ac-Arg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 389); Ac-dArg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 390); Ac-dHis-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 391 ); Ac-His-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 392); Ac-Nle- Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 393); Ac-Nle-c[Asp- Trp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 394); Ac-Nle-c[Asp-Trp-Leu-dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 395); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(1 ']- Lys]-dVal-dPro-NH2 (SEQ ID NO: 399); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-dNal(2')-Lys]- dVal-dPro-NH2 (SEQ ID NO: 403); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro- NH2 (SEQ ID NO: 404); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 405); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 406); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 407); Ac- Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 408); Ac-Nle-c[Asp- Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 409); Ac-Nle-c[Asp-Trp-Pro- dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 410); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp- Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 411 ); Ac-Nle-c[Asp-Phe-Pro-dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 412); Ac-Nle-c[Asp-His-Pro-dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 413); Ac-Nle-c[Asp-Tyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 414); Ac-Nle-c[Asp-dPhe-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 415); Ac-Nle-c[Asp-dHis-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 416); and Ac-Nle-c[Asp-dTyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 417), wherein c represents cyclization through R1 and R7 via a lactam bond or a disulfide bond.

[0293] In some embodiments, the sequence of any one of Formulae (l)-(ID) is: Ac-Nle- c[Asp-Hyp-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 419), wherein c represents cyclization through R2 and R8 via a lactam bond.

[0294] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-Phe-Phe-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 421 ); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 422); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 423); and Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 424), wherein c represents cyclization through R1 and R7 via a lactam bond.

[0295] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 187); Ac-Nle-c[Asp-Pro-dPhe-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 233); Ac- Nle-c[Asp-Pro-dPhe-Arg-Aba-Lys]-dVal-dPro-NH2 (SEQ ID NO: 234); Ac-Nle-c[Asp-Pro- dPhe-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 235); Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(1 ')- Lys]-dVal-dPro-NH2 (SEQ ID NO: 427); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Phe-Lys]-dVal- dPro-NH2 (SEQ ID NO: 429), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0296] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 218); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 433); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 434); Ac- Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 435); Ac-dArg-c[Asp- Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 436); Ac-Arg-c[Asp-Pro- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 437); Ac-Lys-c[Asp-Pro-p(F)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 438); Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 439); Ac-His-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 440); Ac-dHis-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 441 ); Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 442); Ac-Nle-c[Asp-Pro-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 443); Ac- Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 446); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 447); Ac-Nle- c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 448); Ac-Nle-c[Asp- Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 449); Ac-Nle-Nle-c[Asp-Pro- p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 450); Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe- Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 451 ); Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp- Lys]-dTle-dPro-NH2 (SEQ ID NO: 452); Ac-dArg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 453); Ac-Arg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 454); Ac-Lys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 455); Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 456); Ac-His- c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 457); Ac-dHis-c[Asp-Pro- p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 458); Ac-Nle-c[Cys-His-p(F)dPhe-Arg- Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 459); Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-Cys]- dVal-dPro-NH2 (SEQ ID NO: 460); Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro- NH2 (SEQ ID NO: 461 ); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 472); Ac-Nle-c[Asp-dGln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 492); and Ac-Nle-c[Asp-dTyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 496), wherein c represents cyclization through R2 and R7 via a lactam bond or a disulfide bond.

[0297] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Aba-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 209); Ac-Nle-c[Asp-Aia-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 210); Ac-Nle-c[Asp-Ata-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 211 ); Ac-Nle- c[dCys-His-p(CI)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 499); Ac-dArg-c[Asp- His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 501 ); Ac-Arg-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 502); Ac-Lys-c[Asp-His-p(CI)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 503); Ac-dLys-c[Asp-His-p(CI)dPhe-Arg-Trp- Lys]-dVal-dPro-NH2 (SEQ ID NO: 504); Ac-His-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 505); Ac-dHis-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 506); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 511 ); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 512); Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 513); Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 515); Ac-dArg-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 518); Ac-Arg-c[Asp- His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 519); Ac-Lys-c[Asp-His- p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 520); Ac-dLys-c[Asp-His-p(CI)dPhe- Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 521 ); Ac-His-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 522); and Ac-dHis-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 523), wherein c represents cyclization through R2 and R7 via a lactam bond or a disulfide bond.

[0298] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 536); or Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 537), wherein c represents cyclization through R2 and R7 via a disulfide bond.

[0299] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 573); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 574); Ac-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 575); Ac-Nle-c[Asp-Pro-dPhe- Arg-Trp-Lys]-Val-NH2 (SEQ ID NO: 576); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 577); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 578); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dArg-NH2 (SEQ ID NO: 579); Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 580); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp- Lys]-Arg-NH2 (SEQ ID NO: 581 ); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 582); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 583); Ac- Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 584); Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-Lys-Val-Pro-NH2 (SEQ ID NO: 585); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp- Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 586); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys- dVal-dPro-NH2 (SEQ ID NO: 587); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 588); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 589); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 590); Ac- Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 591 ); Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dTle-dTle-dPro-NH2 (SEQ ID NO: 592); Ac-Nle-c[Asp-Pro-dPhe-Arg- Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 593); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dTle-NH2 (SEQ ID NO: 594); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dPro- NH2 (SEQ ID NO: 595); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 596); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 597); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQ ID NO: 598); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 599); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Trp-NH2 (SEQ ID NO: 600); Ac-Nle-c[Asp- Pro-dPhe-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 601 ); Ac-Nle-c[Asp-Pro-dPhe- Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ ID NO: 602); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asp- NH2 (SEQ ID NO: 603); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dHyp-NH2 (SEQ ID NO: 604); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ ID NO: 605); Ac-Nle-c[Asp-Pro- dPhe-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 606); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]- Asn-dPro-NH2 (SEQ ID NO: 607); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Hyp-NH2 (SEQ ID NO: 608); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 609); Ac-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-Gly-Gly-NH2 (SEQ ID NO: 610); Ac-Nle-c[Asp-Pro-dPhe-Arg- Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO: 611 ); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsn- dPro-NH2 (SEQ ID NO: 612); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asn-NH2 (SEQ ID NO: 613); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsp-NH2 (SEQ ID NO: 614); Ac-Nle-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 615); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp- Lys]-Lys-dPro-NH2 (SEQ ID NO: 616); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 617); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-NH2 (SEQ ID NO: 618); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-OH (SEQ ID NO: 619); Ac-Nle- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 620); Ac-Nle-c[dAsp-Pro-dPhe- Arg-Trp-dLys]-dPro-dVal-NH2 (SEQ ID NO: 622); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]- pPro-p2Val-NH2 (SEQ ID NO: 623); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-pPro-p3Val-NH2 (SEQ ID NO: 624); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-p2Val-pPro-NH2 (SEQ ID NO: 625); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-p3Val-pPro-NH2 (SEQ ID NO: 626); and Ac- Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-pPro-pPro-NH2 (SEQ ID NO: 627), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0300] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 628); Ac-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 629); and Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 630), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0301] In some embodiments, the sequence of any one of Formulae ( I )-(l D) is selected from the group consisting of: Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 631 ); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 632); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 633); Ac-His- c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 634); Ac-dHis-c[Asp-Pro-dPhe- Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 635); Ac-Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]- dTle-dPro-NH2 (SEQ ID NO: 636); Ac-dOrn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal- dPro-NH2 (SEQ ID NO: 637); Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 638); Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 640); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 641 ); Ac-Arg-c[Asp- Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 642); Ac-Lys-c[Asp-Pro-dPhe-Arg- Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 643); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle- dPro-NH2 (SEQ ID NO: 644); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 645); and Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 646), wherein c represents cyclization through R2 and R7 via a lactam bond.

[0302] In some embodiments, the non-naturally occurring melanocortin analog includes any one of SEQ ID NOs: 8, 187, 198, 207-218, 226, 231 -235, 281 , 291 , 294-296, 298-322, 324, 351 -355, 358-362, 364, 366-368, 371-375, 381 -395, 399, 403-417, 419, 421- 425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646.

[0303] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 187, 212, 218, 226, 291 , 295, 298-322, 324, 351-355, 358-360, 362, 364, 366-368, 371 -375, 381-395, 399, 403-417, 419, 421 -425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573- 598, 600-646.

[0304] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 187, 218, 231 -235, 291 , 295, 298-322, 351-353, 425, 427, 429, 433-443, 446-458, 573-599, 600-620, 622-646.

[0305] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 226, 383-393, 399, 403-417.

[0306] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 209-211 , 499, 501 -506, 511 -513, 515, 518-523.

[0307] In some embodiments, the non-naturally occurring melanocortin analog is present in a pharmaceutical composition.

[0308] In some embodiments, the pharmaceutical composition includes one or more pharmaceutically acceptable excipients and / or carriers.

[0309] In some embodiments, the one or more pharmaceutically acceptable excipients and / or carriers of the pharmaceutical composition include water.

[0310] In some embodiments, the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 5 mg / kg to about 20 mg / kg administered once a day for about 5 days to about 10 days; (ii) at a second dose of about 10 mg / kg to about 40 mg / kg administered once a day after administration of the first dose for about 5 days to about 10 days; (iii) at a third dose of about 5 mg / kg to about 30 mg / kg administered twice a day after administration of the second dose for at least about 5 days to about 10 days.

[0311] In some embodiments, the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 5 mg / kg administered once a day for about 7 days; (ii) at a second dose of about 15 mg / kg administered once a day after administration of the first dose for about 7 days; (iii) at a third dose of about 10 mg / kg administered twice a day after administration of the second dose for at least about 7 days.

[0312] In some embodiments, the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 10 mg / kg administered once a day for about 7 days; (ii) at a second dose of about 20 mg / kg administered once a day after administration of the first dose for about 7 days; (iii) at a third dose of about 15 mg / kg administered twice a day after administration of the second dose for at least about 7 days.

[0313] In some embodiments, the present technology comprises a method or the use wherein the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 15 mg / kg administered once a day for about 7 days; (ii) at a second dose of about 25 mg / kg administered once a day after administration of the first dose for about 7 days; (iii) at a third dose of about 20 mg / kg administered twice a day after administration of the second dose for at least about 7 days.

[0314] In some embodiments, the non-naturally occurring melanocortin analog is administered at a dose of about 0.5 mg / kg to about 10 mg / kg per body weight of the subject once daily.

[0315] In some embodiments, the non-naturally occurring melanocortin analog is administered at a dose of about 1 mg / kg or 3 mg / kg per body weight of the subject once daily.

[0316] In some embodiments, the non-naturally occurring melanocortin analog is administered at a dose of about 0.1 mg to about 100 mg once daily.

[0317] In some embodiments, the non-naturally occurring melanocortin analog is administered at a dose of about 10 mg or about 50 mg once daily.

[0318] In some embodiments, the non-naturally occurring melanocortin analog is administered via intraperitoneal, intravenous, parenteral, subcutaneous, intramuscular, intracerebroventricular, intranasal, or oral administration.

[0319] In some embodiments, the non-naturally occurring melanocortin analog crosses a blood-brain-barrier of a subject.

[0320] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 8, 187, 198, 207-218, 226, 231 -235, 281 , 291 , 294-296, 298-322, 324, 351 -355, 358-362, 364, 366-368, 371-375, 381 -395, 399, 403-417, 419, 421 -425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511 -513, 515, 518-523, 536-537, 573-599, 600-620, 622-646 and is administered at least once daily in an amount ranging from 0.001 mg / kg to 25 mg / kg per body weight of the subject.

[0321] In some embodiments, the non-naturally occurring melanocortin analog includes any one of the sequences of SEQ ID NOs: 8, 187, 198, 207-218, 226, 231 -235, 281 , 291 , 294-296, 298-322, 324, 351 -355, 358-362, 364, 366-368, 371-375, 381 -395, 399, 403-417, 419, 421 -425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511 -513, 515, 518-523, 536-537, 573-599, 600-620, 622-646 and is administered at least once daily in an amount ranging from 0.5 mg / kg to 10 mg / kg per body weight of the subject.

[0322] In some embodiments, the non-naturally occurring melanocortin analog is administered to a subject for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, or 5 years.

[0323] In some embodiments, the non-naturally occurring melanocortin analog is administered to a subject for 1 day, 5 days, 7 days, 14 days, 21 days, 28 days, 35 days, 40 days, 45 days, 50 days, 60 days, 75 days, 90 days, 100 days, 110 days, or 120 days. In some embodiments, the present technology comprises a method of reducing a pain level in a subject in need thereof relative to a control, including administering to the subject a non- naturally occurring melanocortin analog of Formula (I): X1 -X2-X3-R1-R2-R3-R4-R5-R6-R7- R8-Y1 -Y2-Y3-Y4-Y5-Y6-Y7 (I), wherein: X1 is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D-norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D-cysteine (dCys); R2 is selected from the group consisting of Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-amino-1 ,2,4,5- tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H-[1 ,2,3]triazolo-[1 ,5- a][ 1 ,4]diazepin-6(5H)-one (Ata), 4-amino-1 ,4,5,6-tetrahydroazepino[4,3-b]indol-3(2H)-one (Aia), 2-aminotetraline-2-carboxylic acid (Ate), 1 -amino-4-phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid (APPC), octohydroindole-2-carboxylic acid (Oic), 1 -amino-1 -cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline- 3-carboxylic acid (Tic), indoline-2-carboxylic acid (loc), 1 -am ino-1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of Phe, dPhe, 2'- D-naphthylalanine (dNal(2')), para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D- phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')), and T-naphthylalanine (Nal(1 ')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D-valine (dVal), b2-valine (b2-Val), b3- valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D- tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 when each of R1 or R2 and R7 are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that: when R4 is dNal(2'), then R3 is His and R7 is Pro; when R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGIn, dTyr, R6 is Trp, and the non-naturally occurring melanocortin analog is not cyclized between Cys at R2 and Cys at R7 or (ii) R3 is His and either R6 is Nal(2') or the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between R2 and R7; when R4 is p(Br)dPhe, then the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and Cys or dCys at R7; when R4 is dPhe, then (i) R3 is not His, Pro, or absent, (ii) R3 is His and either R2 is Phe or dAla or R2 is Ala and X1 is Arg or dArg, (iii) R3 is Pro and (a) R2 is Trp, andR5 is not His or R6 is not Phe or (b) R2 is not Trp or Pro, and either R5 is not dNal(2') or Nal(2') or X1 and Y3 are not both present, or (iv) R3 is absent and R2 and R7 are not both dPen; when R4 is p(CI)dPhe, then (i) R3 is selected from Aba, Aia, and Ata or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non- naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2 and dCys at R7, or (b) if R1 is Nle, and Y1 Y2 is not dVal-dPro, then either X1 or Y3 is present; and when R2 is dAla, then R4 is dPhe and Y1 -Y7 are absent.

[0324] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for reducing a pain level in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0325] In some embodiments, the present technology comprises a method of treating, preventing, or reducing an addiction in a subject relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0326] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for treating, preventing, or reducing an addiction in a subject relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0327] In some embodiments, the present technology comprises a method of preventing or reducing a use of or dependence on an addictive substance in a subject relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0328] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for treating, preventing, or reducing a use of or dependence on an addictive substance in a subject relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0329] In some embodiments, the present technology comprises a method of treating or preventing an opioid use disorder (OUD) in a subject in need thereof relative to a control,including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0330] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for treating or preventing an OUD in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0331] In some embodiments, the present technology comprises a method of treating or preventing an alcohol use disorder (AUD) in a subject in need thereof relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0332] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for treating or preventing an AUD in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0333] In some embodiments, the method or the use includes reducing a dose used or consumed of an addictive substance, relative to a control.

[0334] In some embodiments, the method or the use includes reducing a dependency on an addictive substance, relative to a control.

[0335] In some embodiments, the method or the use includes reducing a frequency of an addictive substance use, relative to a control.

[0336] In some embodiments, the method or the use includes reducing a dose or dosage of a conventional medication used to treat an addiction, relative to a control.

[0337] In some embodiments, the present technology comprises a method of augmenting an effect of a conventional medication used to treat an addiction in a subject in need thereof, relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0338] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for augmenting an effect of a conventional medication usedto treat an addiction in a subject in need thereof, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0339] In some embodiments, the present technology comprises a method of reducing or eliminating a need for a conventional medication used to treat an addiction in a subject in need thereof, relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0340] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for reducing or eliminating a need for a conventional medication used to treat an addiction in a subject in need thereof, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0341] In some embodiments, the treatment of the addiction is improved during or after administration of the non-naturally occurring melanocortin analog relative to treatment of the addiction using the conventional medication to treat the addiction alone.

[0342] In some embodiments, the conventional medication to treat the addiction is selected from the group consisting of buprenorphine, naltrexone, acamprosate, methadone, naloxone, nalmefene, xycodone, levo-alpha-acetylmethadol (LAAM), codeine, lofexidine, and a slow-release morphine.

[0343] In some embodiments, the present technology comprises a method of reducing a need for a hospitalization or rehabilitation associated with addiction or use of an addictive substance, relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0344] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for reducing a need for a hospitalization or rehabilitation associated with addiction or use of an addictive substance, relative to a control, the non- naturally occurring melanocortin analog including a sequence of Formula (I).

[0345] In some embodiments, the present technology comprises a method of preventing or reducing a withdrawal from an addictive substance in a subject, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0346] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for preventing or reducing a withdrawal from an addictive substance in a subject, relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0347] In some embodiments, the present technology comprises a method of preventing or reducing a symptom associated with withdrawal from an addictive substance in a subject relative to a control, including administering to the subject a non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0348] In some embodiments, the present technology comprises use of a non-naturally occurring melanocortin analog for preventing or reducing a symptom associated with withdrawal from an addictive substance in a subject, relative to a control, the non-naturally occurring melanocortin analog including a sequence of Formula (I).

[0349] In some embodiments, the symptom associated with withdrawal from an addictive substance is selected from the group consisting of pain, anxiety, depression, diarrhea, dizziness, fatigue, muscle aches, nausea, sleep problems, suicidal ideation, tremors, and visual disturbances.

[0350] In some embodiments, the subject has an addiction to an addictive substance or is susceptible to an addiction to an addictive substance.

[0351] In some embodiments, the subject has used or is using one or more addictive substances.

[0352] In some embodiments, the present technology comprises a method or the use wherein the addictive substance includes a prescription medication, a substance in an over- the-counter medication, a recreational substance, or an illegal substance.

[0353] In some embodiments, the addictive substance is selected from the group consisting of an opioid, a painkiller, a stimulant, a narcotic, an alcohol, a sedative, marijuana, a cannabis, a tetrahydrocannabinol (THC), a cannabidiol (CBD), and an inhalant.

[0354] In some embodiments, the opioid is selected from the group consisting of morphine, heroin, codeine, oxycodone, hydrocodone, and fentanyl.

[0355] In some embodiments, the stimulant is selected from the group consisting of caffeine, nicotine, methamphetamines, cocaine, and amphetamines.

[0356] In some embodiments, the sedative includes a barbiturate or a benzodiazepine.

[0357] In some embodiments, the barbiturate is selected from the group consisting of phenobarbital, methohexital, butalbital, pentobarbital, primidone, and amobarbital.

[0358] In some embodiments, the benzodiazepine is selected from the group consisting of alprazolam, lorazepam, clonazepam, diazepam, and temazepam.

[0359] In some embodiments, the sedative is selected from the group consisting of tranquilizers, xylazine, eszopiclone, zaleplon, zolpidem, and zopiclone.

[0360] In some embodiments, the inhalant is selected from the group consisting of aerosols, butanes, freon, helium, nitrous oxide, propane, and nitrites.

[0361] In some embodiments, the nicotine includes a tobacco chew, a nicotine pouch, or a smoking device.

[0362] In some embodiments, the smoking device is selected from the group consisting of cigarettes, electronic cigarettes, cigars, and vape products.

[0363] In some embodiments, the control includes the subject before administration of the non-naturally occurring melanocortin analog.

[0364] In some embodiments, the control includes the subject at baseline.

[0365] In some embodiments, the non-naturally occurring melanocortin analog is a melanocortin 4 receptor (MC4R) agonist.

[0366] In some embodiments, the MC4R agonist is a full MC4R agonist.

[0367] In some embodiments, the MC4R agonist is a partial MC4R agonist.

[0368] In some embodiments, the non-naturally occurring melanocortin analog is a MC3R antagonist.

[0369] In some embodiments, the MC3R antagonist is a full MC3R antagonist.

[0370] In some embodiments, the MC3R antagonist is a partial MC3R antagonist.

[0371] In some embodiments, the non-naturally occurring melanocortin analog does not have MC3R activity.

[0372] In some embodiments, the non-naturally occurring melanocortin analog includes a sequence according to Formula (I), wherein: X1 is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of Nle, D- norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D- ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D- cysteine (dCys); R2 is selected from the group consisting of Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is absent or is selected from the group consisting of His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4- amino-1 ,2,4,5-tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H- [1 ,2,3]triazolo-[1 , 5-a][1 ,4]diazepin-6(5H)-one (Ata), 4-amino-1 ,4,5,6-tetrahydroazepino[4,3- b]indol-3(2H)-one (Aia), 2-aminotetraline-2-carboxylic acid (Ate), 1 -amino-4- phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid (APPC), octohydroindole-2 -carboxylic acid (Oic), 1 -am ino-1 -cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indoline-2 -carboxylic acid (loc), 1 - am ino-1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')), and T-naphthylalanine (Nal(1')); R7 is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is absent or is selected from the group consisting of valine (Vai), D- valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro, D-proline (dPro), b-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2is absent or is selected from the group consisting of Vai, dVal, b2-Val, b3-Val, Pro, dPro, b- Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-naturally occurring melanocortin analog does not include a sequence selected from the group consisting of: Ac-Nle-c[Asp- Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 194); Ac-Nle-c[Asp-Pro-His- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 5); Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg- Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 10); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dPro (SEQ ID NO: 2); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 3); Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 4); Ac-Nle- c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 6); Ac-Nle-c[Asp-Phe- His-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 7); Ac-Nle-c[Asp-Hyp-dNal(2')-Arg- Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 9); Ac-Nle-Phe-Phe-c[Asp-Phe-His-dNal(2')-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 12); Ac-dArg-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 15); Ac-dLeu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 18); Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 20); Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 21 ); Ac-dNIe- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 24); Ac-dCys-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 28); Ac-dPhe-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 29); Ac-dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 30); dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 35); Tyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 36); Ac-Nle- c[Cys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 40); Ac-Nle-c[dCys-Pro- dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 41 ); Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 42); Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-dCys]- dVal-dPro-NH2 (SEQ ID NO: 43); Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 48); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 54); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 64); Ac-Nle- c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 68); Ac-Nle-c[Asp-Ala-dNal(2')- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 69); Ac-Nle-c[Asp-Leu-dNal(2')-Arg-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 76); Ac-Nle-c[Asp-Trp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 82); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 115); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 116); Ac-Nle-c[Asp- Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 117); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 118); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dHyp-NH2 (SEQ ID NO: 119); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Hyp-NH2 (SEQ ID NO: 120); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-dHyp-NH2 (SEQ ID NO: 121 ); Ac- Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-dVal-NH2 (SEQ ID NO: 122); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dHyp-dVal-NH2 (SEQ ID NO: 123); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-Hyp-Val-NH2 (SEQ ID NO: 124); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp- Val-NH2 (SEQ ID NO: 125); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-NH2 (SEQ ID NO: 126); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2 (SEQ ID NO: 127); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 128); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dPro-NH2 (SEQ ID NO: 129); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp- Lys]-Val-NH2 (SEQ ID NO: 130); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 131 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-NH2 (SEQ ID NO: 132); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-NH2 (SEQ ID NO: 133); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-dHyp-NH2 (SEQ ID NO: 134); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp- NH2 (SEQ ID NO: 135); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ ID NO: 136); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 137); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Gly-Gly-NH2 (SEQ ID NO: 138); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 139); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 140); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal- dArg-NH2 (SEQ ID NO: 143); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ ID NO: 144); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO:145); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-NH2 (SEQ ID NO: 146); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-dPro-NH2 (SEQ ID NO: 147); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dAsp-dPro-NH2 (SEQ ID NO: 148); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 149); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn- dPro-NH2 (SEQ ID NO: 150); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-NH2 (SEQ ID NO: 151 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-NH2 (SEQ ID NO: 152); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-NH2 (SEQ ID NO: 153); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-dAsp-NH2 (SEQ ID NO: 154); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg- NH2 (SEQ ID NO: 155); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 156); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 157); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 158); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dLys-dPro-dVal-NH2 (SEQ ID NO: 159); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-Lys-dPro-NH2 (SEQ ID NO: 160); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]- dLys-dPro-NH2 (SEQ ID NO: 161 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Val-Pro- NH2 (SEQ ID NO: 162); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 164); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 164); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 165); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-dVal-NH2 (SEQ ID NO: 166); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dArg-dPro-dVal-NH2 (SEQ ID NO: 167); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 168); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]- Arg-dVal-dPro-NH2 (SEQ ID NO: 169); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dVal- dPro-NH2 (SEQ ID NO: 170); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-dPro-NH2 (SEQ ID NO: 171 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 172); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-NH2 (SEQ ID NO: 173); Ac-Nle- c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-NH2 (SEQ ID NO: 174); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-Trp-Lys]-dTle-dTle-dPro-NH2 (SEQ ID NO: 175); Ac-Nle-c[Asp-Pro-dNal(2')- Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 176); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp- Lys]-dPro-dTle-NH2 (SEQ ID NO: 177); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dTle- NH2 (SEQ ID NO: 178); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dPro-NH2 (SEQ ID NO: 179); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 180); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 181 );Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQ ID NO: 182); Ac- Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 183); Ac-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 184); Ac-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 185); Ac-Nle- Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 186); Ac-Nle- c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 195); Ac-Nle-c[Asp-Pro- dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 196); Ac-Nle-c[Asp-Pro-dNal(2')-Arg- Trp-Lys]-Trp-NH2 (SEQ ID NO: 203); Ac-Nle-c[Asp-Aba-dNal(2')-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 204); Ac-Nle-c[Asp-Aia-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 205); Ac-Nle-c[Asp-Ata-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 206); Ac- Nle-c[Asp-Cpe-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 240); Ac-Nle-c[Asp-Che- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 241 ); Ac-Nle-c[Asp-Oic-dNal(2')-Arg- Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 242); Ac-Nle-c[Asp-Tic-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 244); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 245); Ac-Nle-c[Asp-His-dNal(2')-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 247); Ac-Nle-c[Asp-His-dNal(2')-cisPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 248); Ac-Nle-c[Asp-Pro-dNal(2')-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 250); Ac-Nle-c[Asp-Pro-dNal(2')-cisPro(guan)Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 251 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aba-Lys]-dVal-dPro-NH2 (SEQ ID NO: 253); Ac- Nle-c[Asp-Pro-dNal(2')-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 254); Ac-Nle-c[Asp-Glu- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 255); Ac-Nle-c[Asp-Glu-dNal(2')-Arg- Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 256); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly- Lys]-dVal-dPro-NH2 (SEQ ID NO: 259); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro- dPro-Lys-Asp-NH2 (SEQ ID NO: 260); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro- dPro-dLys-dAsp-NH2 (SEQ ID NO: 261 ); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro- dPro-dLys-dAsp-NH2 (SEQ ID NO: 263); Ac-Nle-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal- dPro-NH2 (SEQ ID NO: 273); Ac-Arg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 274); Ac-dArg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 275); Ac-dLeu-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 327); Ac-dNle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 328); Ac-dArg- c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 329); Ac-Arg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 330); Ac-dPhe-c[dPen-Pro-dNal(2')- Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 331 ); Ac-dTyr-c[dPen-Pro-dNal(2')-Arg-Trp- dPen]-dVal-dPro-NH2 (SEQ ID NO: 332); Ac-Ala-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal- dPro-NH2 (SEQ ID NO: 333); Ac-dHis-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 334); Ac-His-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 335); Ac-dLys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 336); Ac- Lys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 337); Ac-Nle-c[dPen- Pro-dNal(2')-Arg-Trp-dPen]-dArg-dVal-dPro-NH2 (SEQ ID NO: 344); Ac-Nle-c[dPen-Pro- dNal(2')-Arg-Trp-dPen]-dLys-dVal-dPro-NH2 (SEQ ID NO: 345); Ac-Nle-c[dPen-Pro- dNal(2')-Arg-Trp-dPen]-dArg-dPro-NH2 (SEQ ID NO: 346); Ac-Nle-c[dPen-Pro-dNal(2')- Arg-Trp-dPen]-dLys-dPro-NH2 (SEQ ID NO: 347); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp- dPen]-dVal-dHyp-NH2 (SEQ ID NO: 348); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dTle- dPro-NH2 (SEQ ID NO: 349); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-Gly-dPen]-dVal-dPro- NH2 (SEQ ID NO: 350); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 103); Ac-Nle-c[Asp-loc-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 243); Ac- Nle-c[Cys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 44); Ac-Nle-c[dCys-dNal(2')- Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 45); Ac-Nle-c[Cys-dNal(2')-Arg-Trp-dCys]-dVal- dPro-NH2 (SEQ ID NO: 46); Ac-Nle-c[dCys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 47); Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 56); Ac-Nle- c[dPen-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 62); Ac-Nle-c[Asp-dTrp- dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 83); Ac-Nle-c[dPen-Ala-dNal(2')-Arg- Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 338); Ac-Nle-c[dPen-Leu-dNal(2')-Arg-Trp-dPen]- dVal-dPro-NH2 (SEQ ID NO: 339); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro- NH2 (SEQ ID NO: 223); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 464); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465); Ac- dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466); Ac-His-c[Asp- His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467); Ac-dHis-c[Asp-His- p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468); Ac-Nle-Nle-c[Asp-His-p(F)dPhe- Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469); Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]- dVal-dPro-NH2 (SEQ ID NO: 470); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal- dVal-dPro-NH2 (SEQ ID NO: 474); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 475); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ I...

Claims

CLAIMSI / We claim:1 . A method of reducing a pain level in a subject in need thereof relative to a control, comprising administering to the subject a non-naturally occurring melanocortin analog of FormulaX1-wherein:X1is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D- histidine (dHis);X2is absent, phenylalanine (Phe), or Nle;X3is absent, Phe, or Nle;R1is selected from the group consisting of Nle, D-norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D- tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D-cysteine (dCys);R2is selected from the group consisting of Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr;R3is absent or is selected from the group consisting of His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-amino-1 ,2,4,5- tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H-[1 ,2,3]triazolo-[1 ,5- a][1 ,4]diazepin-6(5H)-one (Ata), 4-amino-1 ,4,5,6-tetrahydroazepino[4,3-b]indol-3(2 / - / )-one (Aia), 2-aminotetraline-2-carboxylic acid (Ate), 1 -amino-4-phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid (APPC), octohydroindole-2- carboxylic acid (Oic), 1 -amino-1 -cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline- 3-carboxylic acid (Tic), indoline-2-carboxylic acid (loc), 1 -am ino-1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip);R4is selected from the group consisting of Phe, dPhe, 2’-D-naphthylalanine (dNal(2’)), para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe);R5is selected from the group consisting of Arg, His, c / sPro(guan), and transPro(guan);R6is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2’), 2’- naphthylalanine (Nal(2’)), and 1 ’-naphthylalanine (Nal(1 ’));R7is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn;R8is absent or Lys;Y1is absent or is selected from the group consisting of valine (Vai), D-valine (dVal), 02-valine (P2-Val), p3-valine (P3-Val), Pro, D-proline (dPro), 0-proline (0-Pro), Hyp, D- hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr);Y2is absent or is selected from the group consisting of Vai, dVal, p2-Val, p3-Val, Pro, dPro, P-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn;Y3is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys;Y4is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp;Y5is absent or dVal;Y6is absent or dVal;Y7is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1or R2and R7when each of R1or R2and R7are independently selected from the group consisting of Cys, dCys, and dPen;a disulfide bond between R2and R7when R2is Cys, R7is Pen, and R3is absent; a lactam bridge between R1or R2and R7or R8when R1or R2is Asp and R7or R8is Lys or Orn; and a lactam bridge between R2and R7when R2is dAsp and R7is dLys; provided that: when R4is dNal(2’), then R3is His and R7is Pro; when R4is p(F)dPhe, then (i) R3is selected from Pro, dGIn, dTyr, R6is Trp, and the non-naturally occurring melanocortin analog is not cyclized between Cys at R2and Cys at R7or (ii) R3is His and either R6is Nal(2’) or the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between R2and R7; when R4is p(Br)dPhe, then the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2and Cys or dCys at R7; when R4is dPhe, then (i) R3is not His, Pro, or absent, (ii) R3is His and either R2is Phe or dAla or R2is Ala and X1is Arg or dArg, (iii) R3is Pro and (a) R2is Trp, and R5is not His or R6is not Phe or (b) R2is not Trp or Pro, and either R5is not dNal(2’) or Nal(2’) or X1and Y3are not both present, or (iv) R3is absent and R2and R7are not both dPen; when R4is p(CI)dPhe, then (i) R3is selected from Aba, Aia, and Ata or (ii) R3is His, R1is not Ala, and (a) if R1is Nle and Y1Y2is dVal-dPro, then X1is absent and the non- naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2and dCys at R7, or (b) if R1is Nle, and Y1Y2is not dVal-dPro, then either X1or Y3is present; and when R2is dAla, then R4is dPhe and Y1-Y7are absent.

2. Use of a non-naturally occurring melanocortin analog for reducing a pain level in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

3. A method of treating, preventing, or reducing an addiction in a subject relative to a control, comprising administering to the subject a non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

4. Use of a non-naturally occurring melanocortin analog for treating, preventing, or reducing an addiction in a subject relative to a control, the non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

5. A method of preventing or reducing a use of or dependence on an addictive substance in a subject relative to a control, comprising administering to the subject a non- naturally occurring melanocortin analog comprising a sequence of Formula (I).

6. Use of a non-naturally occurring melanocortin analog for treating, preventing, or reducing a use of or dependence on an addictive substance in a subject relative to a control, the non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

7. A method of treating or preventing an opioid use disorder (OUD) in a subject in need thereof relative to a control, comprising administering to the subject a non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

8. Use of a non-naturally occurring melanocortin analog for treating or preventing an OUD in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

9. A method of treating or preventing an alcohol use disorder (AUD) in a subject in need thereof relative to a control, comprising administering to the subject a non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

10. Use of a non-naturally occurring melanocortin analog for treating or preventing an AUD in a subject in need thereof relative to a control, the non-naturally occurring melanocortin analog comprising a sequence of Formula (I).11 . The method or the use of any one of claims 3-9, wherein the method or the use comprises reducing a dose used or consumed of an addictive substance, relative to a control.

12. The method or the use of any one of claims 3-11 , wherein the method or the use comprises reducing a dependency on an addictive substance, relative to a control.

13. The method or the use of any one of claims 3-12, wherein the method or the use comprises reducing a frequency of an addictive substance use, relative to a control.

14. The method or the use of any one of claims 3-13, wherein the method or the use comprises reducing a dose or dosage of a conventional medication used to treat an addiction, relative to a control.

15. A method of augmenting an effect of a conventional medication used to treat an addiction in a subject in need thereof, relative to a control, comprising administering to the subject a non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

16. Use of a non-naturally occurring melanocortin analog for augmenting an effect of a conventional medication used to treat an addiction in a subject in need thereof, the non- naturally occurring melanocortin analog comprising a sequence of Formula (I).

17. A method of reducing or eliminating a need for a conventional medication used to treat an addiction in a subject in need thereof, relative to a control, comprising administering to the subject a non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

18. Use of a non-naturally occurring melanocortin analog for reducing or eliminating a need for a conventional medication used to treat an addiction in a subject in need thereof, the non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

19. The method or the use of claim 17 or 18, wherein the treatment of the addiction is improved during or after administration of the non-naturally occurring melanocortin analog relative to treatment of the addiction using the conventional medication to treat the addiction alone.

20. The method or the use of any one of claims 14-19, wherein the conventional medication to treat the addiction is selected from the group consisting of buprenorphine, naltrexone, acamprosate, methadone, naloxone, nalmefene, xycodone, levo-alpha- acetylmethadol (LAAM), codeine, lofexidine, and a slow-release morphine.21 . A method of reducing a need for a hospitalization or rehabilitation associated with addiction or use of an addictive substance, relative to a control, comprising administering to the subject a non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

22. Use of a non-naturally occurring melanocortin analog for reducing a need for a hospitalization or rehabilitation associated with addiction or use of an addictive substance, relative to a control, the non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

23. A method of preventing or reducing a withdrawal from an addictive substance in a subject, comprising administering to the subject a non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

24. Use of a non-naturally occurring melanocortin analog for preventing or reducing a withdrawal from an addictive substance in a subject, relative to a control, the non- naturally occurring melanocortin analog comprising a sequence of Formula (I).

25. A method of preventing or reducing a symptom associated with withdrawal from an addictive substance in a subject relative to a control, comprising administering to the subject a non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

26. Use of a non-naturally occurring melanocortin analog for preventing or reducing a symptom associated with withdrawal from an addictive substance in a subject, relative to a control, the non-naturally occurring melanocortin analog comprising a sequence of Formula (I).

27. The method or the use of claim 25 or 26, wherein the symptom associated with withdrawal from an addictive substance is selected from the group consisting of pain, anxiety, depression, diarrhea, dizziness, fatigue, muscle aches, nausea, sleep problems, suicidal ideation, tremors, and visual disturbances.

28. The method or the use of any one of claims 1 -27, wherein the subject has an addiction to an addictive substance or is susceptible to an addiction to an addictive substance.

29. The method or the use of any one of claims 1 -28, wherein the subject has used or is using one or more addictive substances.

30. The method or the use of any one of claims 5-29 wherein the addictive substance comprises a prescription medication, a substance in an over-the-counter medication, a recreational substance, or an illegal substance.

31. The method or the use of any one of claims 5-30, wherein the addictive substance is selected from the group consisting of an opioid, a painkiller, a stimulant, a narcotic, an alcohol, a sedative, marijuana, a cannabis, a tetrahydrocannabinol (THC), a cannabidiol (CBD), and an inhalant.

32. The method or the use of claim 31 , wherein the opioid is selected from the group consisting of morphine, heroin, codeine, oxycodone, hydrocodone, and fentanyl.

33. The method or the use of claim 31 , wherein the stimulant is selected from the group consisting of caffeine, nicotine, methamphetamines, cocaine, and amphetamines.

34. The method or the use of claim 31 , wherein the sedative comprises a barbiturate or a benzodiazepine.

35. The method or the use of claim 34, wherein the barbiturate is selected from the group consisting of phenobarbital, methohexital, butalbital, pentobarbital, primidone, and amobarbital.

36. The method or the use of claim 34, wherein the benzodiazepine is selected from the group consisting of alprazolam, lorazepam, clonazepam, diazepam, and temazepam.

37. The method or the use of claim 31 , wherein the sedative is selected from the group consisting of tranquilizers, xylazine, eszopiclone, zaleplon, zolpidem, and zopiclone.

38. The method or the use of claim 31 , wherein the inhalant is selected from the group consisting of aerosols, butanes, freon, helium, nitrous oxide, propane, and nitrites.

39. The method or the use of claim 33, wherein the nicotine comprises a tobacco chew, a nicotine pouch, or a smoking device.

40. The method or the use of claim 39, wherein the smoking device is selected from the group consisting of cigarettes, electronic cigarettes, cigars, and vape products.

41. The method or the use of any one of claims 1 -40, wherein the control comprises the subject before administration of the non-naturally occurring melanocortin analog.

42. The method or the use of any one of claims 1 -41 , wherein the control comprises the subject at baseline.

43. The method or the use of any one of claims 1 -42, wherein the non-naturally occurring melanocortin analog is a melanocortin 4 receptor (MC4R) agonist.

44. The method or the use of claim 43, wherein the MC4R agonist is a full MC4R agonist.

45. The method or the use of claim 43, wherein the MC4R agonist is a partial MC4R agonist.

46. The method or the use of any one of claims 1 -45, wherein the non-naturally occurring melanocortin analog is a MC3R antagonist.

47. The method or the use of claim 46, wherein the MC3R antagonist is a full MC3R antagonist.

48. The method or the use of claim 46, wherein the MC3R antagonist is a partial MC3R antagonist.

49. The method or the use of any one of claims 1 -45, wherein the non-naturally occurring melanocortin analog does not have MC3R activity.

50. The method or the use of any one of claims 1 -49, wherein the non-naturally occurring melanocortin analog comprises a sequence according to Formula (I), wherein:X1is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D- histidine (dHis);X2is absent, phenylalanine (Phe), or Nle;X3is absent, Phe, or Nle;R1is selected from the group consisting of Nle, D-norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D- tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D-cysteine (dCys);R2is selected from the group consisting of Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr;R3is absent or is selected from the group consisting of His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-amino-1 ,2,4,5- tetrahydro-2-benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H-[1 ,2,3]triazolo-[1 ,5- a][ 1 ,4]diazepin-6(5H)-one (Ata), 4-amino-1 ,4,5,6-tetrahydroazepino[4,3-b]indol-3(2 / - / )-one (Aia), 2-aminotetraline-2-carboxylic acid (Ate), 1 -amino-4-phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid (APPC), octohydroindole-2- carboxylic acid (Oic), 1 -amino-1 -cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline- 3-carboxylic acid (Tic), indoline-2-carboxylic acid (loc), 1 -am ino-1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip);R4is selected from the group consisting of Phe, dPhe, 2’-D-naphthylalanine (dNal(2’)), para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe);R5is selected from the group consisting of Arg, His, c / sPro(guan), and fransPro(guan);R6is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2’), 2’- naphthylalanine (Nal(2’)), and 1 ’-naphthylalanine (Nal(1 ’));R7is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn;R8is absent or Lys;Y1is absent or is selected from the group consisting of valine (Vai), D-valine (dVal), p2-valine (P2-Val), p3-valine (P3-Val), Pro, D-proline (dPro), p-proline (P-Pro), Hyp, D- hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr);Y2is absent or is selected from the group consisting of Vai, dVal, p2-Val, p3-Val, Pro, dPro, P-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn;Y3is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys;Y4is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp;Y5is absent or dVal;Y6is absent or dVal;Y7is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1or R2and R7or R8when each of R1or R2and R7or R8are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2and R7when R2is Cys, R7is Pen, and R3is absent; a lactam bridge between R1or R2and R7or R8when R1or R2is Asp and R7or R8is Lys or Orn; and a lactam bridge between R2and R7when R2is dAsp and R7is dLys;provided that the non-naturally occurring melanocortin analog does not comprise a sequence selected from the group consisting of:Ac-Nle-c[Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 194);Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 5);Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg-Trp-Lys]-dPro-dVal-NH2(SEQ ID NO: 10);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro (SEQ ID NO: 2);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 3);Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2(SEQ ID NO: 4);Ac-Nle-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dLeu-dPro-NH2(SEQ ID NO: 6);Ac-Nle-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 7);Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2(SEQ ID NO: 9);Ac-Nle-Phe-Phe-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 12);Ac-dArg-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 15);Ac-dLeu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 18);Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 20);Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 21 );Ac-dNle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 24);Ac-dCys-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 28);Ac-dPhe-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 29);Ac-dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 30); dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 35);Tyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 36);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 40);Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 41 );Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2(SEQ ID NO: 42);Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2(SEQ ID NO: 43);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2(SEQ ID NO: 48);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 54);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2(SEQ ID NO: 64);Ac-Nle-c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 68);Ac-Nle-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 69);Ac-Nle-c[Asp-Leu-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 76);Ac-Nle-c[Asp-Trp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 82);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Pro-NH2(SEQ ID NO: 115);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 116);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 117);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Hyp-NH2(SEQ ID NO: 118);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dHyp-NH2(SEQ ID NO: 119);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Hyp-NH2(SEQ ID NO: 120);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-dHyp-NH2(SEQ ID NO: 121 );Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-dVal-NH2(SEQ ID NO: 122);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-dVal-NH2(SEQ ID NO: 123);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-Val-NH2(SEQ ID NO: 124);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-Val-NH2(SEQ ID NO: 125);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-NH2(SEQ ID NO: 126);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2(SEQ ID NO: 127);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2(SEQ ID NO: 128);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-NH2(SEQ ID NO: 129);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-NH2(SEQ ID NO: 130);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Pro-NH2(SEQ ID NO: 131 );Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-NH2(SEQ ID NO: 132);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-NH2(SEQ ID NO: 133);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-NH2(SEQ ID NO: 134);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-NH2(SEQ ID NO: 135);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-dAla-NH2(SEQ ID NO: 136);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-Ala-NH2(SEQ ID NO: 137);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Gly-Gly-NH2(SEQ ID NO: 138);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Asp-NH2(SEQ ID NO: 139);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Arg-NH2(SEQ ID NO: 140);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dArg-NH2(SEQ ID NO: 143);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dAsn-NH2(SEQ ID NO: 144);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-dPro-NH2(SEQ ID NO: 145);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-NH2(SEQ ID NO: 146);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-dPro-NH2(SEQ ID NO: 147);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsp-dPro-NH2(SEQ ID NO: 148);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2(SEQ ID NO: 149);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-dPro-NH2(SEQ ID NO: 150);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-NH2(SEQ ID NO: 151 );Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-NH2(SEQ ID NO: 152);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-NH2(SEQ ID NO: 153);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsp-NH2(SEQ ID NO: 154);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-NH2(SEQ ID NO: 155);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-NH2(SEQ ID NO: 156);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Pro-Val-NH2(SEQ ID NO: 157);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-dVal-NH2(SEQ ID NO: 158);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dPro-dVal-NH2(SEQ ID NO: 159);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-NH2(SEQ ID NO: 160);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dPro-NH2(SEQ ID NO: 161 );Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Val-Pro-NH2(SEQ ID NO: 162);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dVal-dPro-NH2(SEQ ID NO: 164);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dVal-dPro-NH2(SEQ ID NO: 164);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Pro-Val-NH2(SEQ ID NO: 165);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-dVal-NH2(SEQ ID NO: 166);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-dVal-NH2(SEQ ID NO: 167);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Val-Pro-NH2(SEQ ID NO: 168);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dVal-dPro-NH2(SEQ ID NO: 169);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dVal-dPro-NH2(SEQ ID NO: 170);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-dPro-NH2(SEQ ID NO: 171 );Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 172);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-NH2(SEQ ID NO: 173);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-NH2(SEQ ID NO: 174);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-dPro-NH2(SEQ ID NO: 175);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-dVal-NH2(SEQ ID NO: 176);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dTle-NH2(SEQ ID NO: 177);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dTle-NH2(SEQ ID NO: 178);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dPro-NH2(SEQ ID NO: 179);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 180);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 181 );Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2(SEQ ID NO: 182);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 183);Ac-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 184);Ac-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 185);Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 186);Ac-Nle-c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 195);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2(SEQ ID NO: 196);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Trp-NH2(SEQ ID NO: 203);Ac-Nle-c[Asp-Aba-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 204);Ac-Nle-c[Asp-Aia-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 205);Ac-Nle-c[Asp-Ata-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 206);Ac-Nle-c[Asp-Cpe-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 240);Ac-Nle-c[Asp-Che-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 241 );Ac-Nle-c[Asp-Oic-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 242);Ac-Nle-c[Asp-Tic-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 244);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2(SEQ ID NO: 245);Ac-Nle-c[Asp-His-dNal(2')-transPro(guan)-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 247);Ac-Nle-c[Asp-His-dNal(2')-cisPro(guan)-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 248);Ac-Nle-c[Asp-Pro-dNal(2')-transPro(guan)-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 250);Ac-Nle-c[Asp-Pro-dNal(2')-cisPro(guan)Pro-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 251 );Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aba-Lys]-dVal-dPro-NH2(SEQ ID NO: 253);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Ata-Lys]-dVal-dPro-NH2(SEQ ID NO: 254);Ac-Nle-c[Asp-Glu-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 255);Ac-Nle-c[Asp-Glu-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH2(SEQ ID NO: 256);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH2(SEQ ID NO: 259);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2(SEQ ID NO: 260);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp-NH2(SEQ ID NO: 261 );Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-dLys-dAsp-NH2(SEQ ID NO: 263);Ac-Nle-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 273);Ac-Arg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 274);Ac-dArg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 275);Ac-dLeu-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 327);Ac-dNle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 328);Ac-dArg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 329);Ac-Arg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 330);Ac-dPhe-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 331 );Ac-dTyr-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 332);Ac-Ala-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 333);Ac-dHis-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 334);Ac-His-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 335);Ac-dLys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 336);Ac-Lys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 337);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dArg-dVal-dPro-NH2(SEQ ID NO: 344);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dLys-dVal-dPro-NH2(SEQ ID NO: 345);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dArg-dPro-NH2(SEQ ID NO: 346);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dLys-dPro-NH2(SEQ ID NO: 347);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dHyp-NH2(SEQ ID NO: 348);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dTle-dPro-NH2(SEQ ID NO: 349);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-Gly-dPen]-dVal-dPro-NH2(SEQ ID NO: 350);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aia-Lys]-dVal-dPro-NH2(SEQ ID NO: 103);Ac-Nle-c[Asp-loc-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 243);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 44);Ac-Nle-c[dCys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 45);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2(SEQ ID NO: 46);Ac-Nle-c[dCys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2(SEQ ID NO: 47);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2(SEQ ID NO: 56);Ac-Nle-c[dPen-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 62);Ac-Nle-c[Asp-dTrp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 83);Ac-Nle-c[dPen-Ala-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 338);Ac-Nle-c[dPen-Leu-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 339);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 223);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 464);Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 465);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 466);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 467);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 468);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 469); Ac-Nle- c[Asp-His-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 470);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 474);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 475);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 476);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 477);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 478);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 481 );Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 482);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 483);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 484);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 485);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 463);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 462);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 479);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2(SEQ ID NO: 473);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 480);Ac-Nle-c[Asp-Gln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 491 );Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 489);Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 493);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 444);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 445);Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 495);Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 487);Ac-Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 488);Ac-Nle-c[Asp-dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 494);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 471 );Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 432);Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 217);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 222);Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 535);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 538);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 545);Ac-Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 546);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 547);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 548);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2(SEQ ID NO: 549);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 551 );Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 552);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 553);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 555);Ac-Nle-c[Asp-dHis-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 562);Ac-Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 563);Ac-Nle-c[Asp-dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 564);Ac-Nle-c[Asp-Bip-p(Br)dPhe-Arg-Trp-Lys]-d al-dPro-NH2(SEQ ID NO: 565);Ac-Nle-c[Asp-dGln-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 568);Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 569);Ac-Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 570);Ac-Nle-c[Asp-Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 571 );Ac-Nle-c[Asp-dTyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 572);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 539);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 544);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 561 );Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 556);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 542);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 560);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 543);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 559);Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 557);Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 541 );Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 550);Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 558);Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 540);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 554);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 363);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2(SEQ ID NO: 418);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2(SEQ ID NO: 621 );Ac-Nle-c[Asp-His-dPhe-transPro(guan)-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 228);Ac-Nle-c[Asp-His-dPhe-cisPro(guan)-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 229);Ac-Nle-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 380);Ac-Nle-c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 398);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2(SEQ ID NO: 401 );Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 639);Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 430);Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 431 );Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 225);Ac-Nle-c[dPen-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 326);Ac-Nle-c[Asp-Pro-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 297);Ac-Nle-c[Asp-Pro-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 215);Ac-Nle-c[Asp-Phe-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 525);Ac-Nle-c[Asp-dPhe-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 526);Ac-Nle-c[Asp-Bip-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 527);Ac-Nle-c[Asp-Trp-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 531 );Ac-Nle-c[Asp-Tyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 533);Ac-Nle-c[Asp-dTyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 534);Ac-Nle-c[Asp-dTrp-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 532);Ac-Nle-c[dCys-His-p(CI)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 498);Ac-Nle-c[Cys-His-p(CI)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 497);Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 509);Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 510);Ac-Nle-c[Asp-His-p(CI)dPhe-His-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 508);Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 220);Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 507);Ac-Ala-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 517);Ac-Ala-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 500);Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 516);Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 514);Ac-Nle-c[Asp-dGln-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 530);Ac-Arg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 268);Ac-Nle-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 378);Ac-dArg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 379);Ac-Nle-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 266);Ac-Arg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 267);Ac-Arg-c[Cys-dAla-His-dNal(2’)-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 269);Ac-dArg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 270);Ac-Arg-c[Cys-dAla-His-dNal(2’)-Arg-Trp-Cys]-NH2(SEQ ID NO: 282); andAc-Arg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-NH2(SEQ ID NO: 283).

51. The method or use of any one of claims 1 -49, wherein the non-naturally occurring melanocortin analog comprises a sequence according to Formula (IA):X1-X2-X3-R1-R2-R3-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4(IA), wherein:X1is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D- histidine (dHis);X2is absent, phenylalanine (Phe), or Nle;X3is absent, Phe, or Nle;R1is selected from the group consisting of Nle, D-norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D- tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D-cysteine (dCys);R2is selected from the group consisting of Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr;R3is absent or is selected from the group consisting of His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2- aminotetraline-2-carboxylic acid (Ate), octohydroindole-2-carboxylic acid (Oic), 1-amino-1 - cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino- 1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip);R4is selected from the group consisting of dPhe, para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe);R5is Arg or His;R6is selected from the group consisting of Trp, dTrp, Phe, dNal(2’), 2’- naphthylalanine (Nal(2’))_ and T-naphthylalanine (Nal(1 ’));R7is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn;R8is absent or Lys;Y1is selected from the group consisting of valine (Vai), D-valine (dVal), p2-valine (P2- Val), p3-valine (P3-Val), Pro, D-proline (dPro), p-proline (p-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr);Y2is absent or is selected from the group consisting of Vai, dVal, p2-Val, p3-Val, Pro, dPro, p-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn;Y3is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys;Y4is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of:a disulfide bond between R1or R2and R7or R8when each of R1or R2and R7or R8are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2and R7when R2is Cys,R7is Pen, and R3is absent; a lactam bridge between R1or R2and R7or R8when R1or R2is Asp and R7or R8is Lys or Orn; and a lactam bridge between R2and R7when R2is dAsp and R7is dLys; provided that: when R4is p(F)dPhe, then (i) R3is selected from Pro, dGIn, dTyr, R6is Trp, and the non-naturally occurring melanocortin analog is not cyclized between Cys at R2and Cys at R7or (ii) R3is His and either R6is Nal(2’) or the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between R2and R7, where R2and R7are the same; when R4is p(Br)dPhe, then the non-naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2and Cys or dCys at R7; when R4is dPhe, then (i) R3is not His, Pro, or absent, (ii) R3is His and either R2is Phe or dAla or R2is Ala and X1is Arg or dArg, (iii) R3is Pro and (a) R2is Trp, and R5is not His or R6is not Phe or (b) R2is not Trp or Pro, and either R5is not dNal(2’) or Nal(2’) or X1and Y3are not both present, or (iv) R3is absent and R2and R7are not both dPen; and when R4is p(CI)dPhe, then (i) R3is selected from Aba, Aia, and Ata or (ii) R3is His, R1is not Ala, and (a) if R1is Nle and Y1Y2is dVal-dPro, then X1is absent and the non- naturally occurring melanocortin analog is cyclized through a disulfide bond between dCys at R2and dCys at R7, or (b) if R1is Nle, and Y1Y2is not dVal-dPro, then either X1or Y3is present.

52. The method or the use of any one of claims 1 -50, wherein the non-naturally occurring melanocortin analog comprises a sequence according to Formula (IA), wherein: X1is absent or is selected from the group consisting of norleucine (Nle), arginine (Arg), D- arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis);X2is absent, phenylalanine (Phe), or Nle;X3is absent, Phe, or Nle;R1is selected from the group consisting of Nle, D-norleucine (dNIe), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D- tryptophan (dTrp), aspartic acid (Asp), cysteine (Cys), and D-cysteine (dCys);R2is selected from the group consisting of Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr;R3is absent or is selected from the group consisting of His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGIn), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2- aminotetraline-2-carboxylic acid (Ate), octohydroindole-2-carboxylic acid (Oic), 1-amino-1 - cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino- 1 -cyclopentane carboxylic (Cpe), and biphenylalanine (Bip);R4is selected from the group consisting of dPhe, para-chloro-D-phenylalanine (p(CI)dPhe), para-bromo-D-phenylalanine (p(Br)dPhe), and para-fluoro-D-phenylalanine (p(F)dPhe);R5is Arg or His;R6is selected from the group consisting of Trp, dTrp, Phe, dNal(2’), 2’- naphthylalanine (Nal(2’)), and T-naphthylalanine (Nal(1 ’));R7is selected from the group consisting of Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn;R8is absent or Lys;Y1is selected from the group consisting of valine (Vai), D-valine (dVal), p2-valine (P2- Val), p3-valine (P3-Val), Pro, D-proline (dPro), p-proline (p-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr);Y2is absent or is selected from the group consisting of Vai, dVal, p2-Val, p3-Val, Pro, dPro, 0-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn;Y3is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys;Y4is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1or R2and R7or R8when each of R1or R2and R7or R8are independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2and R7when R2is Cys, R7is Pen, and R3is absent; a lactam bridge between R1or R2and R7or R8when R1or R2is Asp and R7or R8is Lys or Orn; and a lactam bridge between R2and R7when R2is dAsp and R7is dLys; provided that the non-naturally occurring melanocortin analog does not comprise a sequence selected from the group consisting of:Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 223);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 464);Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 465);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 466);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 467);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 468);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 469);Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 470);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 474);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 475);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 476);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 477);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 478);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 481 );Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 482);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 483);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 484);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 485);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 463);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 462);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 479);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2(SEQ ID NO: 473);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 480);Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 489);Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 493);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 444);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 445);Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 495);Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 487);Ac-Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-d al-dPro-NH2(SEQ ID NO: 488);Ac-Nle-c[Asp-dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 494);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 471 );Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 432);Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 460);Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 217);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 222);Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 535);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 538);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 545);Ac-Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 546);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 547);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 548);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2(SEQ ID NO: 549);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 551 );Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 552);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 553);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 555);Ac-Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 563);Ac-Nle-c[Asp-dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 564);Ac-Nle-c[Asp-Bip-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 565);Ac-Nle-c[Asp-dGln-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 568);Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 569);Ac-Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 570);Ac-Nle-c[Asp-Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 571 );Ac-Nle-c[Asp-dTyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 572);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 539);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 544);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 561 );Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 556);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 542);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 560);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 543);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 559);Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 557);Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 541 );Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 550);Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 558);Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 540);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 554);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 363);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2(SEQ ID NO: 418);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2(SEQ ID NO: 621 );Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 639);Ac-Nle-c[dPen-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 326);Ac-Nle-c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 398);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Phe-Lys]-d al-dPro-NH2(SEQ ID NO: 401 );Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 225);Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 430);Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 431 );Ac-Nle-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 380);Ac-Nle-c[Asp-Pro-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 215);Ac-Nle-c[Asp-Phe-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 525);Ac-Nle-c[Asp-dPhe-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 526);Ac-Nle-c[Asp-Bip-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 527);Ac-Nle-c[Asp-Trp-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 531 );Ac-Nle-c[Asp-Tyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 533);Ac-Nle-c[Asp-dTyr-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 534);Ac-Nle-c[Asp-dTrp-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 532);Ac-Nle-c[dCys-His-p(CI)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 498);Ac-Nle-c[Cys-His-p(CI)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 497);Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 509);Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 510);Ac-Nle-c[Asp-His-p(CI)dPhe-His-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 508);Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 220);Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 507);Ac-Ala-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 517);Ac-Ala-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 500);Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 516); andAc-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 514).

53. The method or use of any one of claims 1 -49, wherein the non-naturally occurring melanocortin analog comprises a sequence of Formula (IB):X1-X2-X3-R1-R2-Pro-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7(IB), wherein:X1is absent or norleucine (Nle);X2is absent or Nle;X3is absent or Nle;R1is selected from the group consisting of Nle, D-norleucine (dNIe), alanine (Ala), D- alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis), ornithine (Orn), D-omithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp);R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), cysteine (Cys), D-cysteine (dCys), and D-penicillamine (dPen);R4is dPhe or para-fluoro-D-phenylalanine (p(F)dPhe);R5is selected from the group consisting of Arg, His, czsPro(guan), and fransPro(guan);R6is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, and T- naphthylalanine (Nal(1 ’));R7is selected from the group consisting of Gly, Lys, dLys, Cys, dCys, dPen, and Orn;R8is absent or Lys;Y1is absent or is selected from the group consisting of valine (Vai), D-valine (dVal), p2-valine (P2-Val), p3-valine (P3-Val), Pro, D-proline (dPro), 0-proline (0-Pro), Hyp, D- hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr);Y2is absent or is selected from the group consisting of Vai, dVal, p2-Val, p3-Val, Pro, dPro, p-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn;Y3is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys;Y4is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp;Y5is absent or dVal;Y6is absent or dVal;Y7is absent or dPro; andthe non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2and R7when each of R2and R7are independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2and R7when R2is Asp or dAsp and R7is Lys, dLys, or Orn; provided that: when R4is p(F)dPhe, then the non-naturally occurring melanocortin analog is not cyclized between Cys at R2and Cys at R7; and when R4is dPhe and one or more of X1, X2, and X3is present, then Y3-Y7are absent.

54. The method or use of any one of claims 1 -50, wherein the non-naturally occurring melanocortin analog comprises a sequence of Formula (IB), wherein:X1-X2-X3-R1-R2-Pro-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7(IB), wherein:X1is absent or norleucine (Nle);X2is absent or Nle;X3is absent or Nle;R1is selected from the group consisting of Nle, D-norleucine (dNIe), alanine (Ala), D- alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis), ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp);R2is selected from the group consisting of aspartic acid (Asp), D-aspartic acid (dAsp), cysteine (Cys), D-cysteine (dCys), and D-penicillamine (dPen);R4is dPhe or para-fluoro-D-phenylalanine (p(F)dPhe);R5is selected from the group consisting of Arg, His, c / sPro(guan), and fransPro(guan);R6is selected from the group consisting of Trp, dTrp, Phe, Aia, Aba, Ata, and T- naphthylalanine (Nal(1 ’));R7is selected from the group consisting of Gly, Lys, dLys, Cys, dCys, dPen, and Orn;R8is absent or Lys;Y1is absent or is selected from the group consisting of valine (Vai), D-valine (dVal), 02-valine (P2-Val), p3-valine (P3-Val), Pro, D-proline (dPro), p-proline (P-Pro), Hyp, D- hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr);Y2is absent or is selected from the group consisting of Vai, dVal, p2-Val, p3-Val, Pro, dPro, p-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn;Y3is absent or is selected from the group consisting of Vai, dVal, Pro, dPro, dThr, Lys, and dLys;Y4is absent or is selected from the group consisting of dVal, dPro, Asp, and dAsp;Y5is absent or dVal;Y6is absent or dVal;Y7is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2and R7when each of R2and R7are independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2and R7when R2is Asp or dAsp and R7is Lys, dLys, or Orn; provided that the non-naturally occurring melanocortin analog does not comprise a sequence of:Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 432); orAc-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 639).

55. The method or use of any one of claims 1 -49, wherein the non-naturally occurring melanocortin analog comprises a sequence of Formula (IC):X1-X2-R1-R2-Pro-dPhe-R5-R6-R7-Y1-Y2-Y3-Y4(IC), wherein:X1is selected from the group consisting of norleucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis);X2is absent or Nle;R1is selected from the group consisting of aspartic acid (Asp), cysteine (Cys), and D-cysteine (dCys);R2is selected from the group consisting of tryptophan (Trp), phenylalanine (Phe), D- phenylalanine (dPhe), histidine (His), D-histidine (dHis), tyrosine (Tyr), and D-tyrosine (dTyr);R5is Arg;R6is selected from the group consisting of Trp, 2’-D-naphthylalanine (dNal(2’)), 2’- naphthylalanine (Nal(2’)), and T-naphthylalanine (Nal(1 ’));R7is selected from the group consisting of Lys, Cys, and dCys;Y1is absent or is selected from the group consisting of D-valine (dVal), D-tert-leucine (dTle), dArg, and dLys;Y2is absent or is selected from the group consisting of dVal, dPro, and D- hydroxyproline (dHyp);Y3is absent, dVal, or dPro;Y4is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R1and R7when both of R1and R7are independently selected from the group consisting of Cys, dCys, and dPen; anda lactam bridge between R1and R7when R1is Asp and R7is Lys.

56. The method or use of any one of claims 1 -49, wherein the non-naturally occurring melanocortin analog comprises a sequence of Formula (ID):X1-R1-R2-R3-p(CI)dPhe-Arg-Trp-R7-Y1-Y2-Y3-Y4(ID), wherein:X1is absent or norleucine (Nle);R1is selected from the group consisting of Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis);R2is aspartic acid (Asp) or D-cysteine (dCys);R3is selected from the group consisting of His, 4-amino-1 ,2,4,5-tetrahydro-2- benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H-[1 , 2 , 3]triazolo-[ 1 , 5-a][ 1 ,4]diazepin-6(5H)- one (Ata), and 4-amino-1 ,4,5,6-tetrahydroazepino[4,3-b]indol-3(2 / - / )-one (Aia);R7is Lys or dCys;Y1is selected from the group consisting of D-valine (dVal), D-proline (dPro), and D- tert-leucine (dTle);Y2is absent or is selected from the group consisting of dVal, dPro, and dTle;Y3is absent, dVal, or dPro;Y4is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2and R7when both of R2and R7are dCys; and a lactam bridge between R2and R7when R2is Asp and R7is Lys; provided that when R3is His and R1is Nle, then (i) Y1Y2is dVal-dPro, X1is absent, and the non-naturally occurring melanocortin analog is cyclized through a disulfide bond, or (b) Y1Y2is not dVal-dPro and either X1or Y3is present.

57. The method or use of any one of claims 1 -50, wherein the non-naturally occurring melanocortin analog comprises a sequence of Formula (ID), wherein:X1is absent or norleucine (Nle);R1is selected from the group consisting of Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis);R2is aspartic acid (Asp) or D-cysteine (dCys);R3is selected from the group consisting of His, 4-amino-1 ,2,4,5-tetrahydro-2- benzazepin-3-one (Aba), 7-amino-7,8-dihydro-4H-[1 ,2,3]triazolo-[1 , 5-a][ 1 ,4]diazepin-6(5H)- one (Ata), and 4-amino-1 ,4,5,6-tetrahydroazepino[4,3-b]indol-3(2 / - / )-one (Aia);R7is Lys or dCys;Y1is selected from the group consisting of D-valine (dVal), D-proline (dPro), and D- tert-leucine (dTle);Y2is absent or is selected from the group consisting of dVal, dPro, and dTle;Y3is absent, dVal, or dPro;Y4is absent or dPro; and the non-naturally occurring melanocortin analog is cyclized through a moiety selected from the group consisting of: a disulfide bond between R2and R7when both of R2and R7are dCys; and a lactam bridge between R2and R7when R2is Asp and R7is Lys; provided that the non-naturally occurring melanocortin analog does not comprise a sequence selected from the group consisting of:Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 220);Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 507);Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 516);Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 514); and.

58. The method or the use of any one of claims 1 -57, wherein an N-terminus of the non-naturally occurring melanocortin analog is modified by an acyl group.

59. The method or the use of claim 58, wherein the acyl group is an acetyl group.

60. The method or the use of any one of claims 1 -57, wherein an N-terminus of the non-naturally occurring melanocortin analog is not modified.61 . The method or the use of any one of claims 1 -60, wherein a C-terminus of the non-naturally occurring melanocortin analog is modified by an amide group.

62. The method or the use of any one of claims 1 -60, wherein a C-terminus of the non-naturally occurring melanocortin analog is not modified.

63. The method or the use of any one of claims 1 -67, wherein Y1-Y2are present and Y3- Y8are absent.

64. The method or the use of any one of claims 1-63, wherein Y1is D-valine and Y2is D-proline.

65. The method or the use of any one of claims 1 -63, w wherein Y1is D-tert-leucine and Y2is D-proline.

66. The method or the use of any one of claims 1 -62, wherein R4is dNal(2’).

67. The method or the use of claim 66, wherein the sequence of Formula (I) is: Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 8), wherein c represents cyclization through R2and R8via a lactam bond.

68. The method or the use of any one of claims 1 -62, wherein R4is Phe or dPhe.

69. The method or the use of claim 68, wherein the sequence of any one ofFormulae (l)-(ID) is selected from the group consisting of:Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 291 );Ac-Nle-c[Asp-Pro-Phe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 294);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 295; E2); andAc-Nle-c[Asp-Pro-His-Phe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 296). wherein c represents cyclization through R2and R7via a lactam bond.

70. The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae ( l)-( I D) is selected from the group consisting of:Ac-dLeu-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO:298);Ac-dAla-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 299);Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro- NH2(SEQ ID NO: 300);Ac-dNle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 301 );Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 302);Ac-dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 303);Ac-dTyr-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 304);Phe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 305);His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 306);Trp-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 307); dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 308); dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 309); dTrp-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 310);Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 311 );Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 312);Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 313);Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 314);Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 315);Ac-Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 316); andAc-dOrn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 317), wherein c represents cyclization through R2and R7via a lactam bond.71 . The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of:Ac-Nle-c[Cys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 318);Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 319);Ac-Nle-c[dPen-Pro-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2(SEQ ID NO: 320);Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2(SEQ ID NO: 321 );Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2(SEQ ID NO: 322); andAc-Nle-c[Cys-dPhe-Arg-Trp-Pen]-dVal-dPro-NH2(SEQ ID NO: 324), wherein c represents cyclization through R2and R7via a disulfide bond.

72. The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of:Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dVal-dPro-NH2(SEQ ID NO: 351 );Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2(SEQ ID NO: 352); andAc-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp-NH2(SEQ ID NO: 353), wherein c represents cyclization through R2and R8via a lactam bond.

73. The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of:Ac-Nle-c[Asp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 354);Ac-Nle-c[Asp-Leu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 355);Ac-Nle-c[Asp-Cpe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 358);Ac-Nle-c[Asp-Che-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 359);Ac-Nle-c[Asp-Oic-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 360);Ac-Nle-c[Asp-loc-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 361 );Ac-Nle-c[Asp-Tic-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 362);Ac-Nle-c[Asp-Hyp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 364);Ac-Nle-c[Asp-Phe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 366);Ac-Nle-c[Asp-dPhe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 367);Ac-Nle-c[Asp-Bip-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 368);Ac-Nle-c[Asp-dGln-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 371 );Ac-Nle-c[Asp-Trp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 372);Ac-Nle-c[Asp-dTrp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 373);Ac-Nle-c[Asp-Tyr-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 374);Ac-Nle-c[Asp-dTyr-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 375);Ac-Nle-c[Asp-Aba-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 198);Ac-Nle-c[Asp-Aia-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 207);Ac-Nle-c[Asp-Ata-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 208);Ac-Nle-c[Asp-Atc-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 212);Ac-Nle-c[Asp-APC-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 213); andAc-Nle-c[Asp-APPC-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 214),wherein c represents cyclization through R2and R7via a lactam bond.

74. The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of:Ac-Arg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-NH2(SEQ ID NO: 281 );Ac-Arg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 381 ); andAc-dArg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 382), wherein c represents cyclization through R1and R7via a lactam bond.

75. The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of:Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 226);Ac-Nle-c[Cys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 383);Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 384);Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2(SEQ ID NO: 385);Ac-Ala-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 386);Ac-Lys-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 387);Ac-dLys-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 388);Ac-Arg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 389);Ac-dArg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 390);Ac-dHis-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 391 );Ac-His-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 392);Ac-Nle-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 393);Ac-Nle-c[Asp-Trp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 394);Ac-Nle-c[Asp-Trp-Leu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 395);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(T]-Lys]-dVal-dPro-NH2(SEQ ID NO: 399);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 403);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(2’)-Lys]-dVal-dPro-NH2(SEQ ID NO: 404);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2(SEQ ID NO: 405);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2(SEQ ID NO: 406);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2(SEQ ID NO: 407);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2(SEQ ID NO: 408);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2(SEQ ID NO: 409);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 410);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 411 );Ac-Nle-c[Asp-Phe-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 412);Ac-Nle-c[Asp-His-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 413);Ac-Nle-c[Asp-Tyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 414);Ac-Nle-c[Asp-dPhe-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 415);Ac-Nle-c[Asp-dHis-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 416); andAc-Nle-c[Asp-dTyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 417), wherein c represents cyclization through R1and R7via a lactam bond or a disulfide bond.

76. The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae (l)-(ID) is: Ac-Nle-c[Asp-Hyp-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2(SEQ ID NO: 419), wherein c represents cyclization through R2and R8via a lactam bond.

77. The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of:Ac-Nle-Phe-Phe-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 421 );Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2(SEQ ID NO: 422);Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 423); andAc-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 424), wherein c represents cyclization through R1and R7via a lactam bond.

78. The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of:Ac-Nle-c[Asp-Pro-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2(SEQ ID NO: 187);Ac-Nle-c[Asp-Pro-dPhe-Arg-Aia-Lys]-dVal-dPro-NH2(SEQ ID NO: 233);Ac-Nle-c[Asp-Pro-dPhe-Arg-Aba-Lys]-dVal-dPro-NH2(SEQ ID NO: 234);Ac-Nle-c[Asp-Pro-dPhe-Arg-Ata-Lys]-dVal-dPro-NH2(SEQ ID NO: 235);Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(1’)-Lys]-dVal-dPro-NH2(SEQ ID NO: 427); andAc-Nle-c[Asp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2(SEQ ID NO: 429), wherein c represents cyclization through R2and R7via a lactam bond.

79. The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of:Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 218);Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 433);Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2(SEQ ID NO: 434);Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 435);Ac-dArg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 436);Ac-Arg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 437);Ac-Lys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 438);Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 439);Ac-His-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 440);Ac-dHis-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 441 );Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 442);Ac-Nle-c[Asp-Pro-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 443);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2(SEQ ID NO: 446);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 447);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 448);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 449);Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 450);Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 451 );Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 452);Ac-dArg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 453);Ac-Arg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 454);Ac-Lys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 455);Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 456);Ac-His-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 457);Ac-dHis-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 458);Ac-Nle-c[Cys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 459);Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 460);Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2(SEQ ID NO: 461 );Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Nal(2’)-Lys]-dVal-dPro-NH2(SEQ ID NO: 472);Ac-Nle-c[Asp-dGln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 492); andAc-Nle-c[Asp-dTyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 496), wherein c represents cyclization through R2and R7via a lactam bond or a disulfide bond.

80. The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae ( l)-( I D) is selected from the group consisting of:Ac-Nle-c[Asp-Aba-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 209);Ac-Nle-c[Asp-Aia-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 210);Ac-Nle-c[Asp-Ata-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 211 );Ac-Nle-c[dCys-His-p(CI)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2(SEQ ID NO: 499);Ac-dArg-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 501 );Ac-Arg-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-d al-dPro-NH2(SEQ ID NO: 502);Ac-Lys-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 503);Ac-dLys-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 504);Ac-His-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 505);Ac-dHis-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 506);Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2(SEQ ID NO: 511 );Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 512);Ac-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 513);Ac-Nle-Nle-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 515);Ac-dArg-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 518);Ac-Arg-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 519);Ac-Lys-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 520);Ac-dLys-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 521 );Ac-His-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 522); andAc-dHis-c[Asp-His-p(CI)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 523), wherein c represents cyclization through R2and R7via a lactam bond or a disulfide bond.81 . The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of:Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 536); or Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2(SEQ ID NO: 537), wherein c represents cyclization through R2and R7via a disulfide bond.

82. The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of:Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Val-Pro-NH2(SEQ ID NO: 573);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Hyp-NH2(SEQ ID NO: 574);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2(SEQ ID NO: 575);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Val-NH2(SEQ ID NO: 576);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Pro-NH2(SEQ ID NO: 577);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Arg-NH2(SEQ ID NO: 578);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dArg-NH2(SEQ ID NO: 579);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2(SEQ ID NO: 580);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-NH2(SEQ ID NO: 581 );Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-NH2(SEQ ID NO: 582);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-Pro-Val-NH2(SEQ ID NO: 583);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2(SEQ ID NO: 584);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-Val-Pro-NH2(SEQ ID NO: 585);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dVal-dPro-NH2(SEQ ID NO: 586);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2(SEQ ID NO: 587);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Pro-Val-NH2(SEQ ID NO: 588);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Val-Pro-NH2(SEQ ID NO: 589);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2(SEQ ID NO: 590);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 591 );Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dTle-dPro-NH2(SEQ ID NO: 592);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2(SEQ ID NO: 593);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dTle-NH2(SEQ ID NO: 594);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dPro-NH2(SEQ ID NO: 595);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2(SEQ ID NO: 596);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 597);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2(SEQ ID NO: 598);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 599);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Trp-NH2(SEQ ID NO: 600);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dPro-dVal-NH2(SEQ ID NO: 601 );Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAla-dAla-NH2(SEQ ID NO: 602);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asp-NH2(SEQ ID NO: 603);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dHyp-NH2(SEQ ID NO: 604);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dAsn-NH2(SEQ ID NO: 605);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Asp-NH2(SEQ ID NO: 606);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asn-dPro-NH2(SEQ ID NO: 607);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Hyp-NH2(SEQ ID NO: 608);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Ala-Ala-NH2(SEQ ID NO: 609);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Gly-Gly-NH2(SEQ ID NO: 610);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asp-dPro-NH2(SEQ ID NO: 611 );Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsn-dPro-NH2(SEQ ID NO: 612);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asn-NH2(SEQ ID NO: 613);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsp-NH2(SEQ ID NO: 614);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsn-NH2(SEQ ID NO: 615);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dPro-NH2(SEQ ID NO: 616);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 617);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-NH2(SEQ ID NO: 618);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-OH (SEQ ID NO: 619);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2(SEQ ID NO: 620);Ac-Nle-c[dAsp-Pro-dPhe-Arg-Trp-dLys]-dPro-dVal-NH2(SEQ ID NO: 622);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-pPro-p2Val-NH2(SEQ ID NO: 623);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-pPro-[33Val-NH2(SEQ ID NO: 624);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-p2Val-pPro-NH2(SEQ ID NO: 625);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-p3Val-pPro-NH2(SEQ ID NO: 626); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-pPro-[3Pro-NH2(SEQ ID NO: 627), wherein c represents cyclization through R2and R7via a lactam bond.

83. The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of:Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 628);Ac-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 629); and Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 630), wherein c represents cyclization through R2and R7via a lactam bond.

84. The method or the use of any one of claims 1 -62, wherein the sequence of any one of Formulae (l)-(ID) is selected from the group consisting of:Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2(SEQ ID NO: 631 );Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2(SEQ ID NO: 632);Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 633);Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 634);Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2(SEQ ID NO: 635);Ac-Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 636);Ac-dOrn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 637);Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 638);Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 640);Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 641 );Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 642);Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 643);Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 644);Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 645); andAc-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 646), wherein c represents cyclization through R2and R7via a lactam bond.

85. The method or the use of any one of claims 1 -57, wherein the non-naturally occurring melanocortin analog comprises any one of SEQ ID NOs: 8, 187, 198, 207-218, 226, 231-235, 281 , 291 , 294-296, 298-322, 324, 351 -355, 358-362, 364, 366-368, 371 -375, 381-395, 399, 403-417, 419, 421 -425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646.

86. The method or the use of claim 85, wherein the non-naturally occurring melanocortin analog comprises any one of the sequences of SEQ ID NOs: 187, 212, 218, 226, 291 , 295, 298-322, 324, 351 -355, 358-360, 362, 364, 366-368, 371 -375, 381 -395, 399,403-417, 419, 421 -425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499-506, 511 -513, 515, 518-523, 536-537, 573-598, 600-646.

87. The method or the use of claim 85, wherein the non-naturally occurring melanocortin analog comprises any one of the sequences of SEQ ID NOs: 187, 218, 231 - 235, 291 , 295, 298-322, 351 -353, 425, 427, 429, 433-443, 446-458, 573-599, 600-620, 622- 646.

88. The method or the use of claim 85, wherein the non-naturally occurring melanocortin analog comprises any one of the sequences of SEQ ID NOs: 226, 383-393, 399, 403-417.

89. The method or the use of claim 85, wherein the non-naturally occurring melanocortin analog comprises any one of the sequences of SEQ ID NOs: 209-211 , 499, 501-506, 511 -513, 515, 518-523.

90. The method or the use of any one of claims 1 -89, wherein the non-naturally occurring melanocortin analog is present in a pharmaceutical composition.

91. The method or the use of claim 90, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients and / or carriers.

92. The method or the use of claim 91 , wherein the one or more pharmaceutically acceptable excipients and / or carriers of the pharmaceutical composition comprise water.

93. The method or the use of any one of claims 1 -92, wherein the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 5 mg / kg to about 20 mg / kg administered once a day for about 5 days to about 10 days; (ii) at a second dose of about 10 mg / kg to about 40 mg / kg administered once a day after administration of the first dose for about 5 days to about 10 days; (iii) at a third dose of about 5 mg / kg to about 30 mg / kg administered twice a day after administration of the second dose for at least about 5 days to about 10 days.

94. The method or the use of any one of claims 1 -92, wherein the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 5 mg / kg administered once a day for about 7 days; (ii) at a second dose of about 15 mg / kg administered once a day after administration of the first dose for about 7 days; (iii) at a third dose of about 10 mg / kg administered twice a day after administration of the second dose for at least about 7 days.

95. The method or the use of any one of claims 1 -92, wherein the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 10 mg / kg administered once a day for about 7 days; (ii) at a second dose of about 20 mg / kg administered once a day after administration of the first dose for about 7 days; (iii) at a third dose of about 15 mg / kg administered twice a day after administration of the second dose for at least about 7 days.

96. The method or the use of any one of claims 1 -92 wherein the non-naturally occurring melanocortin analog is administered (i) at a first dose of about 15 mg / kg administered once a day for about 7 days; (ii) at a second dose of about 25 mg / kg administered once a day after administration of the first dose for about 7 days; (iii) at a third dose of about 20 mg / kg administered twice a day after administration of the second dose for at least about 7 days.

97. The method or the use of any one of claims 1 -92, wherein the non-naturally occurring melanocortin analog is administered at a dose of about 0.5 mg / kg to about 10 mg / kg per body weight of the subject once daily.

98. The method or the use of claim 97, wherein the non-naturally occurring melanocortin analog is administered at a dose of about 1 mg / kg or 3 mg / kg per body weight of the subject once daily.

99. The method or the use of any one of claims 1 -92, wherein the non-naturallyoccurring melanocortin analog is administered at a dose of about 0.1 mg to about 100 mg once daily.

100. The method or the use of any one of claims 1 -92, wherein the non-naturally occurring melanocortin analog is administered at a dose of about 10 mg or about 50 mg once daily.101 . The method or the use of any one of claims 1 -100, wherein the non-naturally occurring melanocortin analog is administered via intraperitoneal, intravenous, parenteral, subcutaneous, intramuscular, intracerebroventricular, intranasal, or oral administration.

102. The method or the use of any one of claims 1 -101 , wherein the non-naturally occurring melanocortin analog crosses a blood-brain-barrier of a subject.

103. The method or the use of any one of claims 101 or 102, wherein the non- naturally occurring melanocortin analog comprises any one of the sequences of SEQ ID NOs: 8, 187, 198, 207-218, 226, 231-235, 281 , 291 , 294-296, 298-322, 324, 351 -355, 358- 362, 364, 366-368, 371 -375, 381 -395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446- 461 , 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646 and is administered at least once daily in an amount ranging from 0.001 mg / kg to 25 mg / kg per body weight of the subject.

104. The method or the use of claim 103, wherein the non-naturally occurring melanocortin analog comprises any one of the sequences of SEQ ID NOs: 8, 187, 198, 207- 218, 226, 231-235, 281 , 291 , 294-296, 298-322, 324, 351-355, 358-362, 364, 366-368, 371 - 375, 381-395, 399, 403-417, 419, 421 -425, 427, 429, 433-443, 446-461 , 472, 492, 496, 499- 506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646 and is administered at least once daily in an amount ranging from 0.5 mg / kg to 10 mg / kg per body weight of the subject.

105. The method or the use of any one of claims 1 -92, wherein the non-naturally occurring melanocortin analog is administered to a subject for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, or 5 years.

106. The method or the use of any one of claims 1 -104, wherein the non-naturally occurring melanocortin analog is administered to a subject for 1 day, 5 days, 7 days, 14 days, 21 days, 28 days, 35 days, 40 days, 45 days, 50 days, 60 days, 75 days, 90 days, 100 days, 110 days, or 120 days.